{"meta":{"query_hash":"caafb69b4be7","filters":{"venue":"Dermatology and Therapy"},"cohort_total":183,"direct_labels_cover":0,"predictions_cover":183,"exported":183,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/caafb69b4be7","api":"https://metacan.xera.ac/api/v1/cohort?venue=Dermatology+and+Therapy"},"results":[{"id":"W1762442364","doi":"10.1007/s13555-015-0077-2","title":"Perceptions on the Psychological Impact of Facial Erythema Associated with Rosacea: Results of International Survey","year":2015,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Rosacea; Erythema; Psychology; Perception; Clinical psychology; Medicine; Dermatology","score_opus":0.07179059397305979,"score_gpt":0.3655215687370648,"score_spread":0.293730974764005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1762442364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99759805,0.000091168105,0.000006581529,0.00093162985,0.000039337483,0.00012472156,0.00007247769,0.000007463218,0.0011285464],"genre_scores_gemma":[0.99950266,0.00015149733,0.000009712332,0.00015339741,0.000011634686,0.0000040447435,0.00008705519,0.0000037523298,0.00007626601],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999498,0.00012923176,0.00011748096,0.00008972236,0.00008739116,0.0000781424],"domain_scores_gemma":[0.9995227,0.0001778868,0.00007596182,0.00009474922,0.0000881359,0.000040560742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017012378,0.000072349896,0.0001960643,0.000032518277,0.000035290774,0.000002519897,0.000037642425,0.00008513283,0.000040392595],"category_scores_gemma":[0.00009033679,0.00003044273,0.000046282992,0.000061261744,0.00015965266,0.000016265438,0.000006075147,0.000079022204,0.0000026116486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005700949,0.0008855355,0.98570913,0.0000014477758,0.0005882515,0.000028152035,0.00094757613,0.0000061684236,0.00033606007,0.00011501672,0.004006341,0.0016753488],"study_design_scores_gemma":[0.0049603935,0.0016250573,0.99260724,0.000019640727,0.000014910201,0.00010689079,0.0000716742,0.000056860037,0.00031476084,0.00006784121,0.00011989288,0.0000348504],"about_ca_topic_score_codex":0.000061441104,"about_ca_topic_score_gemma":0.000014141589,"teacher_disagreement_score":0.006898075,"about_ca_system_score_codex":0.000008860231,"about_ca_system_score_gemma":0.00002469043,"threshold_uncertainty_score":0.12414185},"labels":[],"label_agreement":null},{"id":"W1977644637","doi":"10.1007/s13555-013-0033-y","title":"Triple-Blind, Prospective, Internally Controlled Comparative Study Between AbobotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Facial Rhytids","year":2013,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; ABO blood group system; Adverse effect; Botulinum toxin; Surgery; Internal medicine","score_opus":0.044182538008597894,"score_gpt":0.3278096531584924,"score_spread":0.2836271151498945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977644637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813043,0.008608401,0.00020102331,0.0029873748,0.00011469962,0.006541455,0.000011580475,0.00003487781,0.00019627086],"genre_scores_gemma":[0.9922303,0.0062742094,0.00006962859,0.0003488104,0.00005697708,0.0007624308,0.0000070415977,0.000014061477,0.0002365415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987178,0.00015294467,0.00044427376,0.00032876746,0.00010664599,0.0002496093],"domain_scores_gemma":[0.9986918,0.0007490754,0.00016204012,0.00017997411,0.000117016076,0.000100114055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000880033,0.0002628963,0.0010758535,0.00007720697,0.00018861562,0.000019527442,0.00008352643,0.00020606151,0.00005218345],"category_scores_gemma":[0.000021671385,0.00013398999,0.00015779119,0.000105358515,0.0004493843,0.000051946143,0.00001578359,0.00019130704,0.0000061816017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03651247,0.004761714,0.86328924,0.000044937042,0.00543591,0.000050203565,0.011090175,0.0000043134323,0.0013151496,0.0007344887,0.00040212827,0.07635929],"study_design_scores_gemma":[0.16227953,0.014776662,0.8091944,0.000017533344,0.0005667928,0.0001731144,0.0021553854,0.00088851847,0.0019143064,0.002758152,0.00499678,0.00027880757],"about_ca_topic_score_codex":0.0000311761,"about_ca_topic_score_gemma":0.0000107441365,"teacher_disagreement_score":0.12576707,"about_ca_system_score_codex":0.000010511256,"about_ca_system_score_gemma":0.000030286517,"threshold_uncertainty_score":0.5463953},"labels":[],"label_agreement":null},{"id":"W2003027167","doi":"10.1007/s13555-014-0043-4","title":"Health-Related Quality of Life Worsens Disproportionately to Objective Signs of Psoriasis After Withdrawal of Adalimumab Therapy","year":2014,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"AbbVie","keywords":"Medicine; Discontinuation; Psoriasis; Dermatology Life Quality Index; Adalimumab; Psoriasis Area and Severity Index; Internal medicine; Quality of life (healthcare); Randomized controlled trial; Placebo; Severity of illness; Physical therapy; Disease; Dermatology","score_opus":0.020566537768950222,"score_gpt":0.26867663484768733,"score_spread":0.2481100970787371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003027167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856119,0.012559429,0.00014657814,0.0007136065,0.00029487346,0.00037424828,0.000089175745,0.000024452522,0.00018574194],"genre_scores_gemma":[0.99804026,0.0013745994,0.00009026656,0.00031548942,0.000010241034,0.000045796696,0.000053639043,0.000015330696,0.000054389366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766594,0.00090531877,0.00082893873,0.0002831907,0.000053415402,0.00026320442],"domain_scores_gemma":[0.9986511,0.0003363752,0.00054138637,0.00028575258,0.00013680203,0.00004857485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003587181,0.00021578795,0.00096736074,0.00016258456,0.00008556975,0.0000018669904,0.000117933996,0.0003081472,0.0001773605],"category_scores_gemma":[0.000050022187,0.00016768421,0.00014837433,0.00019351122,0.00037955976,0.000047271275,0.000025024268,0.00011064739,0.00001247421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026492923,0.0019841609,0.6347383,0.00017903038,0.0045006694,0.000007134831,0.013991814,0.000012302201,0.13367297,0.0126431445,0.00033366258,0.17144388],"study_design_scores_gemma":[0.011442126,0.0017506168,0.7515524,0.00005955397,0.00005358861,0.00008119832,0.0004908072,0.0000022326726,0.22928452,0.00300331,0.0019200465,0.0003596204],"about_ca_topic_score_codex":0.00046722722,"about_ca_topic_score_gemma":0.000094089046,"teacher_disagreement_score":0.17108427,"about_ca_system_score_codex":0.000009376957,"about_ca_system_score_gemma":0.00009493195,"threshold_uncertainty_score":0.68379635},"labels":[],"label_agreement":null},{"id":"W2051956976","doi":"10.1007/s13555-015-0070-9","title":"Primary Care Review of Actinic Keratosis and Its Therapeutic Options: A Global Perspective","year":2015,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Actinic keratosis; Medicine; Incidence (geometry); Dermatology; Population; Skin cancer; Perspective (graphical); Intensive care medicine; Family medicine; Basal cell; Cancer; Environmental health; Pathology; Internal medicine","score_opus":0.047600690083379846,"score_gpt":0.34899121349477036,"score_spread":0.3013905234113905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051956976","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21528889,0.77681786,0.0000056334284,0.0040061376,0.000057312314,0.00030013872,0.00000964218,0.000014252562,0.0035001177],"genre_scores_gemma":[0.6799093,0.3170038,0.00008081598,0.0029374678,0.000018676483,0.000030469857,0.0000046333907,0.0000052118444,0.000009630932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994039,0.00008160762,0.00014765354,0.0001694242,0.00008536623,0.00011206495],"domain_scores_gemma":[0.99949396,0.000044744364,0.00006685744,0.00011989868,0.00021111529,0.00006341635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060703693,0.000110134206,0.00040910547,0.00002583911,0.000046874495,0.0000027955912,0.000034218876,0.00006691175,0.000011316409],"category_scores_gemma":[0.000021116342,0.0000843366,0.000038178994,0.00010268828,0.00013621242,0.0000440977,0.000025659407,0.00008087384,0.0000028150794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025017597,0.0004043093,0.81375355,0.01275193,0.0031504154,0.00024009412,0.02068053,1.4147503e-7,0.00044026575,0.04181946,0.0042815986,0.09997597],"study_design_scores_gemma":[0.026017291,0.0027003628,0.7860721,0.0101782475,0.0013274311,0.017172804,0.025649574,0.000019805071,0.006878893,0.01193813,0.11090464,0.0011407478],"about_ca_topic_score_codex":0.000011077758,"about_ca_topic_score_gemma":0.0000033775407,"teacher_disagreement_score":0.4646204,"about_ca_system_score_codex":0.000066787,"about_ca_system_score_gemma":0.00012142739,"threshold_uncertainty_score":0.34391466},"labels":[],"label_agreement":null},{"id":"W2104297249","doi":"10.1007/s13555-015-0076-3","title":"Influence of Psoriasis on Household Chores and Time Spent on Skin Care at Home: A Questionnaire Study","year":2015,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Varsinais-Suomen Sairaanhoitopiiri","keywords":"Psoriasis; Medicine; Quarter (Canadian coin); Quality of life (healthcare); Physical therapy; Nursing; Dermatology","score_opus":0.017903952037004626,"score_gpt":0.2444107126873785,"score_spread":0.22650676065037387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104297249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863025,0.012846149,2.9249563e-7,0.00013049228,0.00015245951,0.00033167936,0.000031575728,0.000042195847,0.00016266818],"genre_scores_gemma":[0.9986517,0.00094679417,0.00000410418,0.00017051151,0.000013555536,0.000039410636,0.000028583896,0.000012731919,0.00013264126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899167,0.00031664077,0.00018691366,0.00028300783,0.00003827013,0.00018349799],"domain_scores_gemma":[0.9995034,0.00009695887,0.00008986388,0.00022804676,0.000044907443,0.000036839254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008422948,0.0001975361,0.00035474618,0.00011512459,0.00014137062,0.0000056975196,0.000091161804,0.00020984662,0.000016782937],"category_scores_gemma":[0.000014558012,0.00014996155,0.000037231264,0.000068200316,0.00019654975,0.000042452528,0.00003782068,0.00009498814,0.00007647495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050005987,0.0011781233,0.934188,0.000031103475,0.0009319678,0.00011602999,0.014028251,0.00005399023,0.0058274,0.00090599945,0.0011888715,0.03654963],"study_design_scores_gemma":[0.010702626,0.0025002202,0.91403717,0.00006133638,0.00010755332,0.0003425291,0.000825304,9.789823e-7,0.0675956,0.00032012127,0.0031940844,0.00031246198],"about_ca_topic_score_codex":0.000056139623,"about_ca_topic_score_gemma":0.000024822384,"teacher_disagreement_score":0.0617682,"about_ca_system_score_codex":0.000021596456,"about_ca_system_score_gemma":0.000023058,"threshold_uncertainty_score":0.6115254},"labels":[],"label_agreement":null},{"id":"W2288009363","doi":"10.1007/s13555-016-0098-5","title":"New Patient-Oriented Tools for Assessing Atrophic Acne Scarring","year":2016,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatologic Treatments and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Galderma","keywords":"Acne scars; Medicine; Acne; Scars; Quality of life (healthcare); Dermatology; Patient-reported outcome; Surgery; Nursing","score_opus":0.045077258011468294,"score_gpt":0.3425518277291313,"score_spread":0.297474569717663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2288009363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98286134,0.0027847884,0.004757461,0.008200231,0.00016745842,0.00045876403,0.0000050779186,0.00006318189,0.00070168194],"genre_scores_gemma":[0.99570185,0.0011112967,0.0020175655,0.00063742825,0.000050071383,0.000039823113,0.000010432136,0.000015029796,0.00041652625],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991621,0.00004415753,0.00017484567,0.00022232499,0.00009394148,0.0003026381],"domain_scores_gemma":[0.99935246,0.00023336113,0.000049688697,0.00016388469,0.000057833055,0.00014277306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041759784,0.00012481178,0.00027775226,0.00007869779,0.00015192201,0.000030195559,0.000042971733,0.00012876846,0.00008320151],"category_scores_gemma":[0.00005157729,0.00006459837,0.000066426015,0.000064674685,0.00009693086,0.00017762386,0.000022409751,0.00006796582,0.000013139551],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049254636,0.0001025977,0.089046754,0.000031527765,0.00021879893,0.00022977004,0.00016354323,4.6913534e-8,0.011862759,0.0026147724,0.001581043,0.89365584],"study_design_scores_gemma":[0.04570382,0.0014608946,0.19993314,0.0005587322,0.0001612834,0.012133848,0.00062954635,0.0001058302,0.12541603,0.0077576446,0.6053774,0.000761849],"about_ca_topic_score_codex":0.000005762289,"about_ca_topic_score_gemma":6.3760336e-7,"teacher_disagreement_score":0.89289397,"about_ca_system_score_codex":0.0000146339935,"about_ca_system_score_gemma":0.00007541068,"threshold_uncertainty_score":0.2634245},"labels":[],"label_agreement":null},{"id":"W2303711714","doi":"10.1007/s13555-016-0107-8","title":"Erratum to: New Patient-Oriented Tools for Assessing Atrophic Acne Scarring","year":2016,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Galderma","keywords":"Section (typography); Engineering; Operations research; Computer science; Business; Advertising","score_opus":0.02408999880148773,"score_gpt":0.30663720799473193,"score_spread":0.2825472091932442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2303711714","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6545259,0.14880402,0.01382117,0.039539736,0.090408325,0.010690154,0.00033539746,0.0008164968,0.04105883],"genre_scores_gemma":[0.41252753,0.054320663,0.008835218,0.03879126,0.014097867,0.0012664956,0.004804527,0.00085563713,0.4645008],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99849373,0.00005599278,0.0003107916,0.0004977832,0.00013975542,0.0005019525],"domain_scores_gemma":[0.9989793,0.00014819826,0.00015532493,0.0003243666,0.00009002861,0.0003028377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000049997965,0.0004086843,0.00085117243,0.00017123159,0.00028360158,0.00007009423,0.00007631102,0.00072285306,0.000044750395],"category_scores_gemma":[0.000059535436,0.00025646883,0.0001898796,0.000102668506,0.00006984994,0.00016870332,0.000043223932,0.00034461275,0.000022324286],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049938256,0.00008955421,0.0010878374,0.00015393354,0.00053381425,0.00021845926,0.00035107936,8.5516454e-8,0.00052832183,0.00012723307,0.7882714,0.20813885],"study_design_scores_gemma":[0.004078673,0.0006082644,0.0009974189,0.00075229804,0.0001686337,0.0006550788,0.000059734004,0.000011107599,0.00080172817,0.00042188916,0.9911201,0.00032508254],"about_ca_topic_score_codex":0.000016529057,"about_ca_topic_score_gemma":0.0000033399874,"teacher_disagreement_score":0.42344198,"about_ca_system_score_codex":0.000035583816,"about_ca_system_score_gemma":0.0002876233,"threshold_uncertainty_score":0.99998873},"labels":[],"label_agreement":null},{"id":"W2339075395","doi":"10.1007/s13555-016-0113-x","title":"How People with Facial Acne Scars are Perceived in Society: an Online Survey","year":2016,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatologic Treatments and Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Clinical Research; Western University","funders":"","keywords":"Scars; Acne; Medicine; Dermatology; Acne scars; Population; Surgery","score_opus":0.06653179374572875,"score_gpt":0.32415352177674506,"score_spread":0.2576217280310163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339075395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853218,0.00071924756,0.000026451797,0.0135104675,0.000034714772,0.00026347008,0.000043498807,0.000036335514,0.000043991822],"genre_scores_gemma":[0.99538577,0.003365429,0.00012736648,0.0005732576,0.00002078218,0.000020425512,0.00006591197,0.000014616349,0.00042646794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990035,0.00017563204,0.000114552175,0.00027498443,0.0001244726,0.00030683403],"domain_scores_gemma":[0.9994754,0.00010238541,0.000044388973,0.00019091416,0.00006763465,0.00011925714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008645324,0.00015333538,0.00040176354,0.0000668601,0.00009130417,0.000019046156,0.000068439695,0.00017599552,0.000037479844],"category_scores_gemma":[0.000013090603,0.00007276881,0.00004054083,0.00012181237,0.00025027734,0.00011141048,0.00001787988,0.00013579072,0.000004824674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006028266,0.00039657342,0.97266334,0.000013091376,0.00010976343,0.0002856976,0.00054255396,3.9855536e-8,0.0006838414,0.000020274314,0.00026295398,0.024419025],"study_design_scores_gemma":[0.006613212,0.00023422415,0.9888177,0.000036408306,0.000008159634,0.001592813,0.000576496,0.000021278434,0.0002650838,0.000059208003,0.0016678969,0.00010755422],"about_ca_topic_score_codex":0.00010340174,"about_ca_topic_score_gemma":0.0012790245,"teacher_disagreement_score":0.02431147,"about_ca_system_score_codex":0.000016967018,"about_ca_system_score_gemma":0.000060834052,"threshold_uncertainty_score":0.2967426},"labels":[],"label_agreement":null},{"id":"W2521785556","doi":"10.1007/s13555-016-0145-2","title":"Use of Lesion Response Rate in Actinic Keratosis Trials","year":2016,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Galderma","keywords":"Actinic keratosis; Medicine; Context (archaeology); Keratosis; Dermatology; Clinical trial; Perspective (graphical); Medical physics; Lesion; Clinical Practice; Confounding; Intensive care medicine; Surgery; Pathology; Physical therapy; Computer science; Artificial intelligence","score_opus":0.16506689133309646,"score_gpt":0.3763824648101496,"score_spread":0.21131557347705313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521785556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878775,0.0027088483,0.000028073679,0.009051239,0.00008269609,0.00020151571,0.0000049268865,0.000009697312,0.00003548737],"genre_scores_gemma":[0.98887813,0.010279129,0.00008397521,0.00060336565,0.000015172683,0.000021269056,5.6549476e-7,0.0000075895755,0.00011082188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852306,0.00087096414,0.00030901068,0.00013485561,0.000044044464,0.000118097414],"domain_scores_gemma":[0.99651814,0.0031712109,0.00010760246,0.00014763321,0.000027068327,0.00002836477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007712594,0.00008312803,0.0005138629,0.000113704424,0.000025734753,0.000002446526,0.000025432697,0.0000927089,0.00005587441],"category_scores_gemma":[0.0006401512,0.0000467763,0.00004502964,0.000076070384,0.00013349563,0.000058454945,0.000014882879,0.000053115524,0.0000056653776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03083695,0.00009709227,0.74712616,0.000021808657,0.00017280315,0.00012485008,0.00049532007,3.9546013e-8,0.17250998,0.00016758757,0.0010870226,0.04736037],"study_design_scores_gemma":[0.0042026667,0.00017022796,0.70456856,0.00010416949,0.000014968743,0.0001449345,0.000029949677,0.0000011954786,0.2732513,0.00026343318,0.017184082,0.00006451799],"about_ca_topic_score_codex":0.000009760344,"about_ca_topic_score_gemma":0.0000077673085,"teacher_disagreement_score":0.10074132,"about_ca_system_score_codex":0.000010848323,"about_ca_system_score_gemma":0.00004222238,"threshold_uncertainty_score":0.19074821},"labels":[],"label_agreement":null},{"id":"W2584044598","doi":"10.1007/s13555-016-0168-8","title":"Acne and Rosacea","year":2017,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Windsor; Western University","funders":"","keywords":"Rosacea; Acne; Dermatology; Medicine; Propionibacterium acnes; Erythema; Disease; Population; Rhinophyma; Pathology","score_opus":0.11968321473126704,"score_gpt":0.42119099341698174,"score_spread":0.3015077786857147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584044598","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037095495,0.99735856,0.000002069414,0.0003039635,0.0001224566,0.00045817415,0.000008280243,0.000025674688,0.001349877],"genre_scores_gemma":[0.0003483526,0.99814117,0.000024618375,0.0002784408,0.00007959136,0.000041181404,0.00006424322,0.00002360485,0.0009987873],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993009,0.00005698148,0.00016722265,0.00025292955,0.000042223972,0.00017975207],"domain_scores_gemma":[0.99941623,0.000065958884,0.00012409715,0.00027824016,0.000011464504,0.0001040188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000046057696,0.00026426234,0.0014239865,0.00006982038,0.00023361083,0.00002485412,0.000049774237,0.00041298085,0.000026403102],"category_scores_gemma":[0.000007840821,0.00014990538,0.0001303492,0.000021355114,0.00017382616,0.000035567184,0.000031086245,0.0002043517,0.000025165644],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020996573,0.000040962146,0.000317133,0.0023989754,0.00043175966,0.0004441624,0.000033569668,3.8670966e-10,1.0732792e-7,0.0001413334,0.0008607318,0.99531025],"study_design_scores_gemma":[0.0010608104,0.00009650636,0.00012567543,0.0016601315,0.00044778996,0.0052964753,0.0000026692926,0.0000011559218,0.0000016539291,0.00006167604,0.99111044,0.00013501976],"about_ca_topic_score_codex":0.0000053658378,"about_ca_topic_score_gemma":6.821467e-7,"teacher_disagreement_score":0.99517524,"about_ca_system_score_codex":0.0000049130385,"about_ca_system_score_gemma":0.00006015049,"threshold_uncertainty_score":0.61129636},"labels":[],"label_agreement":null},{"id":"W2743134732","doi":"10.1007/s13555-017-0196-z","title":"Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy","year":2017,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"LEO Pharma","keywords":"Betamethasone dipropionate; Psoriasis; Calcipotriol; Medicine; Combination therapy; Pharmacology; Fixed-dose combination; Corticosteroid; Dosing; Dermatology; Internal medicine","score_opus":0.029347536833552235,"score_gpt":0.2818068940366248,"score_spread":0.25245935720307255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743134732","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21536331,0.78328645,0.0000056246713,0.00001619489,0.0005291336,0.0007087408,0.000027671953,0.000030470595,0.0000324162],"genre_scores_gemma":[0.07796012,0.9214997,0.000021723736,0.000036473648,0.000015935328,0.00010120922,0.0002259482,0.000039253926,0.00009960695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99789536,0.0006974897,0.0005534052,0.0004951272,0.000033636632,0.00032499683],"domain_scores_gemma":[0.9982023,0.0005547557,0.0006876091,0.00046994587,0.000045603585,0.000039758103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018701176,0.0005420425,0.0019665495,0.000281425,0.00040035535,0.00003262753,0.0002038782,0.0009265413,0.000014661516],"category_scores_gemma":[0.000022853315,0.00042568805,0.00018812783,0.000054000106,0.00067907025,0.00013801373,0.000084922074,0.00029545836,0.000012958644],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010687141,0.00014131243,0.0017983451,0.0020379527,0.00169221,0.000074086136,0.0003548967,1.5896656e-8,0.001522201,0.00026630476,0.000038719354,0.9919671],"study_design_scores_gemma":[0.020644957,0.0010577132,0.037497193,0.0054847486,0.0018281823,0.00483402,0.00006350206,0.0000037742666,0.010129989,0.00031719694,0.91647154,0.0016671717],"about_ca_topic_score_codex":0.000012749908,"about_ca_topic_score_gemma":0.0000026499526,"teacher_disagreement_score":0.99029994,"about_ca_system_score_codex":0.0000132164705,"about_ca_system_score_gemma":0.00007454127,"threshold_uncertainty_score":0.9998195},"labels":[],"label_agreement":null},{"id":"W2766193813","doi":"10.1007/s13555-017-0204-3","title":"Patients’ Perspectives on the Impact of Genital Psoriasis: A Qualitative Study","year":2017,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre","funders":"LEO Pharma; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Sex organ; Itching; Psoriasis; Psychosocial; Quality of life (healthcare); Sexual desire; Dermatology; Psychiatry; Human sexuality","score_opus":0.03300738132252601,"score_gpt":0.32895274583850254,"score_spread":0.29594536451597653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766193813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550605,0.0027936941,0.0000014061146,0.00021213939,0.00017483922,0.0003951672,0.00005148353,0.00001522118,0.0008499867],"genre_scores_gemma":[0.9993972,0.00039789538,0.000002811009,0.00002398919,0.0000124528,0.0000528457,0.000012860596,0.000008804172,0.00009113565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987458,0.0006637425,0.00016444486,0.0002172316,0.000025835188,0.0001829227],"domain_scores_gemma":[0.99895114,0.00034999635,0.00020131363,0.00041142467,0.000072799856,0.000013332552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016261211,0.00017635159,0.0003057245,0.000058575853,0.00061310007,0.000016709264,0.00022939063,0.0001275713,0.0001515635],"category_scores_gemma":[0.00006859237,0.00009528576,0.00012880395,0.000028908526,0.0004468089,0.000070991744,0.00003638744,0.00011625582,0.00004663917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037914703,0.004254484,0.55347717,0.0000046174805,0.006162844,0.000021670121,0.39301887,2.923191e-7,0.0024383941,0.007128059,0.0009301137,0.028772052],"study_design_scores_gemma":[0.0083097145,0.0021778168,0.8966418,0.000009235188,0.00008541334,0.000037707352,0.08396869,6.007928e-7,0.007123488,0.0012523794,0.00018487038,0.00020831304],"about_ca_topic_score_codex":0.00015542172,"about_ca_topic_score_gemma":0.000008944178,"teacher_disagreement_score":0.34316462,"about_ca_system_score_codex":0.000010390456,"about_ca_system_score_gemma":0.000023036617,"threshold_uncertainty_score":0.4715532},"labels":[],"label_agreement":null},{"id":"W2773144918","doi":"10.1007/s13555-017-0211-4","title":"Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies","year":2017,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Centre de Recherche Dermatologique du Québec Métropolitain; Dalhousie University; Dermatrials Research; Université Laval","funders":"Novartis Pharma","keywords":"Secukinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Plaque psoriasis; Internal medicine; Dermatology; Psoriatic arthritis","score_opus":0.03147621493430002,"score_gpt":0.30312334748383063,"score_spread":0.2716471325495306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773144918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963143,0.0027299502,0.00000482315,0.00027459057,0.000057415178,0.00042318838,0.00016901239,0.0000025211766,0.00002418317],"genre_scores_gemma":[0.9951921,0.004583311,0.000015220973,0.000065469794,0.0000036001015,0.00005905328,0.000071675,0.0000049570617,0.00000462236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985967,0.00055992475,0.00044495804,0.00018572184,0.00004270955,0.00016994958],"domain_scores_gemma":[0.9984313,0.0005482562,0.00046981857,0.0004672149,0.00007491052,0.000008458319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014068167,0.00017291313,0.0009102524,0.00026214623,0.0001049225,0.0000032663056,0.00027913143,0.00007895305,0.0000075965904],"category_scores_gemma":[0.00003100777,0.00009462034,0.0001566824,0.00033036174,0.0004126567,0.000038596136,0.000018796889,0.00005292045,6.5827874e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006526818,0.00349195,0.8910244,0.000019180863,0.00711249,0.000015880722,0.034198612,0.000045921763,0.0007501528,0.00018492609,0.000020055084,0.0566096],"study_design_scores_gemma":[0.01285033,0.0012772909,0.97013694,0.000012297526,0.0008893723,0.000008526712,0.0017199081,0.000010319873,0.012774337,0.000056232082,0.00016546673,0.00009899614],"about_ca_topic_score_codex":0.0005092968,"about_ca_topic_score_gemma":0.002653212,"teacher_disagreement_score":0.07911251,"about_ca_system_score_codex":0.00001112779,"about_ca_system_score_gemma":0.00001952394,"threshold_uncertainty_score":0.38585055},"labels":[],"label_agreement":null},{"id":"W2791688326","doi":"10.1007/s13555-018-0225-6","title":"Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States","year":2018,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Medicaid; Medical prescription; Angioedema; Cohort; Pediatrics; Health care; Incidence (geometry); Pharmacy; Diagnosis code; Internal medicine; Population; Family medicine; Environmental health","score_opus":0.017023850962813374,"score_gpt":0.2748602357602909,"score_spread":0.2578363847974775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791688326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98748356,0.0038420998,0.000084219224,0.007906051,0.000024061452,0.00053270586,0.00000734453,0.00003706925,0.00008286108],"genre_scores_gemma":[0.99037635,0.008368815,0.000009403842,0.0009102142,0.00005867966,0.00003726308,0.0002096778,0.000013858016,0.000015759015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990257,0.00023295665,0.00019824882,0.00021297383,0.000098940865,0.0002311785],"domain_scores_gemma":[0.99954545,0.00008962204,0.00005508096,0.00018588435,0.000033117827,0.00009086949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007852294,0.00014605638,0.0002510241,0.00014445858,0.0002555711,0.000018306242,0.000051531155,0.00015226241,0.000036605496],"category_scores_gemma":[0.000008553078,0.00007982013,0.000018681034,0.0002018126,0.00041182476,0.000030874868,0.000009354061,0.00019463043,0.0000024606488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046746683,0.00012443123,0.9857571,0.000010292903,0.0006827767,0.00095191906,0.0073624244,0.0000017898082,0.00001673131,0.0016065516,0.000028224846,0.0029902956],"study_design_scores_gemma":[0.008420495,0.0019073877,0.96400577,0.0001652361,0.00040831137,0.019511163,0.001346352,0.0018719668,0.0002256043,0.00040118265,0.0015743392,0.00016217055],"about_ca_topic_score_codex":0.00044968372,"about_ca_topic_score_gemma":0.0005903884,"teacher_disagreement_score":0.021751305,"about_ca_system_score_codex":0.000030642695,"about_ca_system_score_gemma":0.000057653957,"threshold_uncertainty_score":0.32549706},"labels":[],"label_agreement":null},{"id":"W2806716877","doi":"10.1007/s13555-018-0242-5","title":"Building a Citizen Pscientist: Advancing Patient-Centered Psoriasis Research by Empowering Patients as Contributors and Analysts","year":2018,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Mental Health and Patient Involvement","field":"Health Professions","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; National Institutes of Health; LEO Pharma; Mallinckrodt Pharmaceuticals; Dermira; Regeneron Pharmaceuticals; University of Pennsylvania; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases; Celgene; Coherus Biosciences; National Psoriasis Foundation; Valeant Pharmaceuticals International; Sanofi; Patient-Centered Outcomes Research Institute; Ortho Dermatologics; Eli Lilly and Company; Pfizer; Amgen","keywords":"Crowdsourcing; Cloud computing; Big data; Medicine; Citizen science; The Internet; Data science; Disease; Computer science; Medical education; World Wide Web; Pathology; Data mining","score_opus":0.10161376234067283,"score_gpt":0.4637016269208175,"score_spread":0.3620878645801447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806716877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948115,0.0018180428,0.00008259156,0.00037150047,0.0010512584,0.0010487535,0.00006126483,0.00004286557,0.0007122728],"genre_scores_gemma":[0.995663,0.0011531356,0.00015658143,0.0026710362,0.00006958565,0.00011749366,0.000101930666,0.000019276782,0.00004797706],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968054,0.0009293234,0.00055414275,0.00043525238,0.00030912817,0.0009667355],"domain_scores_gemma":[0.99848807,0.00045311454,0.0001978628,0.00021049354,0.00029577324,0.00035468795],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00072300766,0.00017838451,0.00032498874,0.00022065651,0.0021549372,0.000019014755,0.00011763977,0.00019780827,0.00010876048],"category_scores_gemma":[0.00008217046,0.00015523942,0.00002895415,0.00025829798,0.00028900965,0.00014009929,0.00015224436,0.00040201072,0.00005536723],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007808334,0.00021572545,0.9286996,0.0002615731,0.00007453273,0.0000132923415,0.007880556,2.6828296e-8,0.002149816,0.0009972466,0.009263398,0.049663372],"study_design_scores_gemma":[0.03878071,0.006718292,0.094027966,0.0029349104,0.0000679304,0.000088525645,0.012368764,0.00054622977,0.070882015,0.0155824255,0.7562632,0.0017390456],"about_ca_topic_score_codex":0.00023832488,"about_ca_topic_score_gemma":0.000071965944,"teacher_disagreement_score":0.8346717,"about_ca_system_score_codex":0.00008978294,"about_ca_system_score_gemma":0.00007762759,"threshold_uncertainty_score":0.99914414},"labels":[],"label_agreement":null},{"id":"W2905794790","doi":"10.1007/s13555-018-0279-5","title":"Clinical Goals and Barriers to Effective Psoriasis Care","year":2018,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Université de Sherbrooke; Dermatrials Research; Probity Medical Research","funders":"Cilag; Allergan; Medac; Astellas Pharma; Glenmark Pharmaceuticals; National Psoriasis Foundation; Pfizer; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; University of Connecticut; Eli Lilly and Company; Cardiff University; Celgene; LEO Pharma; Ortho Dermatologics; Gilead Sciences; Sanofi; GlaxoSmithKline; Galderma; Bristol-Myers Squibb; Meiji Seika Pharma; Coherus Biosciences; UCB Pharma; Valeant Pharmaceuticals International; Amgen","keywords":"Psoriasis; Pace; Medicine; Disease; Intensive care medicine; Alternative medicine; Business; Family medicine; Dermatology; Pathology","score_opus":0.013536864592358354,"score_gpt":0.2924971744397164,"score_spread":0.27896030984735803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905794790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802159,0.017004719,0.000030112556,0.00044295192,0.0010109552,0.00037176558,0.000026536727,0.000056574958,0.00084048853],"genre_scores_gemma":[0.9962238,0.0018102499,0.00009241926,0.001556043,0.000086435706,0.00006973917,0.000022294264,0.00001285672,0.00012617491],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986802,0.00045786265,0.00020532933,0.00036674156,0.000015250057,0.00027464377],"domain_scores_gemma":[0.9993028,0.00029963627,0.000049998533,0.00018992343,0.00006162128,0.00009603569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012950938,0.00018400763,0.0003798307,0.00008282472,0.00036212802,0.00001039427,0.00008869925,0.00038032926,0.00021777643],"category_scores_gemma":[0.000064890286,0.00014514392,0.000063748426,0.0000808649,0.0004894526,0.000044720677,0.00004482866,0.00011436485,0.0002367664],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011281844,0.000041062987,0.49177825,0.000009240335,0.0006515545,0.000022810984,0.0042125667,1.887052e-8,0.0039953403,0.00077211845,0.0017891391,0.49559972],"study_design_scores_gemma":[0.01024244,0.0017863598,0.52453303,0.000032283733,0.00019112321,0.0007191413,0.0018606472,9.0336147e-7,0.12131468,0.0008129285,0.3379486,0.0005578791],"about_ca_topic_score_codex":0.000019131196,"about_ca_topic_score_gemma":0.000027972712,"teacher_disagreement_score":0.49504185,"about_ca_system_score_codex":0.0000067237925,"about_ca_system_score_gemma":0.000029461502,"threshold_uncertainty_score":0.5918797},"labels":[],"label_agreement":null},{"id":"W2942826343","doi":"10.1007/s13555-019-0298-x","title":"The Scar Bane, Without the Pain: A New Approach in the Treatment of Elevated Scars: Thermomechanical Delivery of Topical Triamcinolone Acetonide and 5-Fluorouracil","year":2019,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatologic Treatments and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Triamcinolone acetonide; Medicine; Keloid; Visual analogue scale; Scars; Surgery; Adverse effect; Transdermal; Refractory (planetary science); Corticosteroid; Anesthesia; Internal medicine; Pharmacology","score_opus":0.037352579461313526,"score_gpt":0.2999429815741568,"score_spread":0.26259040211284324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942826343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98131746,0.010663993,0.0000208084,0.0065609175,0.000029255276,0.0009896875,0.0000019291092,0.000008664533,0.00040729708],"genre_scores_gemma":[0.9856078,0.013688732,0.00006144211,0.00034387046,0.000015594745,0.000044941084,0.0000055393934,0.000007554985,0.00022454165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984637,0.000644345,0.00028793508,0.00019886726,0.00017024967,0.00023491241],"domain_scores_gemma":[0.99862057,0.000818853,0.00008659637,0.00038230853,0.000044609846,0.000047084744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039535292,0.00014966403,0.00045580041,0.000044791253,0.0001028973,0.000012996252,0.00015024118,0.00015387501,0.00001684412],"category_scores_gemma":[0.00002054024,0.00005329087,0.00007967958,0.00013171199,0.00036434727,0.000025598574,0.000021899485,0.00015678763,0.000002494271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051877503,0.001835497,0.68881357,0.00009956294,0.001133754,0.00015041596,0.008762443,0.0000017762973,0.004725439,0.0066680857,0.0004449275,0.2821768],"study_design_scores_gemma":[0.061087564,0.007948011,0.8391082,0.00020037092,0.00043780223,0.0129082715,0.016897816,0.0057234876,0.024072224,0.0051575233,0.025883688,0.000575029],"about_ca_topic_score_codex":0.00013846958,"about_ca_topic_score_gemma":0.000016017762,"teacher_disagreement_score":0.28160176,"about_ca_system_score_codex":0.0000131426405,"about_ca_system_score_gemma":0.0000751621,"threshold_uncertainty_score":0.21731387},"labels":[],"label_agreement":null},{"id":"W2956154159","doi":"10.1007/s13555-019-0312-3","title":"Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis","year":2019,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; National Institutes of Health; LEO Pharma; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; National Institute of Allergy and Infectious Diseases; Celgene; National Psoriasis Foundation; Valeant Pharmaceuticals International; Sanofi; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer; Amgen","keywords":"Atopic dermatitis; Medicine; Dermatology; MEDLINE; Web of science; Pathology; Meta-analysis","score_opus":0.07293752344279375,"score_gpt":0.43408377549210075,"score_spread":0.361146252049307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956154159","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007435633,0.9945032,0.00031691534,0.00060900336,0.00043754972,0.0014084121,0.000013926628,0.000070266455,0.0018971587],"genre_scores_gemma":[0.0007215731,0.9944719,0.00184552,0.0023110094,0.000046850833,0.00029498964,0.00006840761,0.000052986452,0.00018677299],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99718696,0.0009328405,0.00074477453,0.0005613742,0.00010840878,0.0004656457],"domain_scores_gemma":[0.99850714,0.0006110144,0.00020551658,0.00043741654,0.000047985464,0.00019094371],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022094006,0.00047900333,0.0027804049,0.0006206833,0.000086967724,0.000021027312,0.00018602483,0.0007208149,0.00011510321],"category_scores_gemma":[0.00010596118,0.00038943556,0.00029896683,0.00040518158,0.00012402097,0.00008656336,0.00007866067,0.0006118268,0.00013892433],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021276992,0.00012030799,0.007521466,0.0075954846,0.00038300335,0.000879069,0.00023352724,8.007911e-8,4.9239304e-7,0.000486452,0.0018356242,0.98092324],"study_design_scores_gemma":[0.0010258835,0.000029687204,0.006586248,0.0033363278,0.00031673143,0.007828353,0.00003692491,0.000005830772,0.000019190718,0.0003797557,0.9800799,0.0003551824],"about_ca_topic_score_codex":0.0000111606005,"about_ca_topic_score_gemma":0.000005984402,"teacher_disagreement_score":0.98056805,"about_ca_system_score_codex":0.000039628958,"about_ca_system_score_gemma":0.00032760127,"threshold_uncertainty_score":0.99985576},"labels":[],"label_agreement":null},{"id":"W2981554886","doi":"10.1007/s13555-019-00333-2","title":"Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children’s Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis","year":2019,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; LEO Pharma; Incyte; Regeneron Pharmaceuticals; Sanofi; Valeant Pharmaceuticals International; Pfizer; Eli Lilly and Company","keywords":"Dermatology Life Quality Index; Eczema Area and Severity Index; Atopic dermatitis; Medicine; Quality of life (healthcare); Placebo; Dermatology; Psoriasis; Pathology","score_opus":0.013267611128179596,"score_gpt":0.2682726440320314,"score_spread":0.2550050329038518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981554886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844405,0.010250633,0.00016468417,0.003199031,0.0001418232,0.0015068034,0.000019742309,0.000074461306,0.00020234042],"genre_scores_gemma":[0.9905798,0.00054042676,0.000060338425,0.008553655,0.000018688239,0.00013559447,0.000054946388,0.00003429025,0.000022270524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979105,0.00028885822,0.00054421125,0.0005510112,0.00018916345,0.00051624654],"domain_scores_gemma":[0.9989317,0.00012500376,0.0001808066,0.00039422433,0.00011625645,0.00025201496],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011234041,0.00034638008,0.0008850701,0.00027315892,0.00014654158,0.000018027235,0.00010246667,0.00046555535,0.000037258942],"category_scores_gemma":[0.00006413519,0.000278764,0.00008150482,0.00018112341,0.0003635606,0.0001730049,0.00004833796,0.00035164674,0.000012320291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023071168,0.00033689543,0.9928528,0.00030889982,0.0002074618,0.00017255849,0.00059135666,0.0000010862902,0.00004188546,0.0012557508,0.0006740116,0.0012501628],"study_design_scores_gemma":[0.01406365,0.00015336793,0.97726226,0.00024328195,0.000049007558,0.0047676447,0.0002585232,0.00013704722,0.00068436534,0.0007160914,0.001349714,0.00031506282],"about_ca_topic_score_codex":0.000030981446,"about_ca_topic_score_gemma":0.00007570163,"teacher_disagreement_score":0.015590571,"about_ca_system_score_codex":0.0000188482,"about_ca_system_score_gemma":0.00014836372,"threshold_uncertainty_score":0.99996644},"labels":[],"label_agreement":null},{"id":"W2991027094","doi":"10.1007/s13555-019-00338-x","title":"Pathogenesis, Clinical Signs and Treatment Recommendations in Brittle Nails: A Review","year":2019,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Fragility; Nail (fastener); Medicine; Dermatology; Brittleness; Population; Dentistry; Nail plate; Chemistry; Materials science; Environmental health","score_opus":0.20369369014775887,"score_gpt":0.47578422243440116,"score_spread":0.27209053228664226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991027094","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027450445,0.99675876,9.0678793e-7,0.000897374,0.000108985696,0.0016880567,0.000079453894,0.0000176058,0.00017432989],"genre_scores_gemma":[0.0000531092,0.99795836,0.000056461125,0.0009398709,0.000033598968,0.0002669823,0.00049426936,0.000027108745,0.00017026656],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99836487,0.0003757754,0.0006211413,0.0004038924,0.000048731494,0.00018559814],"domain_scores_gemma":[0.99907815,0.00030165838,0.00017617091,0.00029373966,0.000018199042,0.00013206678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104566716,0.00030154912,0.0021603233,0.00010171674,0.00005162631,0.000008522935,0.000041699852,0.00027804673,0.000104082676],"category_scores_gemma":[0.000020057445,0.00019894545,0.00031201323,0.00011356645,0.00007296091,0.000028202443,0.000020008085,0.00014856212,0.000060157923],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025382209,0.0004390316,0.00632074,0.006245377,0.00046517357,0.00022292668,0.000008990867,3.6711423e-10,2.4455135e-8,0.000044198485,0.000579388,0.98564875],"study_design_scores_gemma":[0.0022353395,0.00035621916,0.0007608907,0.013503888,0.0013552862,0.0012275431,0.0000035321743,4.577596e-7,8.72745e-8,0.000021995174,0.9803813,0.00015343347],"about_ca_topic_score_codex":0.000015820431,"about_ca_topic_score_gemma":0.000011075309,"teacher_disagreement_score":0.9854953,"about_ca_system_score_codex":0.00003118847,"about_ca_system_score_gemma":0.00016584087,"threshold_uncertainty_score":0.81127596},"labels":[],"label_agreement":null},{"id":"W2991496398","doi":"10.1007/s13555-019-00340-3","title":"Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure","year":2019,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Cilag; Sanofi Genzyme; Genentech; Medac; Mitsubishi Tanabe Pharma Corporation; Sanofi; Kyowa Hakko Kirin; LEO Fondet; Astellas Pharma; Regeneron Pharmaceuticals; Mylan; Eli Lilly and Company; Purdue Pharma; Sun Pharma; Dermira; Purdue University; Coherus Biosciences; UCB Pharma; Valeant Pharmaceuticals International; Baxalta; Celgene; Pfizer; Biogen; GlaxoSmithKline; Amgen; Meiji Seika Pharma; Galderma; LEO Pharma; Ortho Dermatologics; Allergan; AstraZeneca; Samsung; Bristol-Myers Squibb","keywords":"Ixekizumab; Psoriasis; Medicine; Dermatology; Psoriatic arthritis","score_opus":0.009983924242019151,"score_gpt":0.21147808006893778,"score_spread":0.20149415582691863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991496398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637043,0.0004978191,0.000008040979,0.00008134428,0.00031589068,0.0011000683,0.0015383335,0.000014799378,0.00007328549],"genre_scores_gemma":[0.99861807,0.0002009349,0.00015757504,0.00014250346,0.0000065820495,0.00010629284,0.000543169,0.000019907182,0.0002049558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872077,0.00015156288,0.00041689488,0.00039197798,0.00004047631,0.0002783108],"domain_scores_gemma":[0.99923164,0.00017087178,0.00015289828,0.00031607968,0.000093761126,0.00003472313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004073018,0.00022251937,0.00058312924,0.00016144385,0.000039582377,0.0000040782697,0.00010998745,0.0002663248,0.000061833416],"category_scores_gemma":[0.000010345745,0.00017318863,0.000075446216,0.00011380171,0.00005478901,0.00005553594,0.000022994003,0.000054419655,0.00002543269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13229549,0.0008464021,0.65633315,0.000022703465,0.0016097631,0.000017572704,0.025553431,0.000117197334,0.0023973156,0.000134595,0.0003702696,0.18030213],"study_design_scores_gemma":[0.057864185,0.004099513,0.881565,0.0001294234,0.00009953794,0.000017382677,0.00066880556,0.0000035216158,0.051812656,0.000096066084,0.0032716535,0.0003722669],"about_ca_topic_score_codex":0.00029574873,"about_ca_topic_score_gemma":0.00013724218,"teacher_disagreement_score":0.22523184,"about_ca_system_score_codex":0.000023761058,"about_ca_system_score_gemma":0.00003198416,"threshold_uncertainty_score":0.70624274},"labels":[],"label_agreement":null},{"id":"W3000932825","doi":"10.1007/s13555-019-00348-9","title":"Correction to: Pathogenesis, Clinical Signs and Treatment Recommendations in Brittle Nails: A Review","year":2020,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Medicine; Psychology","score_opus":0.12100159015021543,"score_gpt":0.4491822011076449,"score_spread":0.32818061095742945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000932825","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010479519,0.9954211,0.000005219447,0.0023800319,0.00031470935,0.0015776006,0.00005070696,0.000026079791,0.0001197669],"genre_scores_gemma":[0.00006903308,0.9971981,0.00007147451,0.001783304,0.000055956618,0.00037208802,0.00032304076,0.000023884817,0.00010309063],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850726,0.00034500306,0.00055221526,0.0003996133,0.000045987126,0.00014994129],"domain_scores_gemma":[0.9991691,0.0002898242,0.00012930574,0.00017757408,0.000018624269,0.00021558322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000073414594,0.00026627732,0.0017150042,0.00009169261,0.000063779684,0.000009254429,0.00003335293,0.00016825699,0.00006231125],"category_scores_gemma":[0.000056892564,0.00018823863,0.00023891566,0.00018934162,0.000041551375,0.000022757511,0.000019159277,0.00015289073,0.00004546659],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004378236,0.00030442054,0.0026918412,0.0018933112,0.0003090331,0.0002842117,0.000019406174,1.0531446e-9,5.4802282e-8,0.000010555898,0.003708266,0.9907351],"study_design_scores_gemma":[0.0012731109,0.0005661357,0.0006966974,0.011314395,0.0008537596,0.0012479646,0.0000057150355,0.0000015185256,2.3249463e-7,0.000008654382,0.98389465,0.00013715372],"about_ca_topic_score_codex":0.000026078369,"about_ca_topic_score_gemma":0.00003043624,"teacher_disagreement_score":0.99059796,"about_ca_system_score_codex":0.000042677195,"about_ca_system_score_gemma":0.00014457986,"threshold_uncertainty_score":0.76761484},"labels":[],"label_agreement":null},{"id":"W3003496094","doi":"10.1007/s13555-020-00356-0","title":"Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Medicine; Anxiety; Embarrassment; Disease; Atopic dermatitis; Depression (economics); Population; Cross-sectional study; Sleep disorder; Quality of life (healthcare); Psychiatry; Clinical psychology; Psychology; Immunology; Pathology; Environmental health; Cognition","score_opus":0.029160031735762943,"score_gpt":0.4033856263678835,"score_spread":0.3742255946321206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003496094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985043,0.00082256756,0.00018658061,0.00014790079,0.000022862107,0.0002503531,0.000011600905,0.000010878297,0.00004297099],"genre_scores_gemma":[0.99912816,0.000033474607,0.0002977916,0.0004661104,0.000007198688,0.000009641839,0.00005121086,0.000004833585,0.0000015987578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897414,0.00024355938,0.00038860008,0.00016537707,0.00013083307,0.00009751495],"domain_scores_gemma":[0.9995052,0.00007226865,0.00016136833,0.000068944726,0.00015231429,0.000039856463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005981784,0.000092913855,0.00041576888,0.00016855284,0.000047697496,0.00000550454,0.000039915853,0.00007751786,0.000041882446],"category_scores_gemma":[0.00004128159,0.000078872785,0.00007457893,0.0003243246,0.00015886428,0.00009475711,0.0000147232795,0.00012574479,3.3535522e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012588316,0.00042647147,0.9744786,0.00013355199,0.00031851517,0.000031995944,0.023577647,0.000009782167,0.00020422663,0.000020657093,0.0000040916825,0.00066856755],"study_design_scores_gemma":[0.0029487028,0.000079957776,0.9811914,0.00001671275,0.00010790856,0.000031071024,0.008433275,0.006951752,0.00015338887,0.000023277109,0.0000010495676,0.0000614804],"about_ca_topic_score_codex":0.00005468425,"about_ca_topic_score_gemma":0.000016217557,"teacher_disagreement_score":0.015144372,"about_ca_system_score_codex":0.000011976636,"about_ca_system_score_gemma":0.00005070403,"threshold_uncertainty_score":0.32163388},"labels":[],"label_agreement":null},{"id":"W3012894524","doi":"10.1007/s13555-020-00367-x","title":"Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Guenther Dermatology Research Centre","funders":"Cilag; LEO Pharma; Mitsubishi Tanabe Pharma Corporation; Sanofi; Kyowa Hakko Kirin; Biogen; Pfizer; Incyte; Fresenius Medical Care North America; Sun Pharma; Dermira; Samsung; UCB Pharma; Valeant Pharmaceuticals International; Medac; Baxalta; Hexal AG; Celgene; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Amgen; Galderma; Eli Lilly and Company; GlaxoSmithKline","keywords":"Ixekizumab; Medicine; Dosing; Dermatology Life Quality Index; Psoriasis; Psoriasis Area and Severity Index; Imputation (statistics); Internal medicine; Randomized controlled trial; Quality of life (healthcare); Tolerability; Adverse effect; Dermatology; Secukinumab; Psoriatic arthritis","score_opus":0.03507305455433154,"score_gpt":0.2892764760050546,"score_spread":0.25420342145072305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012894524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9540812,0.040141564,0.0001135528,0.0029619022,0.00027299055,0.0019107779,0.00038584782,0.00002802962,0.00010415118],"genre_scores_gemma":[0.97878903,0.019533169,0.000052319872,0.0012407872,0.0000437886,0.000099239274,0.0001918761,0.000015836133,0.00003397178],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99554646,0.0026082834,0.001074273,0.00045876802,0.000046847068,0.00026537443],"domain_scores_gemma":[0.99241036,0.0068947733,0.0003883344,0.00022713254,0.00003612004,0.000043288273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008219418,0.00031446968,0.0028205032,0.000060793296,0.00014811265,0.000024955396,0.00014682992,0.00036025702,0.000063383646],"category_scores_gemma":[0.0007817329,0.0001890457,0.00020505484,0.0001289117,0.00035621875,0.00009593211,0.000059310092,0.00019228795,0.00001158683],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9421729,0.00023922314,0.0025752026,0.000011497983,0.0033527068,0.000049765604,0.0076645487,0.000011950267,0.003614033,0.00056522636,0.0002895237,0.03945342],"study_design_scores_gemma":[0.976521,0.00029963825,0.013349531,0.000071361166,0.0005792592,0.00008139008,0.00020987041,0.000023640581,0.0063109966,0.0010074673,0.0012772934,0.0002685262],"about_ca_topic_score_codex":0.00013518787,"about_ca_topic_score_gemma":0.00003700644,"teacher_disagreement_score":0.0391849,"about_ca_system_score_codex":0.000007940145,"about_ca_system_score_gemma":0.000056047436,"threshold_uncertainty_score":0.770906},"labels":[],"label_agreement":null},{"id":"W3015065138","doi":"10.1007/s13555-020-00373-z","title":"Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence","year":2020,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Sanofi Genzyme; AstraZeneca; Allergan; Ortho Dermatologics; LEO Pharma; National Psoriasis Foundation; Pfizer; Biogen; Incyte; Regeneron Pharmaceuticals; Mylan; Castle Biosciences; Novartis Pharmaceuticals Corporation; Dermira; Sun Pharma; Celgene; Sanofi; Galderma; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; Genentech; Valeant Pharmaceuticals International; Amgen","keywords":"Secukinumab; Medicine; Disease; Intensive care medicine; Psoriasis; Psoriatic arthritis; Clinical trial; Immunology; Dermatology; Internal medicine","score_opus":0.04918913432521317,"score_gpt":0.2794191380912929,"score_spread":0.23023000376607972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015065138","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010137592,0.997149,7.034439e-7,0.00024637906,0.00019492663,0.001207614,0.000052351064,0.000012882089,0.00012241548],"genre_scores_gemma":[0.0026695759,0.9968738,0.0000147588125,0.000074180076,0.000008436411,0.00024860736,0.00003865193,0.000022995364,0.000048977294],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997853,0.00079571584,0.00067804696,0.00038338455,0.000044186745,0.00024566991],"domain_scores_gemma":[0.99851227,0.00038660312,0.00060441426,0.0004353987,0.000042707627,0.000018605044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007513914,0.00041419835,0.0022906873,0.000111009096,0.000077637465,0.0000025509441,0.00021810911,0.00035120765,0.00013946145],"category_scores_gemma":[0.000023730929,0.000214652,0.00032558898,0.00031845836,0.0002156785,0.00004033622,0.000042688465,0.00016012049,0.000028949606],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015229495,0.00022857804,0.00034457826,0.014299913,0.001136557,0.000047879603,0.000633004,6.597876e-8,0.000008610054,0.00009001682,0.00009932943,0.98295915],"study_design_scores_gemma":[0.0013679153,0.00054806744,0.00002752656,0.05234702,0.0008348861,0.0009895546,0.000039268463,2.5162137e-7,0.0005444487,0.0000074532045,0.94308037,0.00021321389],"about_ca_topic_score_codex":0.000049801103,"about_ca_topic_score_gemma":0.000013342054,"teacher_disagreement_score":0.98274595,"about_ca_system_score_codex":0.00004323792,"about_ca_system_score_gemma":0.00023401786,"threshold_uncertainty_score":0.87532544},"labels":[],"label_agreement":null},{"id":"W3025530165","doi":"10.1007/s13555-020-00383-x","title":"Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Medicine; Psoriasis; Ixekizumab; Dermatology; Nail (fastener); Psoriasis Area and Severity Index; Ustekinumab; Plaque psoriasis; Internal medicine; Secukinumab; Psoriatic arthritis; Disease; Adalimumab","score_opus":0.029726125524352883,"score_gpt":0.266550465056885,"score_spread":0.23682433953253212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025530165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99431795,0.0018932971,0.000016018796,0.0014347709,0.00026222778,0.001594116,0.0003584273,0.00007203913,0.000051139432],"genre_scores_gemma":[0.9978261,0.00022396383,0.00010305284,0.0012568566,0.00003079995,0.00016035527,0.00033616534,0.000039230625,0.000023488947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970198,0.0007044139,0.00063057785,0.0009986907,0.00007857729,0.00056793255],"domain_scores_gemma":[0.9989559,0.0003326779,0.00013414024,0.00037031126,0.000064446845,0.00014249209],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014266634,0.00049027224,0.00095398986,0.00024087769,0.00020176473,0.000037065805,0.00022824443,0.00037767235,0.00005095946],"category_scores_gemma":[0.00006933912,0.00040125704,0.00005193504,0.0004993947,0.000107686894,0.00015366013,0.00008888646,0.0003339264,0.00009478485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21607822,0.012197364,0.38077036,0.000025344649,0.0015922796,0.0005493129,0.053480987,0.00008504284,0.00080684153,0.000045472665,0.0006544678,0.33371434],"study_design_scores_gemma":[0.22870106,0.006893374,0.75416064,0.00010397514,0.00015978652,0.00006110446,0.0017950278,0.00003454591,0.0029263757,0.00008453122,0.0041724695,0.00090709754],"about_ca_topic_score_codex":0.0005412949,"about_ca_topic_score_gemma":0.00092666934,"teacher_disagreement_score":0.37339032,"about_ca_system_score_codex":0.00003414817,"about_ca_system_score_gemma":0.000057066205,"threshold_uncertainty_score":0.99984396},"labels":[],"label_agreement":null},{"id":"W3035233083","doi":"10.1007/s13555-020-00411-w","title":"Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics","year":2020,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Medicine; Secukinumab; Ixekizumab; Psoriasis; Ustekinumab; Immunology; Dermatology; Disease; Internal medicine; Adalimumab; Psoriatic arthritis","score_opus":0.02435962657866465,"score_gpt":0.27158581235565776,"score_spread":0.24722618577699312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035233083","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3649255,0.6326567,0.00000298329,0.0005924971,0.00013676441,0.0014984636,0.00016180996,0.000019686011,0.000005589814],"genre_scores_gemma":[0.06156364,0.9376111,0.000088984125,0.00031910892,0.00001702664,0.0001618034,0.00012118214,0.00003605202,0.00008110352],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99659055,0.001703817,0.0006262647,0.00065382937,0.000046116384,0.00037939879],"domain_scores_gemma":[0.9981893,0.0010605556,0.00022277719,0.0004037912,0.000052647938,0.000070931674],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034372267,0.00052034645,0.0017796077,0.00025823052,0.0002196233,0.000016158583,0.00026621931,0.0006713796,0.000025148158],"category_scores_gemma":[0.00017358245,0.00027357458,0.00008174579,0.00042611032,0.0002760578,0.000040475687,0.00015691642,0.00033220678,0.000021759946],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023112528,0.00014172362,0.0028708726,0.00032779892,0.0006686032,0.000034721957,0.0012780352,1.6954644e-7,0.0000108843005,0.000045794917,0.000096134194,0.9714127],"study_design_scores_gemma":[0.010086888,0.002590877,0.06474398,0.0010327626,0.000391212,0.00031873668,0.00008492893,7.950657e-8,0.000074057025,0.000011508848,0.9202068,0.00045818152],"about_ca_topic_score_codex":0.000023202358,"about_ca_topic_score_gemma":0.00006499316,"teacher_disagreement_score":0.97095454,"about_ca_system_score_codex":0.000025064635,"about_ca_system_score_gemma":0.00014987738,"threshold_uncertainty_score":0.9999716},"labels":[],"label_agreement":null},{"id":"W3113634853","doi":"10.1007/s13555-020-00472-x","title":"Two-Year US Pharmacovigilance Report on Brodalumab","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Medicine; Pharmacovigilance; Adverse effect; Adverse Event Reporting System; Internal medicine","score_opus":0.023034592902739248,"score_gpt":0.27007475149976373,"score_spread":0.2470401585970245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113634853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835687,0.0068897144,0.000015436059,0.0030475957,0.00049456937,0.00016570788,0.00002052946,0.00011993221,0.0056777946],"genre_scores_gemma":[0.9929743,0.0017420832,0.0000394281,0.004789073,0.000061425475,0.00002542978,0.00009289773,0.000014265571,0.0002611118],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990499,0.00016241538,0.00019002236,0.00033272945,0.00002170243,0.00024324367],"domain_scores_gemma":[0.99961114,0.00008325002,0.00008122445,0.00016657633,0.000019917132,0.000037900183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005099305,0.00017615387,0.0002875938,0.000037074657,0.00016375478,0.0000078052335,0.000106744184,0.0001604815,0.00036510918],"category_scores_gemma":[0.000013765906,0.0001442704,0.00006517301,0.000076685814,0.00012691432,0.000045351473,0.000020916385,0.00015841419,0.000550923],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073094512,0.0006289038,0.6096835,0.000047017907,0.0024365664,0.00408869,0.0018721644,0.000007221232,0.22088571,0.017573278,0.024031075,0.11143638],"study_design_scores_gemma":[0.014350872,0.0004130354,0.03220194,0.000014073079,0.00009048002,0.0048777247,0.000109599634,0.000007781001,0.40970492,0.00046350627,0.5372794,0.00048660577],"about_ca_topic_score_codex":0.000009635707,"about_ca_topic_score_gemma":0.0000012989979,"teacher_disagreement_score":0.5774816,"about_ca_system_score_codex":0.0000049233213,"about_ca_system_score_gemma":0.0000241991,"threshold_uncertainty_score":0.7081184},"labels":[],"label_agreement":null},{"id":"W3114387357","doi":"10.1007/s13555-020-00474-9","title":"Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Pfizer","keywords":"Content validity; Convergent validity; Atopic dermatitis; Medicine; Quality of life (healthcare); Clinical psychology; Physical therapy; External validity; Psychometrics; Psychology; Internal consistency; Dermatology","score_opus":0.02147847622244787,"score_gpt":0.2661775843120621,"score_spread":0.24469910808961426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114387357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914847,0.0042011393,0.00045593744,0.003033491,0.000016381797,0.00076577,0.00000820441,0.00001495138,0.000019393381],"genre_scores_gemma":[0.9950334,0.0008161382,0.001433055,0.002589705,0.000004498545,0.00008692932,0.00002358589,0.000009148154,0.0000035629707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924904,0.000045801593,0.00025685923,0.0002347696,0.00006626426,0.00014724913],"domain_scores_gemma":[0.9996353,0.000041393556,0.00006660651,0.00006212102,0.000049686285,0.00014489146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000038376027,0.0001369135,0.00036415667,0.000065113534,0.000069200774,0.000010662521,0.000024770716,0.00009660293,0.00000255525],"category_scores_gemma":[0.000013416839,0.00010916107,0.000011701027,0.000049764043,0.00010912239,0.000070641996,0.000022925213,0.00007586425,2.831513e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00132811,0.00012530609,0.9650067,0.0008155116,0.000115059134,0.00007412816,0.002734804,9.438085e-7,0.00011979433,0.00022159817,0.000057508998,0.029400555],"study_design_scores_gemma":[0.011154654,0.00026261888,0.9776613,0.00051060965,0.000043790278,0.00092065014,0.0006215542,0.0007038882,0.0068931975,0.00014322753,0.0009039564,0.00018052808],"about_ca_topic_score_codex":0.000004428037,"about_ca_topic_score_gemma":0.000014284386,"teacher_disagreement_score":0.029220026,"about_ca_system_score_codex":0.0000066615594,"about_ca_system_score_gemma":0.000054625198,"threshold_uncertainty_score":0.44514593},"labels":[],"label_agreement":null},{"id":"W3122132687","doi":"10.1007/s13555-021-00490-3","title":"Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Adverse effect; Internal medicine; Ustekinumab; Plaque psoriasis; Open label; Randomized controlled trial; Clinical trial; Dermatology; Gastroenterology; Disease; Adalimumab","score_opus":0.023874858612425512,"score_gpt":0.2783510814867329,"score_spread":0.2544762228743074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122132687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98889077,0.009248866,0.000035205092,0.00023845785,0.0003046637,0.0008420582,0.00037094206,0.000018096429,0.000050936942],"genre_scores_gemma":[0.9959901,0.002400891,0.00008551885,0.00014905308,0.00002009978,0.00003639155,0.001240773,0.000017309158,0.00005984865],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99821866,0.00045376873,0.00045650572,0.0005531131,0.000037127145,0.00028085583],"domain_scores_gemma":[0.99904776,0.00033572348,0.00016329646,0.0003425874,0.00006943224,0.00004122831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010270791,0.0002519523,0.0006716722,0.00009790856,0.00016293387,0.000020050917,0.00014547409,0.00033753045,0.00007409655],"category_scores_gemma":[0.00003345767,0.00019678616,0.000029523137,0.00014718543,0.00013398712,0.00011940569,0.00009639097,0.00016054235,0.000011070509],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8243502,0.0041953125,0.019983128,0.000015357173,0.00093505246,0.00018954353,0.0012909126,0.00000667159,0.0037771435,0.00010531069,0.00013003254,0.14502136],"study_design_scores_gemma":[0.76361126,0.002167144,0.20795822,0.00014404932,0.000121102494,0.000119303484,0.00003800021,0.000008326985,0.024685536,0.000103143524,0.0007094568,0.00033444667],"about_ca_topic_score_codex":0.000078263656,"about_ca_topic_score_gemma":0.00016639761,"teacher_disagreement_score":0.1879751,"about_ca_system_score_codex":0.000024636023,"about_ca_system_score_gemma":0.00012926453,"threshold_uncertainty_score":0.8024707},"labels":[],"label_agreement":null},{"id":"W3123676674","doi":"10.1007/s13555-021-00483-2","title":"Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities","year":2021,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Janssen Biotech; Sun Pharma; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Psoriasis; Medicine; Inflammation; Interleukin 17; Immunology; Interleukin 23; Immune system; Disease; Interleukin; Cytokine; Internal medicine","score_opus":0.04843329614868765,"score_gpt":0.32176808786269695,"score_spread":0.2733347917140093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123676674","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010084208,0.9887885,0.000007125356,0.00007371492,0.00034559198,0.00048994087,0.00012081926,0.000013984745,0.00007615549],"genre_scores_gemma":[0.005295291,0.9937899,0.000024067229,0.00010607962,0.000006866515,0.000099343066,0.0005141513,0.00001936129,0.0001449533],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974239,0.0012257639,0.0007488558,0.00036398298,0.000031231717,0.00020627472],"domain_scores_gemma":[0.9985614,0.0004972803,0.00065220124,0.00019290479,0.00007658647,0.00001964466],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002713171,0.0003843907,0.0026502563,0.00024931188,0.00007275563,0.000006305088,0.00010851119,0.0006961371,0.000108254004],"category_scores_gemma":[0.000060911665,0.00030323016,0.00019790352,0.00018687895,0.0003231642,0.000064993634,0.00007236247,0.00028885907,0.0000020969205],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012095454,0.00024065521,0.00018785933,0.018012289,0.0031901663,0.00005486889,0.002461113,5.2351226e-9,0.00022640142,0.001607884,0.0008418689,0.97305596],"study_design_scores_gemma":[0.008772879,0.0011002754,0.00054170936,0.17797822,0.0037303204,0.005602598,0.0038381836,8.033948e-7,0.0086287055,0.0020963,0.78625804,0.0014519499],"about_ca_topic_score_codex":0.000034744175,"about_ca_topic_score_gemma":0.000065159875,"teacher_disagreement_score":0.971604,"about_ca_system_score_codex":0.000025311501,"about_ca_system_score_gemma":0.00009312154,"threshold_uncertainty_score":0.999942},"labels":[],"label_agreement":null},{"id":"W3125588754","doi":"10.1007/s13555-021-00487-y","title":"Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Clinical Research","funders":"Sanofi Genzyme; LEO Pharma; Astellas Pharma; Kyowa Hakko Kirin; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Genentech; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Australian Wool Innovation; Amgen; Pfizer; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; Astellas Pharma US","keywords":"Atopic dermatitis; Dupilumab; Medicine; Placebo; Disease; Clinical trial; Randomized controlled trial; Dermatology; Internal medicine; Pediatrics; Alternative medicine; Pathology","score_opus":0.015582128925932661,"score_gpt":0.2849635979488684,"score_spread":0.26938146902293575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125588754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9507962,0.01375584,0.00017615483,0.03199875,0.00030891786,0.0023139545,0.000210503,0.00007625899,0.00036343755],"genre_scores_gemma":[0.9685318,0.0032319194,0.00003267823,0.027002059,0.0001068969,0.0003576389,0.0004804805,0.000035279307,0.0002212828],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9959457,0.0014500963,0.0010412777,0.0007714624,0.00027297717,0.000518469],"domain_scores_gemma":[0.9967134,0.0016404466,0.00022815596,0.00075358537,0.00015837143,0.00050602853],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027743267,0.00040596115,0.0013678182,0.0000737952,0.0002527075,0.000058821723,0.00022357597,0.00039297278,0.00024710404],"category_scores_gemma":[0.0006027701,0.00026198235,0.00024847133,0.00018069745,0.0003961234,0.000134006,0.00004376856,0.00055647705,0.00007478756],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5515667,0.0014526864,0.42226312,0.00004387169,0.00089808326,0.0056805043,0.00055436254,0.000004908305,0.00000810885,0.00006977581,0.014344379,0.0031134905],"study_design_scores_gemma":[0.45522356,0.00033757667,0.5388868,0.00032039982,0.00028933448,0.00080453255,0.00012978721,0.00043777906,0.00009765446,0.00067406177,0.0024644725,0.0003340675],"about_ca_topic_score_codex":0.000060849856,"about_ca_topic_score_gemma":0.00038491437,"teacher_disagreement_score":0.11662366,"about_ca_system_score_codex":0.000028798815,"about_ca_system_score_gemma":0.0006066887,"threshold_uncertainty_score":0.99998325},"labels":[],"label_agreement":null},{"id":"W3133150537","doi":"10.1007/s13555-021-00500-4","title":"Tolerability of and Adherence to Topical Treatments in Atopic Dermatitis: A Narrative Review","year":2021,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Pfizer Foundation; LEO Pharma; Eli Lilly and Company; Galderma; Regeneron Pharmaceuticals; Sun Pharma; Mylan; Celgene; Samsung; National Psoriasis Foundation; Valeant Pharmaceuticals International; Sanofi; Pfizer","keywords":"Atopic dermatitis; Medicine; Tolerability; Narrative review; Behavior management; Intensive care medicine; Alternative medicine; Psychotherapist; Psychology; Dermatology","score_opus":0.057337207521575846,"score_gpt":0.3946786122003193,"score_spread":0.33734140467874346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133150537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013031113,0.9846952,0.0000022282436,0.0008665173,0.00005036709,0.0011107269,0.000014814863,0.000011937852,0.00021709189],"genre_scores_gemma":[0.0048749256,0.9928054,0.00007907523,0.0018614954,0.000009422235,0.00025614776,0.000057787754,0.000010048823,0.000045682427],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824226,0.0004775939,0.00064538786,0.0003720345,0.00007633611,0.00018639349],"domain_scores_gemma":[0.99914426,0.00023910281,0.00014348736,0.0002904586,0.0000504565,0.00013221033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006738068,0.00027796367,0.002675968,0.000103967745,0.00003999731,0.0000046972045,0.00007166003,0.00031154408,0.000108915076],"category_scores_gemma":[0.00009973113,0.0002056254,0.00016894245,0.0002005021,0.00019889737,0.000037386617,0.000046993235,0.00023320629,0.000005169921],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021041998,0.00031980418,0.025318323,0.03753449,0.00040709882,0.00083023286,0.0006352073,3.5862857e-9,1.10778245e-7,0.00027166188,0.0018678823,0.93279415],"study_design_scores_gemma":[0.0018816876,0.00022396471,0.014750256,0.0737309,0.00076014653,0.009078322,0.0001083625,0.0000010522233,0.000010692556,0.000336016,0.8987596,0.00035899453],"about_ca_topic_score_codex":0.000009529425,"about_ca_topic_score_gemma":0.000010214517,"teacher_disagreement_score":0.93243515,"about_ca_system_score_codex":0.000016370032,"about_ca_system_score_gemma":0.00020114465,"threshold_uncertainty_score":0.83851606},"labels":[],"label_agreement":null},{"id":"W3133897407","doi":"10.1007/s13555-021-00506-y","title":"Relationship Among Treatment, Pruritus, Investigator’s Static Global Assessment, and Quality of Life in Patients with Atopic Dermatitis","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Bausch Health; Sanofi Genzyme; Incyte; Mylan; Dermira; Argenx; Vanda Pharmaceuticals; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Les Laboratories Pierre Fabre; Celgene; Valeant Pharmaceuticals International; Sanofi; Symrise; Pfizer; Galderma; Eli Lilly and Company","keywords":"Atopic dermatitis; Medicine; Dermatology Life Quality Index; Quality of life (healthcare); Post-hoc analysis; Eczema Area and Severity Index; Longitudinal study; Post hoc; Dermatology; Internal medicine; Disease; Physical therapy; Pathology","score_opus":0.03164830281985107,"score_gpt":0.31869525946197613,"score_spread":0.28704695664212504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133897407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948507,0.0031060781,0.000025990597,0.0012727488,0.000027397742,0.0002489038,0.000029023946,0.000018264122,0.00042091482],"genre_scores_gemma":[0.99774545,0.00046737818,0.0003354155,0.0012972399,0.0000037765217,0.000024374707,0.00010557513,0.0000062067784,0.000014571649],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998893,0.0003245845,0.00035038023,0.00019459552,0.00008793509,0.00014949577],"domain_scores_gemma":[0.9992705,0.00019722269,0.00012853411,0.00016848577,0.000062723935,0.00017251253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004862393,0.00013179524,0.00044835795,0.000050085466,0.00006611768,0.000008240233,0.000024889978,0.00012396068,0.000024997651],"category_scores_gemma":[0.00010652061,0.000104439496,0.0000276657,0.00014202169,0.00037472328,0.00010715661,0.0000129982855,0.00007997582,7.150574e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007707942,0.00035334527,0.9954642,0.00012603299,0.000121075835,0.000073210555,0.00018131486,3.138773e-7,0.0000015541427,0.003028449,0.0001767443,0.00039665302],"study_design_scores_gemma":[0.00746458,0.00006715666,0.98973,0.0000464923,0.00003920806,0.00008628214,0.0000935818,0.000014444798,0.000074702126,0.0021238362,0.00016864369,0.0000910809],"about_ca_topic_score_codex":0.000058192287,"about_ca_topic_score_gemma":0.00017929636,"teacher_disagreement_score":0.0073875003,"about_ca_system_score_codex":0.000021237787,"about_ca_system_score_gemma":0.00030173024,"threshold_uncertainty_score":0.4258919},"labels":[],"label_agreement":null},{"id":"W3134953187","doi":"10.1007/s13555-021-00504-0","title":"Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Boehringer Ingelheim","keywords":"Palmoplantar pustulosis; Medicine; Placebo; Clinical endpoint; Internal medicine; Gastroenterology; Psoriasis Area and Severity Index; Multicenter trial; Placebo-controlled study; Intention-to-treat analysis; Randomized controlled trial; Surgery; Double blind; Immunology; Multicenter study; Psoriasis; Pathology","score_opus":0.0211709192181169,"score_gpt":0.2831314459354729,"score_spread":0.261960526717356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134953187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921109,0.0043014702,0.000009125676,0.00014411104,0.00047059814,0.002674454,0.00014180581,0.000040748528,0.000106766776],"genre_scores_gemma":[0.99628776,0.0020816897,0.000052572384,0.00009545582,0.000017284077,0.0002275387,0.0011049509,0.000026485073,0.00010626328],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963755,0.0016538617,0.00086091354,0.0006073368,0.00006993374,0.00043243048],"domain_scores_gemma":[0.99846375,0.0005111119,0.0003888208,0.00042805276,0.0001584298,0.000049811904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044499454,0.00040513035,0.0017374711,0.0002622606,0.00015500344,0.000020605263,0.00019183027,0.00021149422,0.00012022473],"category_scores_gemma":[0.000040123534,0.00026289158,0.00012256938,0.00019341956,0.00029704982,0.00016169592,0.00004676998,0.00022340074,0.000023430046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8484531,0.014542703,0.123417534,0.000016701484,0.0024259763,0.00013472937,0.002076642,8.5439547e-7,0.006518432,0.000029726249,0.000025167086,0.0023584384],"study_design_scores_gemma":[0.9570782,0.0031834554,0.013567674,0.000061690014,0.00035460637,0.00008710238,0.00065415545,0.0000068912723,0.024433058,0.00000971768,0.00027243485,0.0002910006],"about_ca_topic_score_codex":0.00018790174,"about_ca_topic_score_gemma":0.00028063427,"teacher_disagreement_score":0.10984986,"about_ca_system_score_codex":0.00001691069,"about_ca_system_score_gemma":0.00006971257,"threshold_uncertainty_score":0.99998236},"labels":[],"label_agreement":null},{"id":"W3138117345","doi":"10.1007/s13555-020-00362-2","title":"Correction to: Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study","year":2020,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Atopic dermatitis; Perception; Cross-sectional study; Natural language processing; Medicine; Computer science; Psychology; Dermatology; Pathology","score_opus":0.01997208787336325,"score_gpt":0.3886952547406255,"score_spread":0.36872316686726225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138117345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951332,0.0016170226,0.00017459283,0.00009383441,0.0020429674,0.000589576,0.00003532397,0.000019288982,0.00029415413],"genre_scores_gemma":[0.9983198,0.00014022214,0.00017487443,0.00041339436,0.000052870917,0.00003556803,0.000598189,0.000015563024,0.00024950708],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980749,0.000451044,0.0006981393,0.00034932888,0.0002636372,0.00016295273],"domain_scores_gemma":[0.99890965,0.00012695295,0.00040378293,0.00014406923,0.0003493733,0.00006618471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009706239,0.00022480814,0.0009536397,0.0005953053,0.00008265232,0.00001328905,0.00007596919,0.00029798216,0.000050066403],"category_scores_gemma":[0.00012047617,0.00020296368,0.00016367217,0.0006110614,0.00016993347,0.000097450735,0.0000314506,0.0005525583,8.269665e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019429285,0.00061817566,0.97719955,0.00036549845,0.0007599801,0.000055992426,0.016392358,0.000009728596,0.000025255187,0.0000036298702,0.0033058708,0.0010696516],"study_design_scores_gemma":[0.0020712425,0.00015786731,0.9850926,0.00015490071,0.00032849397,0.00007633392,0.005984786,0.005896057,0.000022761393,0.0000126098785,0.00005368668,0.00014870944],"about_ca_topic_score_codex":0.00025114507,"about_ca_topic_score_gemma":0.00016484036,"teacher_disagreement_score":0.010407572,"about_ca_system_score_codex":0.000056510708,"about_ca_system_score_gemma":0.00020902455,"threshold_uncertainty_score":0.8276619},"labels":[],"label_agreement":null},{"id":"W3152655764","doi":"10.1007/s13555-021-00518-8","title":"Psoriasis Prevalence and Severity by Expert Elicitation","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval; BC Children's Hospital; McMaster University; SKiN Health; Probity Medical Research; University of British Columbia; Dermatrials Research; Ottawa Hospital; Lynde Centre for Dermatology; University of Alberta; University of Ottawa; Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada)","funders":"Janssen Canada; Novartis Pharmaceuticals Canada; LEO Pharma; AbbVie","keywords":"Psoriasis; Medicine; Population; Confidence interval; Credible interval; Expert elicitation; Estimation; Body surface area; Epidemiology; Disease; Demography; Statistics; Internal medicine; Dermatology; Environmental health; Mathematics","score_opus":0.014126296446566627,"score_gpt":0.24875321946604367,"score_spread":0.23462692301947705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152655764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8636046,0.13463251,0.00004898813,0.0010561809,0.0002787181,0.0000780386,0.000027271544,0.00003697928,0.00023669546],"genre_scores_gemma":[0.9490857,0.049228095,0.000082396604,0.000880024,0.00001367535,0.00003272694,0.00010467124,0.000007740297,0.00056494627],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991822,0.0002461686,0.00012647017,0.00025576426,0.000015230227,0.00017414913],"domain_scores_gemma":[0.999635,0.0001413083,0.0000411314,0.00012852336,0.000034271463,0.000019783229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000049955328,0.00012895328,0.00019713353,0.000028212151,0.000195396,0.000011106518,0.000045322704,0.00022368257,0.00022878424],"category_scores_gemma":[0.000015810405,0.000113021844,0.000030486732,0.00005674474,0.00014517449,0.00007655222,0.000021759231,0.000074418946,0.000032023057],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005010066,0.0003689441,0.17148231,0.000056811365,0.0008048026,0.000090128146,0.0034951053,4.5859558e-8,0.27792126,0.0020042988,0.014024165,0.52925116],"study_design_scores_gemma":[0.0055553243,0.00011327222,0.12977867,0.000026064537,0.00007784094,0.0024807886,0.00036166888,0.0000043505797,0.6152636,0.0020492636,0.24387452,0.00041466448],"about_ca_topic_score_codex":0.000015237387,"about_ca_topic_score_gemma":0.000005112402,"teacher_disagreement_score":0.5288365,"about_ca_system_score_codex":0.000004307691,"about_ca_system_score_gemma":0.000018536926,"threshold_uncertainty_score":0.4608897},"labels":[],"label_agreement":null},{"id":"W3153306807","doi":"10.1007/s13555-021-00529-5","title":"A New Era for Truncal Acne: Emerging from a Legacy of Neglect","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Windsor Clinical Research","funders":"Galderma","keywords":"Neglect; Acne; Medicine; History; Dermatology; Psychiatry","score_opus":0.014564188394622,"score_gpt":0.2928310622675647,"score_spread":0.27826687387294274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153306807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97866255,0.014346356,0.001986024,0.0043424917,0.000112546586,0.0001615064,0.000006322461,0.000015751282,0.000366472],"genre_scores_gemma":[0.99417657,0.0018053598,0.0021754734,0.0013154476,0.00008587417,0.0000112519965,0.000061585706,0.000009309945,0.00035914694],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999566,0.00002463311,0.00011269493,0.0001369227,0.000037147718,0.00012255552],"domain_scores_gemma":[0.9996773,0.00009885482,0.000031663276,0.00010305651,0.00002758417,0.000061539424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000014405746,0.00008337778,0.00028698356,0.000025514357,0.00006039171,0.000006415509,0.000018780389,0.000088663444,0.00011961358],"category_scores_gemma":[0.0000114664535,0.00005884609,0.00007488067,0.000053537715,0.000025916579,0.000041213974,0.000008167767,0.000059205846,0.000002070064],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037895609,0.000734938,0.13188374,0.00019448582,0.0025893864,0.0011351894,0.0044284128,0.0000012207759,0.08337577,0.00564763,0.018749015,0.7474707],"study_design_scores_gemma":[0.046965115,0.0013157984,0.120783046,0.0002839122,0.0005821696,0.0028153816,0.0008441829,0.0007600627,0.48148128,0.012856171,0.33082482,0.00048806894],"about_ca_topic_score_codex":0.00006228451,"about_ca_topic_score_gemma":0.0000071456698,"teacher_disagreement_score":0.7469826,"about_ca_system_score_codex":0.0000027883386,"about_ca_system_score_gemma":0.000091419264,"threshold_uncertainty_score":0.23996739},"labels":[],"label_agreement":null},{"id":"W3161437439","doi":"10.1007/s13555-021-00550-8","title":"Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"AbbVie","keywords":"Psoriasis; Plaque psoriasis; Medicine; Quality of life (healthcare); Dermatology; Nursing","score_opus":0.01540259117287134,"score_gpt":0.23959682154864953,"score_spread":0.22419423037577818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161437439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913965,0.0076655447,0.00024444287,0.000103135564,0.000051310315,0.00035872348,0.00014485262,0.000012004943,0.000023523038],"genre_scores_gemma":[0.99888337,0.0005486944,0.00015553863,0.000055628352,0.000001438918,0.00006538907,0.00024971526,0.000011480981,0.000028750484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981416,0.0007727689,0.00062014116,0.00024695342,0.00004011532,0.00017844558],"domain_scores_gemma":[0.99926585,0.00009365346,0.00035419452,0.0001559887,0.000105901636,0.00002442923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011277257,0.0001812631,0.00076029915,0.00011557537,0.0000612711,0.0000020907294,0.000044773245,0.0002136407,0.000032880365],"category_scores_gemma":[0.000015833977,0.0001381455,0.000056072528,0.0001399049,0.00011044853,0.00006551044,0.000017972377,0.000095336225,0.0000012582219],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026841844,0.0011322309,0.9497991,0.000061182225,0.001033263,0.0000057868,0.0071589174,0.0011894105,0.0027960637,0.00012149402,0.0000035078922,0.00985717],"study_design_scores_gemma":[0.029163588,0.002324835,0.9317725,0.000108736305,0.00008210611,0.000032297503,0.00037774132,0.00061436294,0.034961157,0.00028917988,0.000024194238,0.00024933505],"about_ca_topic_score_codex":0.00031399488,"about_ca_topic_score_gemma":0.00026188086,"teacher_disagreement_score":0.032165095,"about_ca_system_score_codex":0.000026521977,"about_ca_system_score_gemma":0.00018990388,"threshold_uncertainty_score":0.56334096},"labels":[],"label_agreement":null},{"id":"W3164736687","doi":"10.1007/s13555-021-00548-2","title":"Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis","year":2021,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Psoriasis; Medicine; Clinical trial; Computer science; Dermatology; Psoriatic arthritis; Internal medicine; Secukinumab","score_opus":0.06649211576710885,"score_gpt":0.4084196808102532,"score_spread":0.34192756504314437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164736687","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.075038165,0.923693,0.000005963071,0.000017082844,0.0007271358,0.00037422258,0.00004303592,0.000012927531,0.00008849139],"genre_scores_gemma":[0.018262781,0.9808495,0.0000433082,0.0000126599025,0.00001361051,0.000035992318,0.00067374913,0.00002155172,0.00008681655],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961728,0.0017418374,0.0013998505,0.00043838672,0.00003082992,0.00021628333],"domain_scores_gemma":[0.9974509,0.0014340489,0.0007237999,0.0003213261,0.000052202515,0.000017717899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024268252,0.0003000237,0.003082291,0.00027045127,0.000040254952,0.000002922576,0.00016283811,0.0011139639,0.00013069843],"category_scores_gemma":[0.00010722761,0.00024021773,0.0005708457,0.00031312782,0.00031232828,0.000035664125,0.000051715375,0.00030521405,0.000020171394],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021565372,0.0005119456,0.0020278944,0.00064756116,0.0013660545,0.00004486662,0.00012859445,7.7795164e-8,0.000017241116,0.00019128992,0.000049279035,0.99479955],"study_design_scores_gemma":[0.020019164,0.0006464718,0.018654672,0.005807775,0.002583575,0.0020801243,0.0002400378,0.000004655742,0.0018415581,0.00021119165,0.9469465,0.0009642806],"about_ca_topic_score_codex":0.00002880769,"about_ca_topic_score_gemma":0.000013536689,"teacher_disagreement_score":0.9938353,"about_ca_system_score_codex":0.000010107738,"about_ca_system_score_gemma":0.00018540249,"threshold_uncertainty_score":0.9795795},"labels":[],"label_agreement":null},{"id":"W3167102770","doi":"10.1007/s13555-021-00560-6","title":"Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits","year":2021,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Tazarotene; Psoriasis; Lotion; Tolerability; Medicine; Pharmacology; Dermatology; Clobetasol propionate; Active ingredient; Clinical trial; Adverse effect; Internal medicine","score_opus":0.050980535848023374,"score_gpt":0.3138735115390394,"score_spread":0.26289297569101605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167102770","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016746318,0.9817422,0.000005660361,0.00015010816,0.00014909802,0.0011245684,0.000061423336,0.0000051556513,0.000015475027],"genre_scores_gemma":[0.016043492,0.983323,0.000024771367,0.00005090659,0.0000049495893,0.00024193365,0.0002794986,0.000011704965,0.000019776035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99783486,0.0011302435,0.0005789286,0.0002785735,0.000038785674,0.0001386239],"domain_scores_gemma":[0.9987736,0.00036184248,0.000564017,0.00021401863,0.000076358905,0.000010167104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019266165,0.0003043105,0.0016891545,0.0001463477,0.00007511252,0.000003195239,0.000086512846,0.00040107802,0.000022456508],"category_scores_gemma":[0.00001115677,0.00017878119,0.00016547399,0.00017745189,0.00019620697,0.000035716603,0.000014032551,0.00010403069,5.4990966e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060682298,0.00041274907,0.00006658512,0.006584587,0.0010756629,0.0000052825458,0.0013555498,2.5033968e-8,0.00020263573,0.0038799988,0.0000070333836,0.9863492],"study_design_scores_gemma":[0.02599848,0.0083116675,0.004099228,0.11073631,0.013191244,0.0073038717,0.0039314376,0.000004431277,0.06848459,0.008409658,0.7474718,0.0020572771],"about_ca_topic_score_codex":0.000018700153,"about_ca_topic_score_gemma":0.000010467833,"teacher_disagreement_score":0.9842919,"about_ca_system_score_codex":0.000012698811,"about_ca_system_score_gemma":0.00006884255,"threshold_uncertainty_score":0.72904855},"labels":[],"label_agreement":null},{"id":"W3170263128","doi":"10.1007/s13555-021-00558-0","title":"Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Atopic dermatitis; Dupilumab; Medicine; Dermatology","score_opus":0.02739593576320092,"score_gpt":0.29707965991119445,"score_spread":0.2696837241479935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170263128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893599,0.009326956,0.00023673674,0.0004470166,0.000037195907,0.00046429056,0.000087480206,0.00001560681,0.000024792414],"genre_scores_gemma":[0.9955545,0.003488229,0.00024322364,0.00057529606,0.000005477476,0.000042282634,0.000059801896,0.000014084453,0.0000171039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982943,0.00040126225,0.00071210944,0.00028169138,0.00011520243,0.00019543264],"domain_scores_gemma":[0.99876124,0.00044549908,0.00023550738,0.00030315274,0.00015560558,0.000099017794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000123533,0.00018349607,0.0015409483,0.00037092454,0.000049260416,0.0000122649,0.000056723242,0.0001828844,0.000042828946],"category_scores_gemma":[0.00011451704,0.00014210431,0.000110457666,0.00041083113,0.00016718132,0.0001324891,0.000029864348,0.00011682522,8.8404903e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007968392,0.0007596939,0.97141516,0.00093924295,0.003977729,0.0020693832,0.003561155,0.00006530746,0.0021363788,0.000090054986,0.00024628235,0.0067711947],"study_design_scores_gemma":[0.04478461,0.00033504632,0.9070702,0.0016114755,0.0017783535,0.009704039,0.0010936265,0.0030504474,0.029931983,0.00011795435,0.00016207244,0.00036015213],"about_ca_topic_score_codex":0.000042579777,"about_ca_topic_score_gemma":0.000060472707,"teacher_disagreement_score":0.06434494,"about_ca_system_score_codex":0.0000067907554,"about_ca_system_score_gemma":0.00010815064,"threshold_uncertainty_score":0.5794846},"labels":[],"label_agreement":null},{"id":"W3179238984","doi":"10.1007/s13555-021-00572-2","title":"The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score","year":2021,"lang":"en","type":"letter","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Sanofi","keywords":"Psoriasis Area and Severity Index; Body surface area; Psoriasis; Plaque psoriasis; Medicine; Severity of illness; Measure (data warehouse); Dermatology; Internal medicine; Computer science; Data mining","score_opus":0.019194619574046435,"score_gpt":0.25204580214016575,"score_spread":0.2328511825661193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179238984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8270318,0.01540798,0.00003983492,0.15520987,0.0005362586,0.0013426414,0.00017590933,0.000058149213,0.00019758995],"genre_scores_gemma":[0.9472775,0.01752932,0.00026928057,0.030881805,0.00017204051,0.00070295675,0.001995586,0.00009199232,0.0010795473],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973525,0.00091159117,0.00050917343,0.000612868,0.00008268,0.0005312257],"domain_scores_gemma":[0.9981826,0.00073214585,0.00034696813,0.00060106657,0.00011220208,0.000025045756],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00016397226,0.0004901809,0.0010067692,0.00017177011,0.0003056479,0.000028853307,0.00033038383,0.0014693023,0.000068406014],"category_scores_gemma":[0.000021981381,0.00029860678,0.00016627352,0.00022207866,0.0009020174,0.00007021826,0.0000677769,0.0011775512,0.0000035000617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064505036,0.0022768932,0.5051907,0.00093496306,0.011090964,0.0075411294,0.0042208275,0.0000042084903,0.00453227,0.0019205646,0.38891858,0.06691846],"study_design_scores_gemma":[0.02804429,0.0011870381,0.14741732,0.0016952271,0.0010927347,0.010140763,0.0014105912,0.00005957823,0.052677218,0.0032178417,0.7505365,0.002520881],"about_ca_topic_score_codex":0.00009153052,"about_ca_topic_score_gemma":0.00027116324,"teacher_disagreement_score":0.36161795,"about_ca_system_score_codex":0.000050612845,"about_ca_system_score_gemma":0.00049023627,"threshold_uncertainty_score":0.9999466},"labels":[],"label_agreement":null},{"id":"W3189146888","doi":"10.1007/s13555-021-00585-x","title":"Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"UCB Pharma; Janssen Pharmaceuticals; Manchester Biomedical Research Centre; Sanofi Genzyme; Allergan; Ortho Dermatologics; Gilead Sciences; LEO Pharma; Bausch Health; Astellas Pharma; National Institute for Health and Care Research; Inozyme Pharma; Pfizer; Incyte; Castle Biosciences; Dermira; Vertex Pharmaceuticals; Regeneron Pharmaceuticals; Celgene; Medac; AbbVie; Sanofi; Amgen; Meiji Seika Pharma; EMD Serono; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Plaque psoriasis; Betamethasone dipropionate; Medicine; Term (time); Psoriasis; Dermatology; Anesthesia; Physics","score_opus":0.014687963623217636,"score_gpt":0.24568417798942385,"score_spread":0.2309962143662062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189146888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97620106,0.022724338,0.000034256947,0.00029617088,0.00015989313,0.00041039966,0.00011407395,0.000020452228,0.00003936715],"genre_scores_gemma":[0.98550403,0.013844318,0.00019926007,0.000023336786,0.000013484487,0.000083309795,0.00019418131,0.000015740161,0.00012233284],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864626,0.00039095964,0.00033283533,0.0003809371,0.00004109655,0.00020789298],"domain_scores_gemma":[0.9990376,0.00027194852,0.0002768344,0.00020002895,0.00017860637,0.00003497117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057502453,0.0002515774,0.00063358113,0.000095289404,0.00012937041,0.000005647121,0.000048409467,0.00026177365,0.000053325377],"category_scores_gemma":[0.000031896136,0.00016869756,0.00006390115,0.00012532667,0.00042466706,0.0000701748,0.000026283118,0.000086195185,0.0000017220165],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011569866,0.0023618739,0.32855612,0.00008969524,0.0033814819,0.00032900803,0.0071672364,4.7393507e-7,0.23638348,0.00043401442,0.000024650768,0.4097021],"study_design_scores_gemma":[0.0044427086,0.0012945987,0.115296565,0.00006887751,0.00022655542,0.00080311496,0.00027948845,0.0000015695455,0.8767173,0.00010194091,0.0006052252,0.00016200352],"about_ca_topic_score_codex":0.000020896994,"about_ca_topic_score_gemma":0.000007653515,"teacher_disagreement_score":0.6403339,"about_ca_system_score_codex":0.000017219814,"about_ca_system_score_gemma":0.0001006591,"threshold_uncertainty_score":0.68792874},"labels":[],"label_agreement":null},{"id":"W3201393437","doi":"10.1007/s13555-021-00586-w","title":"Practical Management of Patients with Atopic Dermatitis on Dupilumab","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Women's College Hospital; McGill University Health Centre; University of Ottawa; McGill University; Ottawa Hospital; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; SKiN Health; Hospital for Sick Children; Innovaderm (Canada); Probity Medical Research","funders":"Sanofi Genzyme; Sanofi","keywords":"Dupilumab; Atopic dermatitis; Medicine; Statement (logic); Adverse effect; Dermatology; MEDLINE; Family medicine; Intensive care medicine; Internal medicine","score_opus":0.013332968362758216,"score_gpt":0.2797698717500938,"score_spread":0.2664369033873356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201393437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896309,0.0011223102,0.00008943301,0.004050839,0.000056564593,0.0001659492,0.000005523071,0.000021747746,0.004856733],"genre_scores_gemma":[0.9950991,0.0010803387,0.00072361965,0.0029291455,0.00000544155,0.000014791676,0.00004777949,0.000007862599,0.00009189779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993872,0.00006947544,0.00014801079,0.00015834314,0.00010491166,0.00013205074],"domain_scores_gemma":[0.99955696,0.00007160219,0.000050742015,0.00018775032,0.0000687161,0.00006420843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000015889827,0.000096730044,0.0002505738,0.000039281415,0.000054400258,0.0000039964957,0.000024660783,0.00008261668,0.00017281022],"category_scores_gemma":[0.000008283536,0.00007217219,0.00003358058,0.00007354755,0.00014393016,0.000042430478,0.000015788934,0.000094933246,0.000014992835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040563144,0.00096484844,0.9703979,0.00020658511,0.0005021578,0.0028266446,0.000084458305,1.5504436e-7,0.0000032970408,0.013781353,0.0051321615,0.005694837],"study_design_scores_gemma":[0.004561458,0.000082887454,0.97827256,0.000076660224,0.0000727315,0.0010967815,0.00007129144,0.000005893791,0.0025065865,0.0005397055,0.0126346005,0.00007884737],"about_ca_topic_score_codex":5.1730444e-7,"about_ca_topic_score_gemma":6.0553054e-7,"teacher_disagreement_score":0.013241648,"about_ca_system_score_codex":0.0000038043668,"about_ca_system_score_gemma":0.00003598142,"threshold_uncertainty_score":0.29430965},"labels":[],"label_agreement":null},{"id":"W3208098493","doi":"10.1007/s13555-021-00631-8","title":"Perception and Experience of Biologic Therapy in Atopic Dermatitis: A Qualitative Focus Group Study of Physicians and Patients in Europe and Canada","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Department of Medicine, University of Toronto; LEO Pharma Research Foundation; Sorbonne Université; Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf; Royal Free London NHS Foundation Trust; LEO Pharma; University of Toronto","keywords":"Medicine; Dupilumab; Atopic dermatitis; Quality of life (healthcare); Tolerability; Psychosocial; Adverse effect; Focus group; Specialty; Intensive care medicine; Family medicine; Dermatology; Psychiatry; Internal medicine; Nursing","score_opus":0.016814737691487294,"score_gpt":0.29568854526150573,"score_spread":0.27887380757001845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208098493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936654,0.0057117273,0.0000023371945,0.00030105142,0.000022030836,0.00025728813,0.000006911048,0.0000036253696,0.000029606146],"genre_scores_gemma":[0.99243885,0.0068903314,0.000019148765,0.0006106072,0.0000020861562,0.000022637716,0.000009907876,0.0000042908828,0.0000021317571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901915,0.00038488352,0.0002424092,0.0001881874,0.000056515175,0.00010883267],"domain_scores_gemma":[0.9996094,0.00014801975,0.00007373191,0.000082730425,0.000057927813,0.000028171233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000044411663,0.00010055433,0.0003725412,0.000065409746,0.000033938963,0.0000028406043,0.000024205949,0.000061502506,0.0000062257227],"category_scores_gemma":[0.000033587756,0.00008288915,0.000008241511,0.00012058052,0.00025114542,0.00005708917,0.000021119256,0.00007892731,4.4496463e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011860336,0.00045932518,0.9591737,0.000042059655,0.00003423896,0.00012574182,0.032200668,5.1076917e-8,0.0003070445,0.000071374314,0.000022888635,0.0074443202],"study_design_scores_gemma":[0.0042249644,0.00022994344,0.9721754,0.000047292393,0.0000066812368,0.00011685923,0.022436788,0.000011085604,0.00041223172,0.0002192189,0.000050391354,0.000069134876],"about_ca_topic_score_codex":0.01814056,"about_ca_topic_score_gemma":0.06928291,"teacher_disagreement_score":0.05114235,"about_ca_system_score_codex":0.0000049561995,"about_ca_system_score_gemma":0.000040344523,"threshold_uncertainty_score":0.9883977},"labels":[],"label_agreement":null},{"id":"W3208931909","doi":"10.1007/s13555-021-00635-4","title":"Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Amgen","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Population; Dermatology; Dactylitis; Disease; Physical therapy; Family medicine; Internal medicine; Enthesitis; Environmental health","score_opus":0.04574691052094136,"score_gpt":0.2830449940988742,"score_spread":0.2372980835779328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208931909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9701904,0.026985552,0.0005373919,0.0011195646,0.00018053933,0.0004670728,0.00049093534,0.000010147195,0.00001838163],"genre_scores_gemma":[0.9928613,0.0063868226,0.000074305965,0.00009335629,0.000028710068,0.000058977592,0.0004737542,0.000009672317,0.000013156643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991156,0.00015079114,0.00028958442,0.00021319713,0.00009950446,0.00013135544],"domain_scores_gemma":[0.9988453,0.0005936948,0.00015030289,0.00023905335,0.00008833839,0.00008334194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000040512496,0.00012591884,0.00033392658,0.00003594938,0.00021441109,0.000005441733,0.000026155923,0.00003913325,0.000013736651],"category_scores_gemma":[0.000123806,0.00008241633,0.00010183417,0.00009984861,0.00011142628,0.000030698557,0.00001473144,0.000028959015,7.655317e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065180296,0.0013255596,0.9713776,0.00008104146,0.0014516949,0.00011711212,0.007931637,0.00002387467,0.00017585077,0.004740988,0.00026870784,0.005987888],"study_design_scores_gemma":[0.010680058,0.00023690709,0.9780454,0.00014594488,0.00032940003,0.000012030064,0.0023537423,0.00039745428,0.00021994377,0.0071068923,0.00038174435,0.000090477806],"about_ca_topic_score_codex":0.0002488837,"about_ca_topic_score_gemma":0.00021875749,"teacher_disagreement_score":0.02267083,"about_ca_system_score_codex":0.00009372441,"about_ca_system_score_gemma":0.00013078046,"threshold_uncertainty_score":0.336084},"labels":[],"label_agreement":null},{"id":"W3211156244","doi":"10.1007/s13555-021-00632-7","title":"A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Palmoplantar pustulosis; Medicine; Double blind; Placebo; Dermatology; Randomized controlled trial; Internal medicine; Psoriasis; Alternative medicine; Pathology","score_opus":0.02480674125765737,"score_gpt":0.29438390573820644,"score_spread":0.2695771644805491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211156244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775658,0.01847811,0.000019777328,0.0007594359,0.00014768308,0.0027705298,0.000017928834,0.000017452323,0.00022324713],"genre_scores_gemma":[0.9961294,0.0030496314,0.000017699134,0.00020530926,0.000010549287,0.00042077174,0.000042768683,0.000013390905,0.00011048839],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971567,0.001695435,0.0004406253,0.00037280953,0.00004729874,0.00028715516],"domain_scores_gemma":[0.9980323,0.0014624322,0.00011366059,0.00028846724,0.00007056118,0.000032631597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074416754,0.0002645837,0.0011600188,0.00013784505,0.00021559646,0.00001448971,0.000116265364,0.00015236747,0.00008585246],"category_scores_gemma":[0.000045427947,0.00014829231,0.00008386746,0.00021681665,0.0002822367,0.00004257504,0.00004641802,0.00017092205,0.000012585128],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9629876,0.0014520965,0.020034814,0.000010955426,0.0025325213,0.00017350426,0.005446983,0.0000039548595,0.0021304968,0.0002767669,0.00003201026,0.004918269],"study_design_scores_gemma":[0.97573084,0.0005096754,0.0035017808,0.000028820206,0.0005214951,0.00080315856,0.0013277022,0.000004677576,0.0169845,0.00007130093,0.00033770225,0.0001783655],"about_ca_topic_score_codex":0.00009951236,"about_ca_topic_score_gemma":0.00034907076,"teacher_disagreement_score":0.018563557,"about_ca_system_score_codex":0.000008095731,"about_ca_system_score_gemma":0.000073401585,"threshold_uncertainty_score":0.6047185},"labels":[],"label_agreement":null},{"id":"W3213457292","doi":"10.1007/s13555-021-00621-w","title":"Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"Sanofi Genzyme; Regeneron Pharmaceuticals; Sanofi","keywords":"Dupilumab; Atopic dermatitis; Medicine; Dermatology Life Quality Index; Placebo; Quality of life (healthcare); Eczema Area and Severity Index; Internal medicine; Dermatology; Disease; Clinical trial; Alternative medicine; Pathology","score_opus":0.011400116157297142,"score_gpt":0.27204845747962947,"score_spread":0.26064834132233233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213457292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9565093,0.030811708,0.000007757704,0.009121303,0.00007720241,0.00017371046,0.000002946198,0.000015478212,0.0032806296],"genre_scores_gemma":[0.9943105,0.0021391392,0.00003520052,0.0034415706,0.000009693654,0.000017369386,0.000008514215,0.000006166408,0.000031860312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992643,0.00016831438,0.00020452775,0.00015189238,0.00006651021,0.00014443778],"domain_scores_gemma":[0.9994132,0.00021475129,0.000052346582,0.0002015586,0.00007808746,0.000040037678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000028109436,0.000091314,0.00028162554,0.000056266406,0.00006273564,0.0000042880392,0.000047290017,0.000101691796,0.00011102747],"category_scores_gemma":[0.000079510726,0.00006376974,0.0000616001,0.00013962376,0.0002641241,0.00003782039,0.000022916389,0.00014932547,0.000007579145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035213775,0.0008453213,0.95173043,0.00007648991,0.0003100901,0.0023390476,0.006630169,0.0000013097128,0.00021958079,0.02302096,0.0037780553,0.0106964195],"study_design_scores_gemma":[0.004331093,0.000036449088,0.96635336,0.000054132397,0.00003256769,0.005118445,0.0020387708,0.000027049231,0.01020501,0.00507007,0.0066466685,0.000086375425],"about_ca_topic_score_codex":0.000017081684,"about_ca_topic_score_gemma":0.000016878785,"teacher_disagreement_score":0.03780122,"about_ca_system_score_codex":0.000008328626,"about_ca_system_score_gemma":0.00009376072,"threshold_uncertainty_score":0.26004544},"labels":[],"label_agreement":null},{"id":"W3217600324","doi":"10.1007/s13555-021-00567-z","title":"Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Atopic dermatitis; Dermatology; Medicine; Content (measure theory); Mathematics","score_opus":0.014611556947680158,"score_gpt":0.2674827593194101,"score_spread":0.25287120237172994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217600324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355173,0.0034773438,0.0009924654,0.0012084715,0.000091318936,0.0006308383,0.0000055104106,0.000012283523,0.000030061297],"genre_scores_gemma":[0.99675393,0.0006942298,0.0010305664,0.0013374649,0.0000044122694,0.0001097682,0.000031656826,0.00000825404,0.000029734798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925315,0.00006106549,0.00023769353,0.00024001619,0.0000653387,0.00014270468],"domain_scores_gemma":[0.9995958,0.000063515174,0.0000539879,0.000077585806,0.000096312535,0.00011275688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047271395,0.00012354142,0.0003197374,0.00009280544,0.00008230347,0.00001321262,0.000016973307,0.00008470709,0.0000030406225],"category_scores_gemma":[0.000024412906,0.00010453161,0.000011545728,0.00006868825,0.00006511385,0.000064057596,0.000021645763,0.000072112634,2.880539e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087075355,0.00018254842,0.94508106,0.00040324018,0.000095220275,0.00008727827,0.0015010769,0.000002639316,0.0001624751,0.00007983562,0.00016407279,0.051369824],"study_design_scores_gemma":[0.0059989765,0.00016742256,0.9716094,0.0007679184,0.000032379405,0.0021863356,0.00055599044,0.0004433541,0.01738231,0.00009994366,0.00061793544,0.00013804102],"about_ca_topic_score_codex":0.00000951598,"about_ca_topic_score_gemma":0.00008719097,"teacher_disagreement_score":0.051231783,"about_ca_system_score_codex":0.000012859979,"about_ca_system_score_gemma":0.000084638734,"threshold_uncertainty_score":0.42626753},"labels":[],"label_agreement":null},{"id":"W4200154151","doi":"10.1007/s13555-021-00642-5","title":"Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Dermatrials Research; Ottawa Hospital; Innovaderm (Canada); University of British Columbia; Probity Medical Research; Centre de Recherche Dermatologique du Québec Métropolitain; University of Alberta; Lynde Centre for Dermatology; McMaster University; SKiN Health; University of Ottawa","funders":"Janssen Canada; AbbVie; LEO Pharma; Novartis","keywords":"Psoriasis; Inference; Computer science; Medicine; Management science; Intensive care medicine; Dermatology; Engineering; Artificial intelligence","score_opus":0.6304445897635514,"score_gpt":0.5953265520917284,"score_spread":0.03511803767182309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200154151","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32188082,0.004906815,0.33229783,0.33961785,0.00032973106,0.000856623,0.000011684174,0.00003095789,0.000067702094],"genre_scores_gemma":[0.48100117,0.011434101,0.48866966,0.018606279,0.00009410273,0.00009384059,0.000056318953,0.000014834632,0.000029673372],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987523,0.0003137729,0.0005378476,0.00019860345,0.00008059213,0.000116906405],"domain_scores_gemma":[0.9943731,0.0047877487,0.00015927677,0.00022310668,0.00040765677,0.00004912377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091823476,0.00008493173,0.00027121033,0.000029538576,0.00007164843,0.000008183786,0.000033202767,0.0000923046,0.000047574234],"category_scores_gemma":[0.001870908,0.000055357672,0.000039814382,0.00006537936,0.0001370674,0.00006469208,0.000024499657,0.00010555422,6.4358966e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005903891,0.0007338162,0.029981684,0.00054067327,0.0018349189,0.00028635305,0.0004906223,0.0000120306395,0.0047500674,0.11426649,0.0055634906,0.83563596],"study_design_scores_gemma":[0.062470876,0.0034973004,0.1444958,0.00037069133,0.004595023,0.007847924,0.021120703,0.054998886,0.07169161,0.11186747,0.5161446,0.00089913607],"about_ca_topic_score_codex":0.00001623367,"about_ca_topic_score_gemma":0.000017858101,"teacher_disagreement_score":0.8347368,"about_ca_system_score_codex":0.000003269828,"about_ca_system_score_gemma":0.00012467036,"threshold_uncertainty_score":0.22574204},"labels":[],"label_agreement":null},{"id":"W4200232143","doi":"10.1007/s13555-021-00661-2","title":"Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; SKiN Health; University of Calgary","funders":"LEO Pharma; Bausch Health; Eisai; Sanofi Genzyme; Incyte; Dermira; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Amgen; Boehringer Ingelheim; Celgene; Sanofi; Meiji Seika Pharma; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Referral; Medicine; Health care; Clinical Practice; Multidisciplinary approach; Front line; Family medicine","score_opus":0.021628210300348567,"score_gpt":0.31553662836221386,"score_spread":0.2939084180618653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200232143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81257784,0.17154707,0.000024144858,0.014658118,0.0003871319,0.0001704428,0.000045142086,0.0000064250585,0.00058366585],"genre_scores_gemma":[0.9440085,0.053339135,0.00076732965,0.0015484088,0.000065637614,0.000040223924,0.00012802728,0.0000051459747,0.00009759038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980837,0.0012040146,0.00028970142,0.00023398268,0.00003697212,0.00015159069],"domain_scores_gemma":[0.9987419,0.0008248064,0.00011129917,0.00025110538,0.000058527603,0.000012333482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031657217,0.00013363984,0.00027175198,0.000023732604,0.00014436686,0.000013692265,0.00014610191,0.00017973862,0.00013686162],"category_scores_gemma":[0.00004295722,0.00007961256,0.00007222239,0.00012904315,0.0002761956,0.000056459863,0.0000472857,0.00013830815,0.000012057442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043176375,0.0045088483,0.5296879,0.000040160114,0.014165419,0.00035542046,0.025299897,0.0000029882924,0.0015891525,0.2560055,0.007792972,0.15623412],"study_design_scores_gemma":[0.011569539,0.00015955693,0.8150629,0.00004413551,0.0008312185,0.0012637413,0.038656205,0.0000048699694,0.001948617,0.013330333,0.11685921,0.00026966608],"about_ca_topic_score_codex":0.00012481379,"about_ca_topic_score_gemma":0.00006450832,"teacher_disagreement_score":0.28537503,"about_ca_system_score_codex":0.000009383106,"about_ca_system_score_gemma":0.00004941179,"threshold_uncertainty_score":0.3246506},"labels":[],"label_agreement":null},{"id":"W4205675137","doi":"10.1007/s13555-021-00649-y","title":"Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Probity Medical Research","funders":"LEO Pharma; Kyowa Hakko Kirin; Sanofi Genzyme; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Genentech; Valeant Pharmaceuticals International; Sanofi; Celgene; Biogen; GlaxoSmithKline; Amgen; Meiji Seika Pharma; Pfizer; Galderma; Ortho Dermatologics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriasis; Quality of life (healthcare); Clinical trial; Medicine; Phase (matter); Quality (philosophy); Intensive care medicine; Internal medicine; Dermatology; Nursing; Philosophy; Physics","score_opus":0.08333823224810268,"score_gpt":0.36791601861026796,"score_spread":0.2845777863621653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205675137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99265814,0.0051345835,0.0000093660865,0.0009018469,0.00058228814,0.00053176825,0.00008454337,0.000018505565,0.000078979574],"genre_scores_gemma":[0.9976459,0.0009086845,0.000042150314,0.0010292231,0.0000123984755,0.0002055869,0.00004504793,0.000010074412,0.00010090153],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99705684,0.0015869283,0.0007313209,0.0003335673,0.00003194119,0.00025940657],"domain_scores_gemma":[0.99904394,0.00059830904,0.00013241907,0.00017370743,0.000014120636,0.00003752294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006438378,0.00017280735,0.00082858594,0.00021815347,0.00012958632,0.000005170922,0.00011614629,0.00021026676,0.00014792834],"category_scores_gemma":[0.000089193505,0.00015252207,0.00007931253,0.00014837935,0.00014091781,0.000046185047,0.00007767589,0.0002515496,0.000007898563],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17450081,0.002142766,0.7628941,0.000016534093,0.0004982258,0.000057844667,0.0025253715,0.000006466444,0.001261343,0.0024603875,0.00017341091,0.053462755],"study_design_scores_gemma":[0.6552362,0.0025000735,0.3201757,0.000019793311,0.000066128065,0.0002883469,0.0019072245,0.000020916881,0.0028481544,0.0033074312,0.01289237,0.00073765253],"about_ca_topic_score_codex":0.00011330212,"about_ca_topic_score_gemma":0.00013340337,"teacher_disagreement_score":0.4807354,"about_ca_system_score_codex":0.000008004579,"about_ca_system_score_gemma":0.000066749315,"threshold_uncertainty_score":0.62196696},"labels":[],"label_agreement":null},{"id":"W4206112747","doi":"10.1007/s13555-021-00679-6","title":"Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"Celgene; Eli Lilly and Company; AbbVie; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Psoriasis Area and Severity Index; Secukinumab; Internal medicine; Body mass index; Psoriasis; Disease; Dermatology","score_opus":0.012722383655553214,"score_gpt":0.23173519781918517,"score_spread":0.21901281416363194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206112747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599165,0.0026532596,0.000008184248,0.00012939016,0.00034884945,0.00063979777,0.00015881145,0.000020930598,0.000049139937],"genre_scores_gemma":[0.99924266,0.00008281694,0.000012167639,0.00013120993,0.00000782888,0.0001632071,0.00032465236,0.000014464794,0.000021011041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981612,0.0007969156,0.00030763622,0.00038981586,0.000071019684,0.0002734395],"domain_scores_gemma":[0.99901456,0.0004026257,0.00013585952,0.00039414607,0.000032713375,0.000020094789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012477778,0.00022341138,0.0005477542,0.00020561887,0.0003639394,0.000007799143,0.00026782937,0.00010426261,0.00043590588],"category_scores_gemma":[0.0000088266925,0.00015117596,0.00009618457,0.00063721696,0.00008819567,0.00004600537,0.000096648684,0.00020877166,0.000012180805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03866224,0.0018441774,0.93706775,0.000001317842,0.0060775587,0.000020060788,0.0062967553,0.00017205454,0.00007208074,0.00008355878,0.00011703413,0.009585401],"study_design_scores_gemma":[0.03825581,0.0009593727,0.9569266,0.0000025022846,0.00061360875,0.000005239763,0.0017193797,0.000006763326,0.0005038564,0.00004053147,0.00076961634,0.00019673519],"about_ca_topic_score_codex":0.00068008195,"about_ca_topic_score_gemma":0.00043795805,"teacher_disagreement_score":0.019858822,"about_ca_system_score_codex":0.000026387796,"about_ca_system_score_gemma":0.0000315368,"threshold_uncertainty_score":0.61647767},"labels":[],"label_agreement":null},{"id":"W4206401696","doi":"10.1007/s13555-021-00656-z","title":"Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey","year":2022,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Mental Health and Psychiatry","field":"Arts and Humanities","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Disease; Perception; Psoriasis; Medicine; Dermatology; Psychology; Pathology; Neuroscience","score_opus":0.05836838919314624,"score_gpt":0.2798845869733298,"score_spread":0.22151619778018355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206401696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6577768,0.0856849,0.001180976,0.0054710032,0.21828282,0.0066637425,0.021266,0.00012317472,0.003550594],"genre_scores_gemma":[0.9890233,0.003287155,0.000007116494,0.00034082268,0.0005438943,0.00022740147,0.0041533276,0.000025882917,0.0023910864],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983656,0.00042833842,0.0005291221,0.00030814303,0.00017065082,0.00019813939],"domain_scores_gemma":[0.99823415,0.00080721214,0.00047710343,0.00028747128,0.000057790447,0.00013626472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011559311,0.00022696529,0.00040594183,0.00012668267,0.0009214361,0.000025144653,0.00010654501,0.00007053292,0.00023360495],"category_scores_gemma":[0.00005662031,0.00016253258,0.00013249496,0.00005775606,0.00013329802,0.00005290265,0.00002131081,0.00014985556,0.0000018858925],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01032711,0.0010082792,0.01341831,0.0005434479,0.00069026777,0.000005732645,0.12222587,0.000070616086,0.0000010645911,0.03422425,0.8122775,0.00520755],"study_design_scores_gemma":[0.007302052,0.001705962,0.13284698,0.000971883,0.0006856075,0.0000054679167,0.03996802,0.003350468,0.0000034149816,0.04905392,0.7632195,0.00088673894],"about_ca_topic_score_codex":0.0031366285,"about_ca_topic_score_gemma":0.0045780754,"teacher_disagreement_score":0.33124653,"about_ca_system_score_codex":0.0002295538,"about_ca_system_score_gemma":0.00032341536,"threshold_uncertainty_score":0.70870346},"labels":[],"label_agreement":null},{"id":"W4213031527","doi":"10.1007/s13555-022-00690-5","title":"Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Manchester Biomedical Research Centre; National Institute for Health and Care Research; Dermira; Castle Biosciences; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Sanofi Genzyme; Incyte; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer","keywords":"Psoriasis Area and Severity Index; Medicine; Psoriasis; Internal medicine; Placebo; Clinical trial; Randomized controlled trial; Ixekizumab; Gastroenterology; Dermatology","score_opus":0.0738873349008602,"score_gpt":0.3023967785833831,"score_spread":0.2285094436825229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213031527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883936,0.010562596,0.000014302453,0.00014086429,0.00009385533,0.0004364831,0.00029546543,0.000007137773,0.000055664004],"genre_scores_gemma":[0.99807626,0.0011431118,0.000079467114,0.00025951804,0.0000064623127,0.00015665582,0.00023115205,0.000006992898,0.000040370298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787146,0.0011866253,0.00041181926,0.000275932,0.000047636186,0.00020653063],"domain_scores_gemma":[0.9988591,0.00058627286,0.00022288195,0.00027303727,0.000044588218,0.00001411069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002304107,0.00018483214,0.0010392454,0.00013387618,0.00015130559,0.000002745618,0.00014657555,0.00014101907,0.00035564648],"category_scores_gemma":[0.0000056560934,0.000099023484,0.0003605839,0.00046679034,0.00013755978,0.000023542538,0.00002856161,0.000093968956,0.0000028380196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004792867,0.0016584157,0.91868335,0.0000021715116,0.062535174,0.0000054469583,0.0021472203,0.002247139,0.0000061683986,0.0011854332,0.000093508716,0.0066431244],"study_design_scores_gemma":[0.009838338,0.0032191311,0.9595038,0.0000013575094,0.020805262,0.000015484426,0.00034688276,0.000022074351,0.00043062956,0.0005596867,0.0050060796,0.0002512574],"about_ca_topic_score_codex":0.00006155449,"about_ca_topic_score_gemma":0.000066790635,"teacher_disagreement_score":0.041729916,"about_ca_system_score_codex":0.000010261645,"about_ca_system_score_gemma":0.000020691528,"threshold_uncertainty_score":0.40380606},"labels":[],"label_agreement":null},{"id":"W4213328363","doi":"10.1007/s13555-022-00687-0","title":"A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma; National Institute for Health and Care Research; Manchester Biomedical Research Centre; UCB","keywords":"Psoriasis; Medicine; Dermatology; Antifungal; Interleukin 17; Disease; Invasive candidiasis; Incidence (geometry); Intensive care medicine; Immunology; Immune system; Internal medicine; Fluconazole","score_opus":0.01712598439463311,"score_gpt":0.2629888597760026,"score_spread":0.2458628753813695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213328363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99575806,0.0011259858,0.000051366897,0.0016683305,0.00030459362,0.0006109866,0.00006225125,0.000019567437,0.00039886578],"genre_scores_gemma":[0.9975954,0.0004362183,0.0006712501,0.0004422364,0.0000037404623,0.00033341994,0.00012202323,0.000015181048,0.00038051908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986652,0.00044541107,0.0002374218,0.00029332013,0.00006025816,0.00029837346],"domain_scores_gemma":[0.99946135,0.00012237496,0.00011755135,0.00025435945,0.000021176162,0.000023186103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016356533,0.00019604093,0.00033482464,0.00013723399,0.0002674474,0.000008590675,0.00016652403,0.000087565655,0.00032259867],"category_scores_gemma":[0.0000037779307,0.00012781988,0.000050472365,0.00019256255,0.00008667013,0.00007345039,0.00011072455,0.00014926383,0.0000129263935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005354952,0.0010947672,0.9359615,0.000014505395,0.0027646401,0.00013847495,0.0027342841,0.00001728743,0.00008553745,0.00055217685,0.0065065185,0.04477538],"study_design_scores_gemma":[0.018526629,0.0012534386,0.83595645,0.00004388467,0.00029443085,0.00031349837,0.0027193585,0.0000035077367,0.0080478685,0.00015989481,0.1322851,0.0003959363],"about_ca_topic_score_codex":0.00016268465,"about_ca_topic_score_gemma":0.00008724453,"teacher_disagreement_score":0.12577859,"about_ca_system_score_codex":0.000052459516,"about_ca_system_score_gemma":0.00002951235,"threshold_uncertainty_score":0.52123433},"labels":[],"label_agreement":null},{"id":"W4220793238","doi":"10.1007/s13555-022-00704-2","title":"Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre; Western University","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Psoriasis; Psoriatic arthritis; Dermatology; Medicine; Nail (fastener); Secukinumab","score_opus":0.03272359154223959,"score_gpt":0.2870244712254104,"score_spread":0.25430087968317083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220793238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95923775,0.03687406,0.00010786276,0.0017424347,0.0005798298,0.0011555799,0.000223267,0.000043367265,0.000035827154],"genre_scores_gemma":[0.9920767,0.0052791717,0.0002337222,0.0014293693,0.000034010067,0.0006438663,0.00006689462,0.000027739177,0.00020855035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976515,0.0008303769,0.00048311902,0.00054890505,0.00003840227,0.00044766537],"domain_scores_gemma":[0.9984002,0.0011919173,0.00011100322,0.00019881997,0.000033880744,0.00006415132],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046030647,0.00028672084,0.0009178186,0.00023312012,0.00055584504,0.000026171647,0.00011813307,0.00023954347,0.00010004028],"category_scores_gemma":[0.00014008723,0.00026801528,0.00007604052,0.00017869579,0.00010359791,0.00006316162,0.0000756391,0.00018892957,0.000016736394],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013658836,0.0002258075,0.0015417708,0.00003065166,0.00039341082,0.0000943886,0.0037390422,0.00013320876,0.0018223851,0.00080269406,0.000569916,0.9769879],"study_design_scores_gemma":[0.19607131,0.00940714,0.08422063,0.00033335685,0.0006272578,0.01627119,0.0048634764,0.0015386307,0.05603919,0.024781484,0.60141706,0.0044292337],"about_ca_topic_score_codex":0.00009394474,"about_ca_topic_score_gemma":0.00023981175,"teacher_disagreement_score":0.9725587,"about_ca_system_score_codex":0.000023536168,"about_ca_system_score_gemma":0.00004256432,"threshold_uncertainty_score":0.99997723},"labels":[],"label_agreement":null},{"id":"W4220927294","doi":"10.1007/s13555-022-00707-z","title":"Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Ustekinumab; Discontinuation; Medicine; Psoriasis; Dermatology; Plaque psoriasis; Internal medicine; Disease; Infliximab","score_opus":0.02282714459850081,"score_gpt":0.23854891269022555,"score_spread":0.21572176809172475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220927294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980082,0.001145649,0.000002119106,0.00006233785,0.0000918834,0.0003648427,0.00013502981,0.000008925432,0.00018103386],"genre_scores_gemma":[0.9988956,0.0006399162,0.000006867219,0.00017230629,0.0000036223785,0.0001334299,0.000114731214,0.000006711443,0.000026814743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986653,0.00082762114,0.00015718429,0.00018365949,0.000023035582,0.00014321848],"domain_scores_gemma":[0.9994432,0.0002584628,0.00014121973,0.00013745442,0.000012781949,0.0000068953163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011487678,0.00014032103,0.00022845952,0.0000917671,0.00023057955,0.0000044075455,0.00007169323,0.000094322466,0.00008865375],"category_scores_gemma":[0.000006642824,0.00007599487,0.000029518105,0.00010493693,0.00018838269,0.000029150999,0.000015720627,0.000100643476,0.0000029394362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010136327,0.00046524883,0.97156745,0.0000010018982,0.00027389763,0.000004894363,0.0019908156,0.0000059025574,0.00010016512,0.0003625477,0.0000150201,0.024199432],"study_design_scores_gemma":[0.006755458,0.0016999004,0.98628664,0.000004344534,0.00006195666,0.000030036768,0.00046952034,0.000003001128,0.0017639276,0.00012248917,0.0027008543,0.00010185603],"about_ca_topic_score_codex":0.000292957,"about_ca_topic_score_gemma":0.00024875827,"teacher_disagreement_score":0.024097575,"about_ca_system_score_codex":0.000015208203,"about_ca_system_score_gemma":0.00001250971,"threshold_uncertainty_score":0.30989808},"labels":[],"label_agreement":null},{"id":"W4220987608","doi":"10.1007/s13555-022-00703-3","title":"Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS)","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dermatrials Research; TransCanada (Canada); Memorial University of Newfoundland; Barrie Urology Group; Lynde Centre for Dermatology","funders":"AbbVie","keywords":"Plaque psoriasis; Adalimumab; Psoriasis; Observational study; Medicine; Dermatology; Internal medicine; Tumor necrosis factor alpha","score_opus":0.11494625202222078,"score_gpt":0.2949359315501205,"score_spread":0.1799896795278997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220987608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948019,0.0011110973,0.000033180393,0.0006029257,0.00030005522,0.0013378651,0.0017571852,0.000009951548,0.000045855486],"genre_scores_gemma":[0.9977854,0.00011705101,0.000033338994,0.00037685927,0.000012844064,0.00078345765,0.00087299495,0.0000067653127,0.000011308163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962676,0.002630045,0.0004649993,0.0003456416,0.00005350555,0.00023821996],"domain_scores_gemma":[0.9979426,0.0016057115,0.00012502928,0.00024790154,0.00004164557,0.000037056478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003585622,0.00018691648,0.0006179531,0.00015790142,0.00023486806,0.0000037493144,0.00021761745,0.00010422198,0.00007376346],"category_scores_gemma":[0.000029984307,0.00013714483,0.000072369636,0.00019227831,0.000051270494,0.000025540185,0.000020378668,0.00008812178,0.000007512516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07811013,0.011175137,0.7189962,0.00009111281,0.0063469796,0.00039473118,0.08120281,0.01235872,0.06670417,0.009191112,0.0011854981,0.0142433625],"study_design_scores_gemma":[0.0145438,0.0017982083,0.9722742,0.0000368262,0.00007056842,0.0001346893,0.002182859,0.000038697715,0.0062232767,0.001337422,0.0011450219,0.00021445776],"about_ca_topic_score_codex":0.015826937,"about_ca_topic_score_gemma":0.006562362,"teacher_disagreement_score":0.25327793,"about_ca_system_score_codex":0.00010434187,"about_ca_system_score_gemma":0.00010587304,"threshold_uncertainty_score":0.99072677},"labels":[],"label_agreement":null},{"id":"W4223967404","doi":"10.1007/s13555-022-00721-1","title":"Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"Janssen Pharmaceuticals; Sanofi Genzyme; LEO Pharma; Bausch Health; Kyowa Hakko Kirin; Lundbeckfonden; Glenmark Pharmaceuticals; Dermira; UCB Pharma; Regeneron Pharmaceuticals; Celgene; Genentech; Valeant Pharmaceuticals International; Kiniksa Pharmaceuticals; AbbVie; Sanofi; Amgen; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Eczema Area and Severity Index; Atopic dermatitis; Medicine; Clinical endpoint; Placebo; Internal medicine; Meta-analysis; Randomized controlled trial; Dermatology; Alternative medicine","score_opus":0.050273596870138305,"score_gpt":0.3224130559871784,"score_spread":0.2721394591170401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223967404","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44549328,0.5463031,0.0011042608,0.0036357492,0.000050345163,0.003271764,0.00006668202,0.0000407591,0.00003403772],"genre_scores_gemma":[0.9859652,0.00389168,0.00024384179,0.008702725,0.0000074673057,0.0010475053,0.000056830944,0.000011227755,0.000073554445],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99803805,0.0006778176,0.00064330304,0.00028771616,0.00012879238,0.00022433393],"domain_scores_gemma":[0.99875814,0.0004712392,0.00024897838,0.00031001904,0.0000986532,0.00011298168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018116219,0.00021774946,0.0031168768,0.000113935785,0.0002493214,0.000010966291,0.00010108068,0.00007210387,0.00012417289],"category_scores_gemma":[0.00003607844,0.00015695355,0.00037842465,0.00026802934,0.00011766283,0.000051944167,0.000048450784,0.00012885452,0.0000015621599],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027728302,0.001188022,0.16753046,0.19771637,0.59845185,0.00032266666,0.013705575,0.0007108944,0.000146552,0.006565626,0.010698675,0.00019050414],"study_design_scores_gemma":[0.018637698,0.0014102249,0.081253454,0.004516075,0.8533237,0.024153195,0.0029730084,0.0056071593,0.0008116773,0.0034028355,0.0020427995,0.0018681511],"about_ca_topic_score_codex":0.000003915331,"about_ca_topic_score_gemma":0.0000033527806,"teacher_disagreement_score":0.54241145,"about_ca_system_score_codex":0.000009807009,"about_ca_system_score_gemma":0.00003649512,"threshold_uncertainty_score":0.640038},"labels":[],"label_agreement":null},{"id":"W4224236679","doi":"10.1007/s13555-022-00722-0","title":"Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lynde Centre for Dermatology; University of Alberta; BC Children's Hospital; Toronto General Hospital; McMaster University; SKiN Health; Probity Medical Research; University of British Columbia; University Health Network; Ottawa Hospital; Dermatrials Research; University of Ottawa; Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada)","funders":"Janssen Canada; Sanofi Genzyme; Novartis Pharmaceuticals Canada; Gilead Sciences; LEO Pharma; Bausch Health; Astellas Pharma; Sanofi; Kyowa Hakko Kirin; Genentech; Coherus Biosciences; Pfizer; Incyte; Sun Pharma; Dermira; BC Children's Hospital; Regeneron Pharmaceuticals; Baxalta; Celgene; ViiV Healthcare; Amgen; Amgen Canada; Meiji Seika Pharma; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Psoriasis; Medicine; Population; Intensive care medicine; Life expectancy; Viral load; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.04170993901513721,"score_gpt":0.26177482557682524,"score_spread":0.22006488656168804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224236679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95990425,0.03844959,0.00026269277,0.00016462321,0.00014411556,0.0007953182,0.0002548092,0.000020061774,0.0000045302645],"genre_scores_gemma":[0.99563587,0.0025608484,0.00027331573,0.00003797384,0.000006890711,0.0012870905,0.00012972998,0.000014932941,0.00005334866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861556,0.00052503566,0.00037120373,0.0002560606,0.000029966342,0.00020218002],"domain_scores_gemma":[0.99751294,0.0019603143,0.0002537012,0.0002190116,0.000041942007,0.000012113448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008173811,0.00020756159,0.0008514091,0.00014470692,0.00016396686,0.000003837465,0.00009660673,0.00012397899,0.000082769235],"category_scores_gemma":[0.000015345138,0.00014594526,0.000117851894,0.00010296771,0.00012461368,0.000055362394,0.000020246369,0.000040423434,8.018359e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014839946,0.0014372992,0.8511564,0.000030785664,0.0015371196,0.000013647686,0.025457455,0.00012889043,0.09584318,0.00022382494,0.000017904655,0.00931351],"study_design_scores_gemma":[0.16934775,0.006612477,0.64408886,0.00049576757,0.00047741018,0.00035485384,0.022102932,0.0010781573,0.1520014,0.00034183773,0.0020159583,0.0010825853],"about_ca_topic_score_codex":0.0004345233,"about_ca_topic_score_gemma":0.00011536532,"teacher_disagreement_score":0.20706756,"about_ca_system_score_codex":0.00002907988,"about_ca_system_score_gemma":0.00008524785,"threshold_uncertainty_score":0.5951475},"labels":[],"label_agreement":null},{"id":"W4280532101","doi":"10.1007/s13555-022-00742-w","title":"Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE)","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"Janssen Biotech; LEO Pharma; Glenmark Pharmaceuticals; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; Biogen; GlaxoSmithKline","keywords":"Dupilumab; Demographics; Atopic dermatitis; Medicine; Baseline (sea); Internal medicine; Dermatology; Demography","score_opus":0.013280773016405872,"score_gpt":0.27087603749648986,"score_spread":0.25759526448008396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280532101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99376744,0.004108583,0.0000019676252,0.001418219,0.00003496815,0.00036130846,0.000035313882,0.000016492515,0.0002557242],"genre_scores_gemma":[0.9898943,0.008874386,0.00008581259,0.00095117104,0.000007906354,0.00008896051,0.00007233342,0.000009045199,0.000016089543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998884,0.0002785006,0.00034588776,0.00022685944,0.00008389484,0.00018084525],"domain_scores_gemma":[0.99945426,0.00019379742,0.00011128243,0.00014163769,0.000033068456,0.00006594412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000867092,0.00014162452,0.00042892856,0.000252697,0.00011381353,0.000004616206,0.000038503833,0.00008698607,0.000025861835],"category_scores_gemma":[0.00004023204,0.00013226616,0.00002935908,0.000211076,0.00020592968,0.00005731649,0.000046255907,0.00018516571,1.7626135e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022333369,0.00030838177,0.9884114,0.0001251719,0.000048573238,0.00030836012,0.0015007271,0.0000012460011,0.000006523663,0.00027642943,0.00009058665,0.008699262],"study_design_scores_gemma":[0.007352889,0.00011580486,0.98906875,0.00007756002,0.000026163067,0.0006544546,0.00047448848,0.0005484698,0.000114526134,0.00073619524,0.0007179371,0.0001127443],"about_ca_topic_score_codex":0.0005306565,"about_ca_topic_score_gemma":0.00051398645,"teacher_disagreement_score":0.008586518,"about_ca_system_score_codex":0.000020160345,"about_ca_system_score_gemma":0.000051331128,"threshold_uncertainty_score":0.5393657},"labels":[],"label_agreement":null},{"id":"W4281731899","doi":"10.1007/s13555-022-00743-9","title":"Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Adverse effect; Internal medicine; Discontinuation; Psoriasis; Incidence (geometry); Mace; Psoriatic arthritis; Gastroenterology; Pediatrics; Disease; Dermatology","score_opus":0.042917860359638765,"score_gpt":0.29590337731369254,"score_spread":0.2529855169540538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281731899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355304,0.0026860647,0.000017295268,0.00007138703,0.00030239785,0.00061679684,0.0026690704,0.000015693528,0.00006823395],"genre_scores_gemma":[0.9971169,0.00066163205,0.00013563398,0.00031688402,0.000010447529,0.00006573524,0.001647797,0.000019676854,0.000025285086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641466,0.0018666204,0.00089149026,0.00049451896,0.000084523315,0.00024816568],"domain_scores_gemma":[0.99798083,0.00082401745,0.0004676182,0.00061691063,0.00007732737,0.00003328416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042645444,0.00021921012,0.0010605855,0.00013840556,0.00011772709,0.00000441136,0.0003272802,0.00023557048,0.0006732741],"category_scores_gemma":[0.00007132087,0.00016405524,0.00006892947,0.00018667988,0.00018437099,0.00010082595,0.00015359862,0.00024050454,0.0000048430843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07342228,0.0015004717,0.82010657,0.000011128836,0.001755168,0.000043253574,0.001697537,0.000059338814,0.00023327502,0.00009970344,0.0013927602,0.0996785],"study_design_scores_gemma":[0.055195108,0.0028595575,0.9308409,0.0000702055,0.00026354034,0.00006535341,0.00073317904,0.00001409785,0.0023232854,0.00017470779,0.007049749,0.00041030245],"about_ca_topic_score_codex":0.00020757955,"about_ca_topic_score_gemma":0.00011683237,"teacher_disagreement_score":0.110734336,"about_ca_system_score_codex":0.000012278285,"about_ca_system_score_gemma":0.000086392,"threshold_uncertainty_score":0.7371879},"labels":[],"label_agreement":null},{"id":"W4281877709","doi":"10.1007/s13555-022-00746-6","title":"Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Allergan; LEO Pharma; Bausch Health; Regeneron Pharmaceuticals; Sun Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Galderma; Incyte; Valeant Pharmaceuticals International; Celgene; Amgen; Pfizer","keywords":"Medicine; Psoriasis; Dermatology; Ixekizumab; Secukinumab; Scalp; Psoriatic arthritis","score_opus":0.02688408479749728,"score_gpt":0.2961091200770096,"score_spread":0.26922503527951236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281877709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005097093,0.99278665,3.5704372e-7,0.00015639202,0.00040813044,0.0011188115,0.000080999846,0.0000145168815,0.00033707093],"genre_scores_gemma":[0.0024002423,0.99668044,0.000004997765,0.00022453313,0.000010324618,0.0003593159,0.00013645936,0.000028151459,0.00015554357],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967432,0.0017287931,0.00079388416,0.00039009887,0.000054717126,0.00028933422],"domain_scores_gemma":[0.99845195,0.0004423641,0.0005503883,0.00049701065,0.000040709627,0.000017607901],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022242921,0.00041985698,0.0021661464,0.0002180292,0.00017321816,0.0000024791766,0.00044598238,0.0003713944,0.000637496],"category_scores_gemma":[0.00003800664,0.0002555397,0.00043604907,0.0006468277,0.00020008703,0.000028687373,0.00012342981,0.00034991797,0.000013344948],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007309597,0.000188416,0.0002615401,0.006214837,0.0007608445,0.0000054307407,0.0025080813,8.066118e-8,0.00011340319,0.0003602823,0.00021578945,0.9892982],"study_design_scores_gemma":[0.0010144494,0.00009466398,0.0001901874,0.0077149207,0.0006221338,0.00034874285,0.0004881694,4.982681e-8,0.000752279,0.00009607882,0.988424,0.00025432318],"about_ca_topic_score_codex":0.00004718112,"about_ca_topic_score_gemma":0.000014138289,"teacher_disagreement_score":0.9890439,"about_ca_system_score_codex":0.00003260964,"about_ca_system_score_gemma":0.00014515837,"threshold_uncertainty_score":0.9999897},"labels":[],"label_agreement":null},{"id":"W4285798219","doi":"10.1007/s13555-022-00763-5","title":"Elastic Silicone Occlusive Sheeting Versus Silicone Occlusive Sheeting in the Treatment of Scars: A Randomized Controlled Trial","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Thyroid and Parathyroid Surgery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Army Medical University","keywords":"Medicine; Scars; Occlusive dressing; Silicone; Occlusive; Surgery; Visual analogue scale; Hypertrophic scars; Thyroidectomy; Total thyroidectomy; Pathology; Internal medicine; Thyroid","score_opus":0.019723960188578547,"score_gpt":0.287402240517108,"score_spread":0.26767828032852947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285798219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9695418,0.023126038,0.000008626728,0.0015506771,0.00059800624,0.0039577866,0.000010282961,0.000028900604,0.0011779007],"genre_scores_gemma":[0.9947044,0.0032399613,0.000017479664,0.0006391425,0.00014679441,0.0011510461,0.0000336206,0.000019077002,0.00004847741],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962963,0.0019200117,0.00084498065,0.0003238127,0.0002560577,0.00035887645],"domain_scores_gemma":[0.99192137,0.0073105153,0.0003771201,0.00026907228,0.00005596583,0.00006594899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010447013,0.0002833934,0.0022045744,0.00024204164,0.00030969083,0.000013114532,0.00011408047,0.000117331634,0.000118240016],"category_scores_gemma":[0.000300791,0.00017664215,0.0004661139,0.00025957308,0.00030749672,0.00003990397,0.00003448133,0.0002696138,0.0000036415252],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9827704,0.0010033039,0.00092593627,0.000011214672,0.0007818825,0.00043159781,0.010572362,0.000053049243,0.0019600955,0.0004035317,0.00010343514,0.000983204],"study_design_scores_gemma":[0.9906773,0.0016358306,0.00018644171,0.000016149248,0.00026671283,0.0006827961,0.0036629778,0.0009295336,0.00071326527,0.00012946491,0.0009406029,0.00015891677],"about_ca_topic_score_codex":0.0000574921,"about_ca_topic_score_gemma":0.000010957701,"teacher_disagreement_score":0.025162619,"about_ca_system_score_codex":0.000050034687,"about_ca_system_score_gemma":0.00015453233,"threshold_uncertainty_score":0.72032577},"labels":[],"label_agreement":null},{"id":"W4288696372","doi":"10.1007/s13555-022-00768-0","title":"Evaluation of Psychological Wellbeing and Social Impact of Combined Facial and Truncal Acne: a Multi-national, Mixed-Methods Study","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Galderma","keywords":"Embarrassment; Feeling; Spouse; Psychology; Clinical psychology; Affection; Acne; Quality of life (healthcare); Developmental psychology; Medicine; Social psychology; Psychotherapist; Dermatology","score_opus":0.07886096000141292,"score_gpt":0.4828050190768056,"score_spread":0.4039440590753927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288696372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806505,0.0011239947,0.00004320978,0.00022725003,0.000048316735,0.00043201094,0.000009224039,0.000006317122,0.000044607576],"genre_scores_gemma":[0.9994859,0.00011079338,0.0002444319,0.000084366904,0.000011127919,0.00003741203,0.000016158208,0.0000044113126,0.000005392203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998779,0.00064795156,0.0001571079,0.00014293409,0.00018948157,0.00008352902],"domain_scores_gemma":[0.999672,0.000103510036,0.00007782065,0.000043652548,0.00007587482,0.000027121247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073028135,0.00008565713,0.00030256313,0.00006502903,0.0001864586,0.0000029648525,0.000020155756,0.00006327354,0.000050007697],"category_scores_gemma":[0.000025990212,0.000058254598,0.000044154724,0.00005895166,0.000121626574,0.000023546057,0.000029001907,0.00009297986,8.8692985e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023317817,0.0034547017,0.81382495,0.00002986414,0.000990979,0.000026369056,0.0073231943,0.0000068782197,0.007008791,0.00024473193,0.0002350136,0.16452274],"study_design_scores_gemma":[0.014414957,0.002148104,0.97929347,0.0000027658546,0.00015676575,0.00021982442,0.00089715846,0.0018967903,0.00026188392,0.00059198466,0.00005660981,0.000059663653],"about_ca_topic_score_codex":0.000019794095,"about_ca_topic_score_gemma":0.0000014409397,"teacher_disagreement_score":0.16546853,"about_ca_system_score_codex":0.000013897173,"about_ca_system_score_gemma":0.000038981558,"threshold_uncertainty_score":0.23755535},"labels":[],"label_agreement":null},{"id":"W4290190465","doi":"10.1007/s13555-022-00764-4","title":"Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); SKiN Health","funders":"Pfizer","keywords":"Eczema Area and Severity Index; Discontinuation; Medicine; Atopic dermatitis; Placebo; Internal medicine; SCORAD; Gastroenterology; Dermatology; Disease; Dermatology Life Quality Index; Pathology","score_opus":0.011163809703424142,"score_gpt":0.2820543683081328,"score_spread":0.2708905586047087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290190465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957739,0.00025364087,0.000014767457,0.002288002,0.000049500508,0.0015198996,0.000057659956,0.000012050405,0.000030565676],"genre_scores_gemma":[0.9976203,0.000019751607,0.000052810046,0.0014349122,0.000004859989,0.0007846692,0.000050949217,0.000008995454,0.00002278437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986318,0.00048628,0.00034290692,0.00023908397,0.000115274255,0.00018466046],"domain_scores_gemma":[0.99949217,0.00014240353,0.00006001693,0.00018836494,0.00003215049,0.0000849206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010602195,0.0001350262,0.00044288478,0.00023109201,0.000058615675,0.000004499167,0.000041409374,0.000061580504,0.00013469774],"category_scores_gemma":[0.000040567047,0.000107890715,0.000038293867,0.00020270683,0.00006386923,0.00006113343,0.000023417857,0.00009686232,0.0000024047476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31494597,0.0021632758,0.6779175,0.0000109162365,0.000038799844,0.00018939088,0.0019261927,0.000013666699,0.000012712627,0.00001787856,0.000048890488,0.0027147995],"study_design_scores_gemma":[0.11864782,0.0017724223,0.8779354,0.00002346306,0.000015226416,0.00007401072,0.00012907636,0.000035059507,0.00033757658,0.00014148791,0.0007845905,0.00010388681],"about_ca_topic_score_codex":0.000021755777,"about_ca_topic_score_gemma":0.00005763839,"teacher_disagreement_score":0.20001788,"about_ca_system_score_codex":0.00005474191,"about_ca_system_score_gemma":0.0000919157,"threshold_uncertainty_score":0.43996558},"labels":[],"label_agreement":null},{"id":"W4293242071","doi":"10.1007/s13555-022-00790-2","title":"Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"LEO Pharma; Bausch Health; Castle Biosciences; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Sanofi Genzyme; Incyte; Regeneron Pharmaceuticals; Helsinn; Celgene; Biogen; Sanofi; Amgen; Helsinn Therapeutics; Meiji Seika Pharma; Pfizer","keywords":"Medicine; Psoriasis; Concomitant; Metabolic syndrome; Internal medicine; Exacerbation; Comorbidity; Observational study; Dermatology; Obesity","score_opus":0.035528050407611284,"score_gpt":0.3204511661888236,"score_spread":0.2849231157812123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293242071","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04886608,0.9487095,2.677886e-7,0.000029538596,0.0002912821,0.001809504,0.00020893935,0.000017788016,0.0000670937],"genre_scores_gemma":[0.0022700033,0.99642634,0.00001966839,0.000110548535,0.000005177181,0.00025712556,0.00081887684,0.000032290493,0.000059961734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956705,0.0023025048,0.0010866593,0.0005844896,0.000049040606,0.0003068311],"domain_scores_gemma":[0.997907,0.0009953113,0.0006655677,0.00036237156,0.000030481651,0.000039299077],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003086841,0.00053801906,0.003967004,0.00020209777,0.00017070041,0.0000039418883,0.00018755299,0.0005130129,0.0003205712],"category_scores_gemma":[0.000039222592,0.0003472211,0.00025961472,0.0002882919,0.00040097762,0.000052872976,0.00007647287,0.000412311,0.000012184265],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007780989,0.00076069875,0.018417958,0.0015912456,0.005392236,0.00007140284,0.00027476344,5.738189e-9,7.67773e-8,0.00010665147,0.000085316366,0.97252154],"study_design_scores_gemma":[0.013976111,0.000877158,0.03237196,0.0042863064,0.0029845992,0.0007704711,0.000032409473,1.2968431e-8,0.0000017484092,0.000014004794,0.9442946,0.00039062704],"about_ca_topic_score_codex":0.000012450481,"about_ca_topic_score_gemma":0.0000046314226,"teacher_disagreement_score":0.9721309,"about_ca_system_score_codex":0.000022720846,"about_ca_system_score_gemma":0.00013640229,"threshold_uncertainty_score":0.99989796},"labels":[],"label_agreement":null},{"id":"W4296977517","doi":"10.1007/s13555-022-00805-y","title":"Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; SKiN Health","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Dermatology; Phase (matter); Pediatrics","score_opus":0.01822436368370999,"score_gpt":0.296372736844235,"score_spread":0.278148373160525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296977517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99519026,0.0017448138,0.0001016319,0.0020654916,0.00001339073,0.00078410073,0.000040242256,0.000023095141,0.00003694988],"genre_scores_gemma":[0.9967139,0.0010375244,0.00023048988,0.0018290492,0.000008628647,0.00009888931,0.000043383207,0.00001589502,0.000022242171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835813,0.00041364672,0.0004864384,0.00034672246,0.00014857572,0.00024648607],"domain_scores_gemma":[0.99908215,0.00031442166,0.00018151132,0.0002018996,0.000040074956,0.00017993017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010192619,0.0002148331,0.001224452,0.0002082783,0.00014039261,0.000012721198,0.00006622196,0.000051992785,0.00006373745],"category_scores_gemma":[0.000038293834,0.00014128059,0.000036345158,0.0003491516,0.0004014057,0.00006800078,0.000034951765,0.00020981401,4.069159e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03871738,0.0006305742,0.937453,0.000108245025,0.00044135746,0.0009038503,0.0020129967,0.000013248863,0.00001233785,0.00004741663,0.00006642224,0.019593222],"study_design_scores_gemma":[0.047716852,0.0022224432,0.93744123,0.000079957754,0.00032979436,0.009176777,0.0009579457,0.0007627246,0.00024778364,0.00003400942,0.0007548774,0.00027563112],"about_ca_topic_score_codex":0.00007246569,"about_ca_topic_score_gemma":0.0008398266,"teacher_disagreement_score":0.01931759,"about_ca_system_score_codex":0.000011596113,"about_ca_system_score_gemma":0.00010115773,"threshold_uncertainty_score":0.5761255},"labels":[],"label_agreement":null},{"id":"W4297878627","doi":"10.1007/s13555-022-00811-0","title":"Unmet Need in People with Psoriasis and Skin of Color in Canada and the United States","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bell (Canada); EVERSANA (Canada); Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Canadian Institute for Energy Training; Women's College Hospital; University of Toronto","funders":"Janssen Canada","keywords":"Psoriasis; Medicine; Ethnic group; Incidence (geometry); Family medicine; Dermatology","score_opus":0.015535834025596386,"score_gpt":0.23544727240543967,"score_spread":0.21991143837984328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297878627","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34298667,0.6563606,1.8869216e-7,0.000094588766,0.000076309974,0.00038774635,0.000073425545,0.0000036037545,0.000016842476],"genre_scores_gemma":[0.02611705,0.97305787,0.0000047671033,0.0001334685,0.0000028378831,0.0002084628,0.0004291974,0.000015606032,0.000030770116],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980233,0.0010929233,0.00036841462,0.0002585353,0.000025499574,0.0002313659],"domain_scores_gemma":[0.99829036,0.0013162011,0.00020548097,0.00016151625,0.000010899553,0.000015514584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018697587,0.00027668948,0.0013860438,0.00026560843,0.00010253624,0.000005085425,0.000118586024,0.00021465324,0.00007511857],"category_scores_gemma":[0.00001121625,0.00016223038,0.000042122705,0.00039382165,0.00029933295,0.000021470438,0.0000519298,0.00027342478,5.1073886e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021289343,0.00014247892,0.048763692,0.0013699959,0.0019502109,0.00015714108,0.003470686,0.000002421371,0.000001842318,0.0012721835,0.0002007883,0.9405396],"study_design_scores_gemma":[0.011158785,0.00013947781,0.0067396862,0.0003535617,0.00041698737,0.0014752169,0.0015092462,0.000005130968,0.00003298581,0.00013864406,0.9776719,0.00035832817],"about_ca_topic_score_codex":0.41637444,"about_ca_topic_score_gemma":0.6159803,"teacher_disagreement_score":0.9774712,"about_ca_system_score_codex":0.000041769177,"about_ca_system_score_gemma":0.00033949086,"threshold_uncertainty_score":0.6615563},"labels":[],"label_agreement":null},{"id":"W4301431315","doi":"10.1007/s13555-022-00819-6","title":"Burden of Atopic Dermatitis in Adults and Adolescents: a Systematic Literature Review","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AbbVie Biotherapeutics","keywords":"Atopic dermatitis; Medicine; Dermatology; Systematic review; Psychology; MEDLINE; Political science","score_opus":0.015943405666096238,"score_gpt":0.3004818760617718,"score_spread":0.28453847039567554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301431315","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002577234,0.997,5.199865e-7,0.00029986518,0.000092770075,0.0021574022,0.000033558565,0.000023848384,0.00013433721],"genre_scores_gemma":[0.0015458486,0.99652356,0.000010677301,0.0012643606,0.0000177946,0.00042072692,0.00016490498,0.000026581089,0.000025520752],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9975801,0.0007790801,0.00094473804,0.0003437491,0.00013185196,0.00022044759],"domain_scores_gemma":[0.9988459,0.0002419536,0.00040451132,0.00037604352,0.0000336317,0.00009798011],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013965403,0.00036423284,0.0034301116,0.00030803497,0.000058640173,0.000008064159,0.00013820686,0.00037502975,0.000088695284],"category_scores_gemma":[0.00010416262,0.00026652782,0.00024286522,0.00034074084,0.0001671052,0.00005880552,0.0000669165,0.00052662025,0.000004851997],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020534255,0.00008163389,0.0010797173,0.92011046,0.00021254634,0.0014415693,0.00028424233,2.6622318e-9,8.883909e-9,0.0000950098,0.0008074713,0.075866796],"study_design_scores_gemma":[0.0010437623,0.000025736606,0.00021706738,0.6725615,0.000540849,0.021683952,0.000030723535,0.0000021827207,1.5276072e-7,0.00004676548,0.30368194,0.00016532482],"about_ca_topic_score_codex":0.000003839863,"about_ca_topic_score_gemma":0.0000013404365,"teacher_disagreement_score":0.30287448,"about_ca_system_score_codex":0.000015514799,"about_ca_system_score_gemma":0.00010504741,"threshold_uncertainty_score":0.9999787},"labels":[],"label_agreement":null},{"id":"W4304687870","doi":"10.1007/s13555-022-00824-9","title":"Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"LEO Pharma","keywords":"Betamethasone dipropionate; Lotion; Calcipotriol; Tazarotene; Medicine; Dermatology; Psoriasis; Plaque psoriasis; Pharmacology","score_opus":0.05013840468471775,"score_gpt":0.3084369931753386,"score_spread":0.2582985884906209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304687870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97835654,0.018710634,0.000104966355,0.0005245494,0.00046788025,0.001588451,0.00021036342,0.000024080222,0.000012547966],"genre_scores_gemma":[0.9953985,0.00349615,0.000068151465,0.00003649403,0.000009868956,0.00044206998,0.00048944243,0.000016837788,0.000042490246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980978,0.00072064885,0.000507938,0.00032739295,0.00006351193,0.00028274953],"domain_scores_gemma":[0.99832916,0.0010614566,0.00031444727,0.00023759335,0.000037878825,0.000019433961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021702566,0.0002735512,0.00091901363,0.00019113334,0.0003597159,0.0000059983804,0.00016697479,0.00021699147,0.000047078647],"category_scores_gemma":[0.000013422788,0.0001848406,0.0001357351,0.00016100761,0.00023656205,0.00004778779,0.000038704922,0.00015173928,0.0000016159039],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05911,0.004893324,0.44023883,0.00022684838,0.005043241,0.000082496525,0.043020226,0.00033915095,0.015599744,0.0028352146,0.000056220026,0.4285547],"study_design_scores_gemma":[0.09423242,0.004706908,0.8262433,0.000041221934,0.00074584025,0.00031517225,0.0019822877,0.00007464071,0.068501666,0.00039582633,0.002263509,0.0004972141],"about_ca_topic_score_codex":0.00015208623,"about_ca_topic_score_gemma":0.00013937126,"teacher_disagreement_score":0.4280575,"about_ca_system_score_codex":0.0000728339,"about_ca_system_score_gemma":0.00006598725,"threshold_uncertainty_score":0.7537581},"labels":[],"label_agreement":null},{"id":"W4306809750","doi":"10.1007/s13555-022-00823-w","title":"The Impact of Global Health Disparities on Atopic Dermatitis in Displaced Populations: Narrowing the Health Equity Gap for Patients with Skin of Color","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"UCB Pharma; Bausch Health; LEO Pharma; Galderma; Dermira; Regeneron Pharmaceuticals; Sanofi; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atopic dermatitis; Medicine; Disease; Refugee; Health equity; Population; Environmental health; Public health; Dermatology; Pathology","score_opus":0.06595687629110283,"score_gpt":0.42764834514242833,"score_spread":0.3616914688513255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306809750","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.039209846,0.95575404,0.000010693641,0.001944717,0.0001218293,0.0024916194,0.00040304233,0.000011694829,0.000052510935],"genre_scores_gemma":[0.23934087,0.75930846,0.0000168221,0.0006372439,0.000009132296,0.00033116553,0.00033620108,0.000015461808,0.0000046442165],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977057,0.00076358777,0.00078770536,0.00021760829,0.00017182724,0.000353596],"domain_scores_gemma":[0.99793863,0.0009058844,0.000704504,0.00033020056,0.00003970644,0.000081071565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002826493,0.0002719671,0.0015874815,0.000074925585,0.00043570498,0.000009293598,0.00019011181,0.00013903287,0.000013952907],"category_scores_gemma":[0.00007771634,0.00013446489,0.0002949479,0.0002352127,0.00036244886,0.00004099876,0.000050285576,0.00025735702,3.0646598e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011020264,0.0009551357,0.42046088,0.010383965,0.0009606433,0.000015160281,0.0005155654,0.000005215926,2.7520197e-9,0.012639243,0.0071736537,0.54578847],"study_design_scores_gemma":[0.008239639,0.0026265774,0.7373991,0.006208368,0.0002935922,0.0008007802,0.00027436513,0.00006144611,3.8495915e-7,0.0050498373,0.23863067,0.00041525575],"about_ca_topic_score_codex":0.00025240134,"about_ca_topic_score_gemma":0.0001814852,"teacher_disagreement_score":0.54537326,"about_ca_system_score_codex":0.00017272985,"about_ca_system_score_gemma":0.0009611171,"threshold_uncertainty_score":0.5483319},"labels":[],"label_agreement":null},{"id":"W4307033179","doi":"10.1007/s13555-022-00822-x","title":"Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"LEO Pharma; Galderma; Incyte; Regeneron Pharmaceuticals; Sanofi; GlaxoSmithKline; Pfizer; Kiniksa Pharmaceuticals; AstraZeneca; Eli Lilly and Company","keywords":"Eczema Area and Severity Index; Atopic dermatitis; Dupilumab; Medicine; Placebo; Age of onset; Post-hoc analysis; Young adult; Severity of illness; Internal medicine; Clinical trial; Disease; Pediatrics; Dermatology; Pathology","score_opus":0.037025115743110085,"score_gpt":0.3742092569094753,"score_spread":0.33718414116636525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307033179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247557,0.0044182395,0.00004523445,0.001455489,0.000040935065,0.0008393497,0.0006530549,0.0000139206,0.00005819298],"genre_scores_gemma":[0.9967101,0.0013156041,0.00007134265,0.0013998492,0.000006410872,0.00013602785,0.00031735777,0.00001364251,0.000029616884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969288,0.00121294,0.0011258704,0.00033811425,0.00018912657,0.00020513686],"domain_scores_gemma":[0.99810874,0.0007379997,0.00042510338,0.0004302215,0.00009998054,0.00019795685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031553503,0.00020951977,0.0019769548,0.0005213322,0.00007477831,0.000003047421,0.000111550515,0.000095118965,0.00021936967],"category_scores_gemma":[0.0000945222,0.00015855706,0.0003583425,0.00052110426,0.000312838,0.000035530258,0.000035763896,0.0001412679,9.3405106e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.075123765,0.006785987,0.8933512,0.00027547614,0.0052710352,0.0026408206,0.0046723546,0.00017086216,0.000052915224,0.00028897787,0.00038900276,0.010977591],"study_design_scores_gemma":[0.14080745,0.005535314,0.8371902,0.0003262034,0.005208802,0.0010365314,0.0015950223,0.0032819011,0.002885403,0.00042607996,0.0011800773,0.0005270014],"about_ca_topic_score_codex":0.000095464355,"about_ca_topic_score_gemma":0.000094365496,"teacher_disagreement_score":0.065683685,"about_ca_system_score_codex":0.000019264395,"about_ca_system_score_gemma":0.0002354578,"threshold_uncertainty_score":0.64657694},"labels":[],"label_agreement":null},{"id":"W4307429571","doi":"10.1007/s13555-022-00827-6","title":"Predicting Clinical Remission of Chronic Urticaria Using Random Survival Forests: Machine Learning Applied to Real-World Data","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharma; Genentech; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Random forest; Artificial intelligence; Machine learning; Medicine; Computer science","score_opus":0.062140667680051456,"score_gpt":0.36461659573821253,"score_spread":0.3024759280581611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307429571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99426526,0.0010044897,0.0010789623,0.0016320208,0.0002616944,0.00038546274,0.00002481735,0.0000621878,0.0012851323],"genre_scores_gemma":[0.9982625,0.00081700046,0.0002921467,0.00018885137,0.00009412832,0.000014596686,0.00023086234,0.000019338462,0.000080527425],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99861264,0.00028637602,0.0004494424,0.00030088986,0.0001453708,0.00020527806],"domain_scores_gemma":[0.9989739,0.00037597053,0.00013746506,0.00036502758,0.000026052974,0.0001216058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000464603,0.0001084505,0.00045633168,0.0001310733,0.0003465711,0.000005537382,0.00013770338,0.00007700123,0.00017012701],"category_scores_gemma":[0.000069962196,0.00008989045,0.00004952567,0.00025617238,0.00014892442,0.000031664455,0.00020671889,0.00059473986,0.0000017156112],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032868844,0.00031126762,0.9758519,0.000019481146,0.0012802277,0.000108110624,0.000392094,0.0004296383,0.008191193,0.0029222397,0.00027241246,0.0069345324],"study_design_scores_gemma":[0.058962066,0.0023383726,0.32290694,0.00023537884,0.0040244353,0.0027256797,0.0011901581,0.5508942,0.003086364,0.0028718088,0.049891368,0.0008731953],"about_ca_topic_score_codex":0.0001489057,"about_ca_topic_score_gemma":0.000093549475,"teacher_disagreement_score":0.652945,"about_ca_system_score_codex":0.000024580075,"about_ca_system_score_gemma":0.00012951545,"threshold_uncertainty_score":0.3665626},"labels":[],"label_agreement":null},{"id":"W4307851580","doi":"10.1007/s13555-022-00840-9","title":"A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dermatrials Research; University of Ottawa","funders":"","keywords":"Medicine; Clinical trial; Psoriasis; Intensive care medicine; Food and drug administration; Limiting; Modalities; Drug; Disease; First line; Pharmacology; Internal medicine; Dermatology","score_opus":0.1323058363091473,"score_gpt":0.40444072710116097,"score_spread":0.2721348907920137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307851580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00075185514,0.9933428,0.0000011406115,0.00018053017,0.002720062,0.0026539622,0.00024845713,0.000020596462,0.00008058973],"genre_scores_gemma":[0.00003664904,0.996985,0.000016050471,0.0009992992,0.000090698784,0.0010596506,0.0007151917,0.000032729775,0.00006471628],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943714,0.0033253157,0.001478726,0.00049325154,0.000029780107,0.00030152278],"domain_scores_gemma":[0.99719626,0.001344293,0.0008092671,0.00060411403,0.000024383533,0.000021659143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011688916,0.00036234077,0.0026878496,0.00012215541,0.00017147367,0.0000045705533,0.00051735656,0.0007868854,0.00041566356],"category_scores_gemma":[0.00013891661,0.00022064963,0.0009283184,0.00022836748,0.00021394608,0.000037753634,0.00008454472,0.00050606194,0.000015785903],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027240172,0.00050651265,0.00013530364,0.005073996,0.0007593258,0.000005582137,0.00003956444,4.9942637e-9,1.1532619e-7,0.00028347154,0.0027278895,0.9877442],"study_design_scores_gemma":[0.01992209,0.00046425837,0.000017634438,0.0037285667,0.00088205584,0.00021690749,0.000017600387,9.021097e-8,0.0000024119847,0.00014748321,0.9743959,0.0002050349],"about_ca_topic_score_codex":0.0000057950774,"about_ca_topic_score_gemma":0.000019461719,"teacher_disagreement_score":0.9875392,"about_ca_system_score_codex":0.000010104676,"about_ca_system_score_gemma":0.00028790536,"threshold_uncertainty_score":0.8997831},"labels":[],"label_agreement":null},{"id":"W4309247569","doi":"10.1007/s13555-022-00843-6","title":"Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; LEO Pharma; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Janssen Pharmaceuticals; Gilead Sciences; Union Chimique Belge; Sanofi; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Psoriasis; Dermatology Life Quality Index; Psoriatic arthritis; Body mass index; Odds ratio; Body surface area; Internal medicine; Visual analogue scale; Confidence interval; Physical therapy; Dermatology","score_opus":0.017252792669996294,"score_gpt":0.22538397874167568,"score_spread":0.20813118607167938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309247569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952228,0.0024562548,0.000007700203,0.0007582852,0.0005327712,0.00043926836,0.00045423995,0.000030618026,0.000098073164],"genre_scores_gemma":[0.9973909,0.00078995625,0.00006713016,0.0008021147,0.000009863205,0.00016228911,0.00067360635,0.000017917728,0.00008621786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980992,0.00072310254,0.00039949318,0.00039327363,0.00005567695,0.00032926933],"domain_scores_gemma":[0.9986868,0.00047110615,0.00029686632,0.00046367146,0.00005959499,0.00002195309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010912836,0.00028623716,0.0006642449,0.000105260064,0.00034536837,0.000010760772,0.00033908995,0.00020655862,0.000278045],"category_scores_gemma":[0.00003238072,0.00017747011,0.00010448827,0.00023373247,0.00031642144,0.00007880435,0.00009521224,0.00028343074,0.000014531527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015009387,0.0004054793,0.9886982,0.000004668867,0.00073119503,0.000023201766,0.0013554832,0.000003105259,0.00047880996,0.00019784435,0.0008709902,0.0057301093],"study_design_scores_gemma":[0.008397324,0.00031324843,0.9850094,0.000013161805,0.00010074023,0.00006443267,0.00088584895,0.000002497382,0.001257189,0.00015646168,0.003585278,0.00021446466],"about_ca_topic_score_codex":0.00061127654,"about_ca_topic_score_gemma":0.0005141759,"teacher_disagreement_score":0.006896385,"about_ca_system_score_codex":0.000023399343,"about_ca_system_score_gemma":0.000039269325,"threshold_uncertainty_score":0.7237021},"labels":[],"label_agreement":null},{"id":"W4310275920","doi":"10.1007/s13555-022-00853-4","title":"Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Eli Lilly (Canada); SKiN Health; Memorial University of Newfoundland","funders":"Eli Lilly Canada; Eli Lilly and Company","keywords":"Ixekizumab; Plaque psoriasis; Persistence (discontinuity); Medicine; Psoriasis; Physical therapy; Dermatology; Psoriatic arthritis; Engineering; Secukinumab","score_opus":0.022458528999022054,"score_gpt":0.23913844214158805,"score_spread":0.216679913142566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310275920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964233,0.001208425,4.572514e-7,0.0009545324,0.00008431528,0.00079142174,0.00006477591,0.000012600742,0.00046015036],"genre_scores_gemma":[0.99689436,0.00015859243,0.000046519508,0.00031978887,0.0000028469951,0.0024506967,0.000097630866,0.00000868886,0.000020880483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866635,0.00044337328,0.00023458048,0.00025184697,0.000038628474,0.00036520392],"domain_scores_gemma":[0.999605,0.00009463547,0.000071232,0.00017796729,0.000020462094,0.000030707168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009039701,0.00016340087,0.00028692276,0.00017419455,0.00031079614,0.000007210044,0.00012465716,0.000097277276,0.00014287306],"category_scores_gemma":[0.0000046187583,0.00010886018,0.00003842365,0.00022774044,0.00009299546,0.000034505945,0.00001815335,0.00013132398,0.0000048611832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00880306,0.0018431584,0.44399402,0.000025626512,0.00046367338,0.00082375825,0.107865036,0.0003960059,0.00015249605,0.0009490327,0.00018058381,0.43450356],"study_design_scores_gemma":[0.08351503,0.03453686,0.6364966,0.00021607323,0.0003592495,0.012710164,0.08268448,0.0005486406,0.034344435,0.0006759032,0.1115935,0.0023190354],"about_ca_topic_score_codex":0.01705564,"about_ca_topic_score_gemma":0.10597512,"teacher_disagreement_score":0.43218452,"about_ca_system_score_codex":0.00008383618,"about_ca_system_score_gemma":0.00018324312,"threshold_uncertainty_score":0.98948985},"labels":[],"label_agreement":null},{"id":"W4310942033","doi":"10.1007/s13555-022-00865-0","title":"Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Janssen Biotech","keywords":"Psoriasis; Plaque psoriasis; Medicine; Dermatology; Internal medicine","score_opus":0.010904188158029003,"score_gpt":0.21603245469819568,"score_spread":0.20512826654016666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310942033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99037814,0.008001879,0.0000296566,0.00017190588,0.00023394317,0.000907219,0.0001236352,0.000032014246,0.00012160709],"genre_scores_gemma":[0.9972843,0.0014970711,0.000022922583,0.00019967742,0.000011407371,0.0004821128,0.00045109144,0.000028213251,0.000023221479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664134,0.0021936113,0.0003047052,0.0004206423,0.00009684907,0.0003428768],"domain_scores_gemma":[0.99836606,0.0008311065,0.0002492512,0.000461187,0.0000717014,0.000020722262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055379514,0.0003224561,0.0005865212,0.00016630514,0.00039362497,0.000010431118,0.00033635716,0.00018964098,0.00015818716],"category_scores_gemma":[0.000013368903,0.00018952311,0.00007735449,0.00038458526,0.00045025468,0.00009361059,0.000041110965,0.00033955686,0.000003678248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013013783,0.0010517972,0.9658841,0.00004822143,0.0009178784,0.00008227585,0.0014023804,0.000021857233,0.000676364,0.00060426415,0.0002283728,0.016068734],"study_design_scores_gemma":[0.024638422,0.0016788756,0.94909304,0.000079672915,0.0001245754,0.00043562186,0.0007439931,0.0000020264845,0.01776705,0.00023660215,0.0048183887,0.00038171612],"about_ca_topic_score_codex":0.00015525857,"about_ca_topic_score_gemma":0.000049441718,"teacher_disagreement_score":0.017090684,"about_ca_system_score_codex":0.000024542718,"about_ca_system_score_gemma":0.0000709279,"threshold_uncertainty_score":0.77285284},"labels":[],"label_agreement":null},{"id":"W4310949919","doi":"10.1007/s13555-022-00864-1","title":"The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Communications Security Establishment","funders":"Pfizer","keywords":"Alopecia areata; Medicine; Dermatology; Association (psychology); Psychology; Psychotherapist","score_opus":0.0038044302198502974,"score_gpt":0.1912139926317998,"score_spread":0.1874095624119495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310949919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968924,0.0005258348,0.000019107585,0.0014584176,0.00005648233,0.0004745353,0.00002097133,0.000023812447,0.0005284264],"genre_scores_gemma":[0.9994557,0.00011205091,0.0000110005985,0.00011724718,0.000011779187,0.00004643031,0.000078246274,0.000012657143,0.00015491933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898636,0.00018996892,0.00013637787,0.00024072547,0.0002522162,0.00019433608],"domain_scores_gemma":[0.9993612,0.000152242,0.00015682046,0.00017938792,0.000090385234,0.000059932216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016604348,0.00013330697,0.00026486447,0.000055419965,0.0004179035,0.0000116457595,0.000054997385,0.00007106902,0.00003122939],"category_scores_gemma":[0.000032536296,0.00008141609,0.000022914737,0.00024451147,0.00023759814,0.00010870621,0.000032768177,0.00024323238,6.3511044e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018053162,0.00027360336,0.9862618,0.000010623864,0.0003201489,0.000008959648,0.0004860392,0.0000051932307,0.000008741148,0.00014159943,0.00029587556,0.01038209],"study_design_scores_gemma":[0.004199538,0.00032398643,0.99250174,0.000016029562,0.00004596691,0.00004987129,0.00010267036,0.000015818025,0.000096910226,0.00012753948,0.0024233505,0.00009656179],"about_ca_topic_score_codex":0.000024735713,"about_ca_topic_score_gemma":0.000080421596,"teacher_disagreement_score":0.010285528,"about_ca_system_score_codex":0.000030310017,"about_ca_system_score_gemma":0.00006759843,"threshold_uncertainty_score":0.33200517},"labels":[],"label_agreement":null},{"id":"W4311115017","doi":"10.1007/s13555-022-00849-0","title":"Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Novartis (Canada); Probity Medical Research","funders":"Novartis Pharma","keywords":"Secukinumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Clinical trial; Latin Americans; Observational study; Population; Dermatology Life Quality Index; Dermatology; Internal medicine; Psoriatic arthritis; Environmental health","score_opus":0.01111867910410766,"score_gpt":0.2270354545668102,"score_spread":0.21591677546270255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311115017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658066,0.0019503884,0.00003237475,0.00021838113,0.00011733963,0.00047696443,0.00051720825,0.000019476742,0.00008718943],"genre_scores_gemma":[0.9986935,0.00041107144,0.000060857354,0.00013903304,0.0000041411718,0.000096699274,0.00055077556,0.000014962819,0.000028957744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984916,0.000627917,0.000204304,0.00040966994,0.000037092308,0.00022945003],"domain_scores_gemma":[0.999237,0.0002054373,0.00012641399,0.00038341124,0.00002317307,0.000024583616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014552462,0.00018836293,0.00046109813,0.00010847501,0.0002173872,0.0000055266096,0.00020507298,0.00009841434,0.00004284725],"category_scores_gemma":[0.000009844552,0.00015438623,0.000019041125,0.00016139759,0.00017607839,0.00007017308,0.00016638242,0.00017967114,0.0000021455692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024162678,0.0004551964,0.9064622,0.000045021272,0.0006446293,0.000052672232,0.0016956558,0.000065240245,0.00093182054,0.00039929536,0.0002220563,0.064863525],"study_design_scores_gemma":[0.015813023,0.00084465975,0.97281003,0.00004043281,0.000060370872,0.00021791422,0.0005517676,0.00001711803,0.003448955,0.00021309762,0.0056552785,0.00032734254],"about_ca_topic_score_codex":0.0001709784,"about_ca_topic_score_gemma":0.00016735915,"teacher_disagreement_score":0.06634783,"about_ca_system_score_codex":0.00001884617,"about_ca_system_score_gemma":0.000043861608,"threshold_uncertainty_score":0.62956876},"labels":[],"label_agreement":null},{"id":"W4311220073","doi":"10.1007/s13555-022-00861-4","title":"Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; UCB Pharma; Regeneron Pharmaceuticals; Sun Pharma; Valeant Pharmaceuticals International; Case Western Reserve University; XBiotech; Celgene; Incyte; Dermira; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Term (time); Quality of life (healthcare); Internal medicine; Dermatology; Adalimumab; Disease","score_opus":0.03323950638803691,"score_gpt":0.28825304511501404,"score_spread":0.25501353872697713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311220073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790267,0.018320482,0.0000045424317,0.00082801044,0.00013715732,0.0009560548,0.0006517068,0.000051536852,0.000023813931],"genre_scores_gemma":[0.9967496,0.0019180087,0.000023095601,0.00008490822,0.0000075760872,0.0001333729,0.0010348486,0.000025289715,0.000023319912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968801,0.0013221022,0.0008134637,0.0005241375,0.00007647837,0.0003837288],"domain_scores_gemma":[0.9983326,0.00065676606,0.000561277,0.00031725425,0.00007260929,0.000059454724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016745653,0.0003497409,0.001266146,0.00019971502,0.00037512474,0.000007973679,0.00013187809,0.00016608599,0.00009214835],"category_scores_gemma":[0.0000369356,0.00024750634,0.000065628,0.00023695854,0.00041228265,0.00008811443,0.00005896448,0.00026198817,0.0000030709098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2028315,0.0009204362,0.7809758,0.000024717006,0.0023757252,0.00008998753,0.0030055346,0.0000026823745,0.00016866668,0.000073813426,0.000059179692,0.009471931],"study_design_scores_gemma":[0.39482534,0.0019280099,0.6008879,0.000043772685,0.00012417114,0.00018277437,0.00052921585,0.0000027139379,0.0009779573,0.00012194653,0.000060782924,0.00031542467],"about_ca_topic_score_codex":0.0011674643,"about_ca_topic_score_gemma":0.000831215,"teacher_disagreement_score":0.19199385,"about_ca_system_score_codex":0.0000411859,"about_ca_system_score_gemma":0.000103728744,"threshold_uncertainty_score":0.99999774},"labels":[],"label_agreement":null},{"id":"W4312163186","doi":"10.1007/s13555-022-00870-3","title":"Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Novartis (Canada); SKiN Health; University of British Columbia; Ottawa Hospital; Lynde Centre for Dermatology; University of Toronto; University of Ottawa; Probity Medical Research; Queen's University","funders":"Novartis Pharmaceuticals Canada","keywords":"Secukinumab; Medicine; Psoriasis; Erythema; Plaque psoriasis; Observational study; Psoriasis Area and Severity Index; Body surface area; Dermatology; Internal medicine; Psoriatic arthritis","score_opus":0.0072825027337107915,"score_gpt":0.2210104133937281,"score_spread":0.2137279106600173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312163186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626756,0.0018377524,0.000041908745,0.00047576005,0.0002534023,0.0006415657,0.00041891722,0.00002517867,0.000037948044],"genre_scores_gemma":[0.99876416,0.0001437814,0.000005730045,0.00019283187,0.000008016589,0.0002839411,0.0005366204,0.000018115019,0.000046810976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797267,0.0010900428,0.00021757011,0.0003451925,0.000050637762,0.00032390823],"domain_scores_gemma":[0.9988957,0.00055760954,0.000119353695,0.00035907305,0.00004603531,0.00002224868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012902149,0.00023119884,0.00045793748,0.000058411886,0.00047491945,0.000009586745,0.00024043786,0.00017823273,0.00007376861],"category_scores_gemma":[0.000012572639,0.00014866646,0.00006141586,0.000173635,0.00016669794,0.000043897904,0.00014262952,0.00026450565,0.000003566167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027344303,0.0009266358,0.9577873,0.0000263919,0.001051321,0.000055166533,0.0041863313,0.00005770278,0.0018994485,0.001993181,0.0003719196,0.004300334],"study_design_scores_gemma":[0.020403497,0.0005540985,0.96157604,0.00003991724,0.00006447782,0.00009826581,0.0016154358,0.0000046608793,0.011804573,0.0020185802,0.0015179302,0.0003024982],"about_ca_topic_score_codex":0.00016664788,"about_ca_topic_score_gemma":0.00009752561,"teacher_disagreement_score":0.009905124,"about_ca_system_score_codex":0.000040455558,"about_ca_system_score_gemma":0.000042262986,"threshold_uncertainty_score":0.6062442},"labels":[],"label_agreement":null},{"id":"W4313339834","doi":"10.1007/s13555-022-00879-8","title":"Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Janssen Biotech","keywords":"Plaque psoriasis; Psoriasis; Medicine; Dermatology","score_opus":0.012117338014736839,"score_gpt":0.23112417089595352,"score_spread":0.2190068328812167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313339834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949924,0.0028001068,0.000010966566,0.00011517585,0.00028248917,0.001086579,0.00017551587,0.00002392252,0.0005128728],"genre_scores_gemma":[0.9975092,0.001558012,0.000027974564,0.0001303855,0.00000863117,0.00046701723,0.00021918277,0.000026445252,0.000053188975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968575,0.0018912443,0.00041953244,0.00039913852,0.00009772458,0.000334859],"domain_scores_gemma":[0.9983415,0.000777231,0.00029158086,0.00049089006,0.000074134914,0.000024635076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043891053,0.00030618004,0.00074059464,0.00026635884,0.0002924709,0.0000075846306,0.00037859814,0.00018336008,0.00011943342],"category_scores_gemma":[0.000013518299,0.00020709062,0.00010744202,0.00041943789,0.00028679147,0.00008507462,0.00006080734,0.00026978002,0.0000030949764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021424279,0.0012078917,0.95636916,0.00006077267,0.0011102383,0.00003654704,0.0031526661,0.000133461,0.0021744526,0.001541722,0.00033335589,0.012455479],"study_design_scores_gemma":[0.016532628,0.0009989343,0.94492394,0.00006037946,0.00009084128,0.00008468932,0.0005313162,0.0000037026232,0.03396612,0.00057000015,0.0019089076,0.0003285224],"about_ca_topic_score_codex":0.0006900384,"about_ca_topic_score_gemma":0.00023244477,"teacher_disagreement_score":0.031791665,"about_ca_system_score_codex":0.000033076536,"about_ca_system_score_gemma":0.00006775565,"threshold_uncertainty_score":0.844491},"labels":[],"label_agreement":null},{"id":"W4316927819","doi":"10.1007/s13555-022-00883-y","title":"Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma; Sun Pharma; Mitsubishi Tanabe Pharma Corporation; Taiho Pharmaceutical; Celgene; Eisai; Sanofi; Amgen; Pfizer; Meiji Seika Pharma; Kyowa Hakko Kirin; LEO Pharma; Torii Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ustekinumab; Plaque psoriasis; Placebo; Medicine; Psoriasis; Dermatology; Internal medicine; Alternative medicine; Pathology; Disease","score_opus":0.013551954605158692,"score_gpt":0.2571772653719167,"score_spread":0.24362531076675803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316927819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951366,0.0026287101,6.349018e-7,0.00032721728,0.00014132584,0.0015916849,0.000047221976,0.000058871985,0.000067733636],"genre_scores_gemma":[0.9976501,0.0017913553,0.0000057233124,0.00011384278,0.0000070546002,0.00022538076,0.000121328325,0.000019929414,0.000065313674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981421,0.00060782087,0.00036215672,0.00046001145,0.00003833619,0.00038954683],"domain_scores_gemma":[0.9990157,0.00063839596,0.0000970757,0.00018994175,0.000022450047,0.000036449565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023636673,0.00029988165,0.0007560062,0.00040066926,0.0001847838,0.000016233469,0.00008479497,0.00027795768,0.00003844541],"category_scores_gemma":[0.000028097773,0.00021903573,0.000029082648,0.00030078183,0.00019179087,0.00010112853,0.000047751626,0.00019181604,0.000025212134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11219616,0.0029660694,0.81512725,0.000023528526,0.0010953569,0.00036543002,0.016743347,0.0000028802356,0.0006288161,0.00007963297,0.000099786914,0.050671723],"study_design_scores_gemma":[0.39790073,0.0012936855,0.5965061,0.000033189448,0.000109578745,0.00017047265,0.0021165037,0.000019008465,0.0003858252,0.00005512389,0.0010705219,0.00033925398],"about_ca_topic_score_codex":0.00010396999,"about_ca_topic_score_gemma":0.00041435234,"teacher_disagreement_score":0.28570458,"about_ca_system_score_codex":0.00001528205,"about_ca_system_score_gemma":0.000028226714,"threshold_uncertainty_score":0.8932018},"labels":[],"label_agreement":null},{"id":"W4318914418","doi":"10.1007/s13555-023-00895-2","title":"Healthcare Provider Experience in Diagnosing and Treating Cutaneous T-Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Health care; Medicine; Lymphoma; Dermatology; Internal medicine; Political science","score_opus":0.037843031647061945,"score_gpt":0.3486308470208937,"score_spread":0.31078781537383177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318914418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98707175,0.006720706,0.0000040763753,0.005306544,0.000029010924,0.00043491094,0.0000021289757,0.000069441565,0.00036141614],"genre_scores_gemma":[0.9901361,0.008287542,0.00004989085,0.0012428464,0.000014875442,0.000097936005,0.000010797232,0.000018690263,0.00014136222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895704,0.00010711112,0.0001820767,0.0002949727,0.00011230094,0.00034649635],"domain_scores_gemma":[0.99941546,0.0002882742,0.000030265557,0.00012705998,0.000036739868,0.00010223223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059095913,0.00012935598,0.00027544526,0.00018705476,0.0001500639,0.000021055745,0.000039802704,0.00011354895,0.000016080174],"category_scores_gemma":[0.0000658814,0.00011142676,0.000020768814,0.00027029664,0.00019409858,0.000049266248,0.000033118416,0.00009850163,0.000010601299],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034483062,0.00012764732,0.8951962,0.0001453907,0.000015286774,0.004450789,0.011053312,7.6217754e-7,0.0024446556,0.0001247251,0.00009383958,0.086002566],"study_design_scores_gemma":[0.05278559,0.002826908,0.43976092,0.0010200233,0.000044526012,0.29172477,0.05408508,0.028164806,0.099659905,0.0065046586,0.021393755,0.0020290622],"about_ca_topic_score_codex":0.00021634232,"about_ca_topic_score_gemma":0.0000889551,"teacher_disagreement_score":0.45543528,"about_ca_system_score_codex":0.0000277344,"about_ca_system_score_gemma":0.00008576389,"threshold_uncertainty_score":0.45438513},"labels":[],"label_agreement":null},{"id":"W4323653185","doi":"10.1007/s13555-023-00913-3","title":"Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"AbbVie","keywords":"Medicine; Placebo; Adverse effect; Internal medicine; Randomized controlled trial; Discontinuation; Clinical endpoint","score_opus":0.026307948664639046,"score_gpt":0.33334590657781665,"score_spread":0.3070379579131776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323653185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731405,0.005934002,0.00013278541,0.011251955,0.00015596862,0.00911943,0.000067984474,0.000034854416,0.00016254825],"genre_scores_gemma":[0.98062855,0.01781457,0.00005791628,0.000008643242,0.00004972015,0.001124271,0.000067780944,0.000015296428,0.00023325834],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99876636,0.00025373735,0.0005018763,0.00019019128,0.00009776127,0.00019005159],"domain_scores_gemma":[0.9956044,0.0039343755,0.00017808283,0.00017908162,0.000043834596,0.000060239545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002303365,0.00019645873,0.0013623165,0.00011470574,0.0001516788,0.0000064636642,0.000040684492,0.00011720306,0.00005318],"category_scores_gemma":[0.000088988505,0.0001020075,0.00024176369,0.00011229641,0.00046101477,0.000039660656,0.0000067602864,0.00004938021,0.0000021285273],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9660618,0.0010268188,0.00013451658,0.00002608903,0.0020012783,0.00074346364,0.0025200222,6.8972376e-8,0.0002331091,0.0007610943,0.00007231756,0.026419474],"study_design_scores_gemma":[0.9841345,0.0028731434,0.00008435866,0.000022626335,0.00059469836,0.006460376,0.00018582743,0.00039202507,0.0033019364,0.00042770497,0.0014462216,0.00007657044],"about_ca_topic_score_codex":0.00001743069,"about_ca_topic_score_gemma":0.000003168617,"teacher_disagreement_score":0.026342902,"about_ca_system_score_codex":0.0000097173115,"about_ca_system_score_gemma":0.0000583016,"threshold_uncertainty_score":0.41597453},"labels":[],"label_agreement":null},{"id":"W4324324651","doi":"10.1007/s13555-022-00850-7","title":"Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey)","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Atopic dermatitis; Medicine; Perception; Dermatology; Family medicine; Psychology","score_opus":0.029108896522085082,"score_gpt":0.26912485975688044,"score_spread":0.24001596323479535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324324651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501354,0.0023539788,0.0000036444885,0.0022246283,0.000036616748,0.00021485315,0.000043974254,0.000018522653,0.00009025467],"genre_scores_gemma":[0.9927771,0.006643554,0.000004249048,0.0004159835,0.000012810571,0.000014317865,0.00011026133,0.0000052836976,0.000016448043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916416,0.00027209643,0.00016806518,0.00015174957,0.000098419485,0.00014553215],"domain_scores_gemma":[0.9994492,0.00033084038,0.00005333929,0.00010277201,0.000032419495,0.000031455653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092415255,0.00010739244,0.0003215179,0.00010899643,0.00010055732,0.000010901605,0.000056926954,0.00012464281,0.000010043227],"category_scores_gemma":[0.000023274355,0.00007719667,0.00002335507,0.000107387736,0.0003668416,0.000067239394,0.000027346427,0.00012309743,0.0000014762107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000283065,0.000031473155,0.9855779,0.00009272362,0.00005279134,0.000029187164,0.0062769246,3.3583795e-8,0.0000070830333,0.000058487076,0.00067741034,0.0071677268],"study_design_scores_gemma":[0.0014224404,0.000047109806,0.99325925,0.000042878244,0.000027882423,0.00005708112,0.0039013922,0.00002179101,0.000026616386,0.00086368335,0.00025860238,0.00007128441],"about_ca_topic_score_codex":0.00013025932,"about_ca_topic_score_gemma":0.00007352329,"teacher_disagreement_score":0.007681385,"about_ca_system_score_codex":0.0000032656812,"about_ca_system_score_gemma":0.000014079361,"threshold_uncertainty_score":0.3147989},"labels":[],"label_agreement":null},{"id":"W4327676480","doi":"10.1007/s13555-023-00910-6","title":"Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Secukinumab; Medicine; Discontinuation; Ixekizumab; Adalimumab; Psoriasis; Psoriasis Area and Severity Index; Psoriatic arthritis; Ustekinumab; Cohort; Dermatology; Internal medicine; Pediatrics; Rheumatoid arthritis","score_opus":0.022863082856469093,"score_gpt":0.2595506901935598,"score_spread":0.2366876073370907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327676480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99260306,0.004602685,0.000024312041,0.0013620653,0.0003872999,0.0005328695,0.000039782677,0.00011375995,0.00033414582],"genre_scores_gemma":[0.99430877,0.003496233,0.000008755855,0.0010742742,0.000037972357,0.00024685622,0.00012874613,0.000025396059,0.0006729692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980422,0.0006317752,0.0002964505,0.00040272117,0.000056839697,0.00056997756],"domain_scores_gemma":[0.9988195,0.0006239052,0.00010469572,0.00039102166,0.000034433913,0.000026452848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024690983,0.00032021262,0.00049312174,0.00022488977,0.00035101213,0.000029589526,0.00031717712,0.00036200986,0.00040664742],"category_scores_gemma":[0.000015590937,0.00017413913,0.00007975085,0.00044908878,0.00032831184,0.00010664897,0.000026742724,0.0002534491,0.0004665547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0105105555,0.0005080045,0.8232662,0.000044435164,0.0016743344,0.0022601623,0.005215241,0.000005302801,0.0021691138,0.0019982255,0.0023925686,0.14995584],"study_design_scores_gemma":[0.024211746,0.0005677844,0.9513234,0.000040691815,0.00014857181,0.0042983256,0.00049322937,0.000006555815,0.0052100983,0.00026723117,0.012993217,0.00043914735],"about_ca_topic_score_codex":0.0000818535,"about_ca_topic_score_gemma":0.0009613914,"teacher_disagreement_score":0.1495167,"about_ca_system_score_codex":0.000014743032,"about_ca_system_score_gemma":0.00006764934,"threshold_uncertainty_score":0.7101188},"labels":[],"label_agreement":null},{"id":"W4327676963","doi":"10.1007/s13555-023-00905-3","title":"Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Lynde Centre for Dermatology; University of Toronto; University of Alberta; BC Children's Hospital; Dalhousie University; SKiN Health; McMaster University; Juravinski Cancer Centre; BC Cancer Agency; Dermatrials Research; Ottawa Hospital; Probity Medical Research; University of British Columbia; University of Ottawa","funders":"Sun Pharma; AbbVie; AbbVie Canada; LEO Pharma; Janssen Canada; Novartis; Amgen Canada; Amgen","keywords":"Psoriasis; Medicine; Systemic therapy; Malignancy; Population; Intensive care medicine; Immunosuppression; Disease; Cancer; Dermatology; Internal medicine; Breast cancer","score_opus":0.05779641493854979,"score_gpt":0.26736302212177254,"score_spread":0.20956660718322276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327676963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98168653,0.017219158,0.00002319229,0.000035766734,0.00015055588,0.0005492365,0.00030342344,0.00002763878,0.0000044692547],"genre_scores_gemma":[0.9966992,0.0024462936,0.00011582709,0.000011711774,0.000004526017,0.00023266552,0.0004128849,0.000014245636,0.00006266001],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989294,0.00022355831,0.00039076936,0.0002341453,0.000028752118,0.00019337158],"domain_scores_gemma":[0.9987976,0.00059245754,0.0002821904,0.00022634154,0.00008815588,0.000013264157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000040860912,0.00020724714,0.00069961796,0.0002190831,0.000034041142,0.0000012475386,0.00007861405,0.00020895775,0.000017604547],"category_scores_gemma":[0.000010990455,0.00014425357,0.00009070053,0.00011685782,0.00025724174,0.00006212421,0.000009310802,0.000024413519,0.0000017747549],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006673797,0.0010149494,0.9061264,0.000044184944,0.00082583254,0.0000069734706,0.008468111,0.000012415163,0.06603456,0.000037062182,0.00006282305,0.010692906],"study_design_scores_gemma":[0.021269409,0.0018964919,0.8385762,0.00022782884,0.00012589908,0.000005909269,0.00053159014,0.00006453043,0.13665108,0.000054889326,0.000371398,0.00022476622],"about_ca_topic_score_codex":0.00048943044,"about_ca_topic_score_gemma":0.00004609494,"teacher_disagreement_score":0.07061651,"about_ca_system_score_codex":0.00004756929,"about_ca_system_score_gemma":0.00009158756,"threshold_uncertainty_score":0.58824897},"labels":[],"label_agreement":null},{"id":"W4380730064","doi":"10.1007/s13555-023-00942-y","title":"Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"LEO Pharma; Allergan; Argenx; Sanofi Genzyme; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Celgene; Sanofi; Galderma; Ortho Dermatologics; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Eczema Area and Severity Index; Medicine; Discontinuation; Atopic dermatitis; Adverse effect; Dermatology Life Quality Index; Clinical endpoint; Internal medicine; Body surface area; Quality of life (healthcare); Clinical trial; Dermatology; Disease","score_opus":0.029611087225123456,"score_gpt":0.3179160238496889,"score_spread":0.28830493662456547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380730064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958836,0.00095797953,0.000020343865,0.0011819084,0.000047061796,0.0016604788,0.000023385104,0.00004586238,0.00017939747],"genre_scores_gemma":[0.9976144,0.00051804434,0.00004253371,0.0016435335,0.000006103207,0.00006320575,0.000059991446,0.000018771158,0.000033411274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986924,0.0001895769,0.00037662487,0.00033519111,0.00012813356,0.00027807575],"domain_scores_gemma":[0.9993223,0.00012138409,0.00008227386,0.00025492944,0.00006743219,0.00015167869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000085401894,0.00020056045,0.00064149976,0.00021864075,0.00012219272,0.00001793619,0.00012458912,0.00011309156,0.00002507835],"category_scores_gemma":[0.00003247288,0.00015721426,0.000017145527,0.0003170174,0.00015554407,0.000120617464,0.00010104121,0.00016514029,0.000012344824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008674266,0.006628383,0.96793956,0.00011596028,0.00021713458,0.0006295712,0.0017200061,0.0000041575695,0.000007804247,0.00012131237,0.001033658,0.012908211],"study_design_scores_gemma":[0.07151181,0.0007948372,0.9255912,0.00015213611,0.00004818515,0.00027748014,0.00029141433,0.00016458763,0.00012278672,0.000115824616,0.000762085,0.00016767519],"about_ca_topic_score_codex":0.000020508944,"about_ca_topic_score_gemma":0.000027258,"teacher_disagreement_score":0.06283755,"about_ca_system_score_codex":0.000010868179,"about_ca_system_score_gemma":0.000072020775,"threshold_uncertainty_score":0.6411012},"labels":[],"label_agreement":null},{"id":"W4383302158","doi":"10.1007/s13555-023-00950-y","title":"Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel","year":2023,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lynde Centre for Dermatology; University of Alberta; BC Children's Hospital; Toronto General Hospital; McMaster University; SKiN Health; Probity Medical Research; University of British Columbia; University Health Network; Ottawa Hospital; Dermatrials Research; University of Ottawa; Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada)","funders":"","keywords":"Psoriasis; Multidisciplinary approach; Inference; Human immunodeficiency virus (HIV); Medicine; Intensive care medicine; Computer science; Dermatology; Artificial intelligence; Family medicine; Sociology","score_opus":0.03847214964924443,"score_gpt":0.2729562787058102,"score_spread":0.23448412905656574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383302158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94110787,0.046673797,0.00055717607,0.00019035923,0.008746734,0.0020059743,0.0006193852,0.000074188436,0.000024497778],"genre_scores_gemma":[0.97282445,0.018849513,0.00018054889,0.00003907016,0.00006778177,0.0019098212,0.0010235672,0.000058628713,0.0050465884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803287,0.0005017068,0.00062221516,0.00048316325,0.00004345615,0.00031656164],"domain_scores_gemma":[0.99539536,0.0036212585,0.00048706905,0.00035084,0.000121327146,0.000024147686],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000092901246,0.00045834813,0.0018139912,0.00037548435,0.0001206476,0.000009874149,0.00013417038,0.00068638666,0.000028162573],"category_scores_gemma":[0.000083333885,0.00032138452,0.0002223249,0.00019716838,0.00014026738,0.00006221088,0.000020459067,0.00010864724,0.0000066288867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053532157,0.003518099,0.7328339,0.0005050301,0.012499611,0.000072306226,0.07313572,0.00017228987,0.04755322,0.00008707406,0.031174082,0.044916496],"study_design_scores_gemma":[0.15631694,0.010558727,0.7280222,0.012267852,0.0017223787,0.00033334046,0.013796464,0.0016585769,0.048411854,0.00016726714,0.023790147,0.002954222],"about_ca_topic_score_codex":0.0014823352,"about_ca_topic_score_gemma":0.001438273,"teacher_disagreement_score":0.10278478,"about_ca_system_score_codex":0.000054567965,"about_ca_system_score_gemma":0.00022452051,"threshold_uncertainty_score":0.9999238},"labels":[],"label_agreement":null},{"id":"W4383302909","doi":"10.1007/s13555-023-00949-5","title":"Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel","year":2023,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Lynde Centre for Dermatology; University of Toronto; University of Alberta; BC Children's Hospital; Dalhousie University; SKiN Health; McMaster University; Juravinski Cancer Centre; BC Cancer Agency; Dermatrials Research; Ottawa Hospital; Probity Medical Research; University of British Columbia; University of Ottawa","funders":"","keywords":"Inference; Psoriasis; Multidisciplinary approach; Medicine; Intensive care medicine; Medical physics; Computer science; Dermatology; Artificial intelligence","score_opus":0.26335187940229954,"score_gpt":0.38045325279385916,"score_spread":0.11710137339155963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383302909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670255,0.021038104,0.0006072266,0.0007430878,0.0063856137,0.002238648,0.0018752225,0.000032865144,0.00005371367],"genre_scores_gemma":[0.98890734,0.0057257833,0.00068257167,0.00036039719,0.00011806473,0.001084653,0.0010156438,0.00007723148,0.0020282958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963348,0.00030860864,0.0025845456,0.0004794629,0.000064684515,0.00022792055],"domain_scores_gemma":[0.99476886,0.0017927237,0.0028184978,0.00040538397,0.00015614717,0.000058384627],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005600524,0.0002961945,0.0021280136,0.0006351933,0.000038393395,0.000006340699,0.00013240508,0.0003590282,0.00001857728],"category_scores_gemma":[0.00032272207,0.0002912916,0.0001301515,0.00013793561,0.00013614213,0.0001328869,0.0000119870065,0.00008335173,0.0000054946354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018021828,0.0008920246,0.9039173,0.0007396311,0.0006325236,0.000001784978,0.021478737,0.00015982124,0.000019058076,0.00019139728,0.06947219,0.00069333345],"study_design_scores_gemma":[0.015483871,0.0031348458,0.9394003,0.0035920078,0.0000644035,0.0000037757695,0.0017953732,0.010673155,0.00016021758,0.0005105459,0.024255967,0.0009255157],"about_ca_topic_score_codex":0.0066049253,"about_ca_topic_score_gemma":0.00063120766,"teacher_disagreement_score":0.04521623,"about_ca_system_score_codex":0.0005360471,"about_ca_system_score_gemma":0.00039158,"threshold_uncertainty_score":0.9999539},"labels":[],"label_agreement":null},{"id":"W4385073537","doi":"10.1007/s13555-023-00980-6","title":"Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; LEO Pharma; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Janssen Pharmaceuticals; Gilead Sciences; Union Chimique Belge; Sanofi; Amgen; Pfizer; GlaxoSmithKline","keywords":"Atopic dermatitis; Ethnic group; Medicine; Dermatology; Political science","score_opus":0.057398201719399536,"score_gpt":0.31788014163360145,"score_spread":0.26048193991420193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385073537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98914975,0.0029413265,9.2730477e-7,0.0071262084,0.00005626031,0.00042966392,0.00026492233,0.000018707333,0.000012247217],"genre_scores_gemma":[0.91801727,0.07731341,0.0000071501954,0.0034231814,0.000019402512,0.000037323465,0.0011677026,0.000008446365,0.000006092815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985013,0.0004881143,0.00036914836,0.00030414024,0.00010949884,0.00022778347],"domain_scores_gemma":[0.99805444,0.0013544088,0.00013995483,0.0003442745,0.00002448362,0.000082408274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012831726,0.00019393516,0.00050854,0.00009936886,0.00019716538,0.000032892327,0.00013769105,0.00011201677,0.0000066748253],"category_scores_gemma":[0.000048437978,0.00010797234,0.000016082415,0.0002473239,0.0011691523,0.00008257713,0.000061863604,0.0002495378,4.2114345e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004786069,0.000074940814,0.9906294,0.000031349577,0.00013366331,0.00034046808,0.001306558,2.3304908e-8,5.31607e-8,0.000054183267,0.002086716,0.0052948096],"study_design_scores_gemma":[0.0028669296,0.00005550907,0.99357504,0.00009104165,0.000078650046,0.000058159785,0.0007288211,0.00024635773,8.806565e-7,0.00036694168,0.0018171583,0.000114530136],"about_ca_topic_score_codex":0.08221066,"about_ca_topic_score_gemma":0.5370061,"teacher_disagreement_score":0.45479542,"about_ca_system_score_codex":0.000008775474,"about_ca_system_score_gemma":0.0000928741,"threshold_uncertainty_score":0.92390096},"labels":[],"label_agreement":null},{"id":"W4385155802","doi":"10.1007/s13555-023-00948-6","title":"Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice","year":2023,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Queen's University","funders":"Pfizer","keywords":"JADE (particle detector); Medicine; Tolerability; Atopic dermatitis; Clinical Practice; Expert opinion; Regimen; Dermatology; Adverse effect; Intensive care medicine; Internal medicine; Family medicine","score_opus":0.12393620639195801,"score_gpt":0.4554051293645459,"score_spread":0.3314689229725879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385155802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00055877044,0.9931762,0.000041740106,0.0031355543,0.00019847877,0.0026360601,0.00007004421,0.000042919408,0.00014019794],"genre_scores_gemma":[0.0002271684,0.98602605,0.00039646972,0.012729423,0.000060776038,0.00028367483,0.00019373637,0.000048230835,0.000034466222],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968161,0.00077982486,0.0013756476,0.00059438404,0.00013067322,0.00030334896],"domain_scores_gemma":[0.9936906,0.005193941,0.00044168156,0.00036858863,0.00010287853,0.00020229546],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043761553,0.0004072088,0.0028286008,0.00022069435,0.00010564936,0.000019562738,0.00011268541,0.00059674133,0.000011285414],"category_scores_gemma":[0.0015136931,0.0003227958,0.0001959305,0.00020634277,0.00025694826,0.00014647086,0.00007192647,0.00045029836,0.000010524491],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017677656,0.00048676843,0.001105621,0.07461365,0.0008042608,0.0004811327,0.00029066444,1.3696817e-7,8.4313875e-8,0.0014910813,0.0168614,0.9020974],"study_design_scores_gemma":[0.004123801,0.00018982215,0.0023632403,0.07251124,0.00020593387,0.0039792345,0.00002814708,0.000011832687,7.186585e-7,0.00013051866,0.9161807,0.00027481213],"about_ca_topic_score_codex":0.0000097355705,"about_ca_topic_score_gemma":0.0000037448297,"teacher_disagreement_score":0.9018226,"about_ca_system_score_codex":0.00001411205,"about_ca_system_score_gemma":0.00021593829,"threshold_uncertainty_score":0.9999224},"labels":[],"label_agreement":null},{"id":"W4385429790","doi":"10.1007/s13555-023-00977-1","title":"Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; LEO Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Genentech; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Pfizer; Kyowa Hakko Kirin","keywords":"Adalimumab; Plaque psoriasis; Psoriasis; Term (time); Medicine; Internal medicine; Matching (statistics); Dermatology; Pathology; Disease; Physics","score_opus":0.05121365840193167,"score_gpt":0.3044505649306275,"score_spread":0.25323690652869585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385429790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99558663,0.002047661,0.00008030337,0.00042212574,0.0009523144,0.0006178854,0.00015844435,0.00006137221,0.00007325064],"genre_scores_gemma":[0.9990534,0.0004110052,0.000045667686,0.00007709053,0.000016942598,0.000078374265,0.00015573167,0.000019527868,0.00014225577],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987884,0.00026246815,0.00035987847,0.00025494077,0.00003574046,0.00029852838],"domain_scores_gemma":[0.9986819,0.00076700374,0.00019188754,0.00027603516,0.00005943511,0.000023710787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011461735,0.00020332697,0.0005890766,0.00013923422,0.00022783995,0.0000056249037,0.00022505729,0.0003060966,0.00004050647],"category_scores_gemma":[0.000025537733,0.00014752934,0.00014855752,0.00024768856,0.00014979472,0.000035894845,0.000057046094,0.000109116256,0.00002463645],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07919064,0.0017512953,0.3976277,0.00047454698,0.00951055,0.000035150722,0.03284756,0.00042744,0.15798151,0.0068654804,0.0049967375,0.30829138],"study_design_scores_gemma":[0.025519753,0.0005428435,0.27503207,0.00008543893,0.00029153438,0.000117448995,0.00056813145,0.000025981819,0.69546485,0.000603306,0.001395491,0.00035311593],"about_ca_topic_score_codex":0.000027504064,"about_ca_topic_score_gemma":0.00007802419,"teacher_disagreement_score":0.53748333,"about_ca_system_score_codex":0.000008865352,"about_ca_system_score_gemma":0.000045067078,"threshold_uncertainty_score":0.6016072},"labels":[],"label_agreement":null},{"id":"W4386332794","doi":"10.1007/s13555-023-01007-w","title":"Causal Associations Between Gut Microbiota and Psoriasis: A Mendelian Randomization Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Natural Science Foundation of China","keywords":"Mendelian randomization; Psoriasis; Odds ratio; Medicine; Internal medicine; Genome-wide association study; Observational study; Genetics; Single-nucleotide polymorphism; Biology; Dermatology; Gene; Genotype","score_opus":0.02638600789472362,"score_gpt":0.2723551934737127,"score_spread":0.24596918557898906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386332794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438184,0.0035573533,0.00001773829,0.00079298357,0.00037410008,0.0004900778,0.00011667978,0.00015517528,0.000114073635],"genre_scores_gemma":[0.9967711,0.0020694856,0.000014543487,0.00011316772,0.000036728914,0.00006858646,0.00052218226,0.000015805615,0.00038840566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986538,0.0004833358,0.0002620544,0.0002976547,0.000023195857,0.00027990094],"domain_scores_gemma":[0.9993703,0.00032126863,0.00009826943,0.00014976219,0.000034610937,0.000025785837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023745002,0.00018527087,0.00042235572,0.00019697084,0.0004311816,0.000020836476,0.00007763793,0.00027845136,0.000049632323],"category_scores_gemma":[0.00002647613,0.00015617377,0.000047284822,0.00023436558,0.00010311227,0.00007139888,0.000039408213,0.00011132288,0.00013821373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006340065,0.00031799282,0.89083344,0.000009235664,0.0029309609,0.0000460885,0.0054887254,6.8815615e-7,0.029011298,0.0005262466,0.0036326596,0.06656867],"study_design_scores_gemma":[0.024641609,0.0002020869,0.9581766,0.000008043464,0.0003051155,0.00011640689,0.0008657676,0.000003345118,0.006060004,0.0006796699,0.008638441,0.00030291564],"about_ca_topic_score_codex":0.00005566128,"about_ca_topic_score_gemma":0.000039283437,"teacher_disagreement_score":0.06734317,"about_ca_system_score_codex":0.000009477402,"about_ca_system_score_gemma":0.000022289696,"threshold_uncertainty_score":0.63685817},"labels":[],"label_agreement":null},{"id":"W4386350153","doi":"10.1007/s13555-023-01000-3","title":"Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"AbbVie","keywords":"Atopic dermatitis; Medicine; Meta-analysis; Dermatology; Internal medicine","score_opus":0.06894312748235608,"score_gpt":0.3402872439910531,"score_spread":0.271344116508697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386350153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98632365,0.008812558,0.0017112639,0.0018076227,0.000084941974,0.0010022895,0.000060205693,0.00014220964,0.000055250013],"genre_scores_gemma":[0.99613106,0.00030706628,0.0004140306,0.0023150824,0.000027213417,0.00019850451,0.00049884466,0.000017307451,0.000090880916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828976,0.00035491798,0.0005230185,0.00035941086,0.00012438117,0.0003484824],"domain_scores_gemma":[0.9988446,0.00030151507,0.00015342749,0.00036537572,0.00015796963,0.00017707262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000111375346,0.00024969838,0.0018666582,0.0002309621,0.00018203391,0.000018131648,0.00012345285,0.00020713014,0.0001561442],"category_scores_gemma":[0.000017140328,0.00018491615,0.0004068891,0.0005435939,0.00018758276,0.00010781692,0.000025729576,0.000120603196,0.000015309568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005031781,0.00088511663,0.6902721,0.0003432366,0.2673164,0.00033250023,0.010364684,0.0022447219,0.00094364723,0.004283198,0.016728902,0.0012537504],"study_design_scores_gemma":[0.014635727,0.00070999213,0.8692384,0.000046389276,0.07316292,0.0021636793,0.0014811748,0.02272122,0.0060063964,0.004009965,0.0048610773,0.0009631028],"about_ca_topic_score_codex":0.000008421938,"about_ca_topic_score_gemma":0.00001565805,"teacher_disagreement_score":0.19415347,"about_ca_system_score_codex":0.000006434331,"about_ca_system_score_gemma":0.000049602757,"threshold_uncertainty_score":0.75406617},"labels":[],"label_agreement":null},{"id":"W4386884687","doi":"10.1007/s13555-023-01002-1","title":"Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Boehringer Ingelheim","keywords":"Medicine; Placebo; Clinical endpoint; Tolerability; Adverse effect; Palmoplantar pustulosis; Internal medicine; Dosing; Confidence interval; Randomized controlled trial; Gastroenterology; Psoriasis; Dermatology","score_opus":0.022892398002283324,"score_gpt":0.27479690215286845,"score_spread":0.25190450415058513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386884687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926296,0.0018851076,0.00000692845,0.00017260374,0.00023763174,0.004809033,0.000049503204,0.00009939772,0.000110233545],"genre_scores_gemma":[0.9979586,0.0009709055,0.000015388025,0.00014205594,0.0000148174295,0.00050004805,0.0002454929,0.000030400082,0.00012229128],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99778694,0.00051114033,0.00047252083,0.00058497,0.00006053607,0.00058389583],"domain_scores_gemma":[0.99902886,0.00046637547,0.0001372201,0.00024977393,0.000044199987,0.00007356958],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027930998,0.0004103677,0.00097049476,0.00040708258,0.0004094502,0.000033852473,0.0001394824,0.00027955347,0.000060600534],"category_scores_gemma":[0.000018879431,0.00029595802,0.0000630286,0.00031674816,0.00010571174,0.00011790521,0.000059036905,0.00022732113,0.000102714075],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7897075,0.0021869834,0.19188935,0.000013669036,0.0015182134,0.00015897943,0.0041232407,0.000030042791,0.00023895245,0.0000302086,0.000062713036,0.01004017],"study_design_scores_gemma":[0.8992212,0.0007524099,0.09760282,0.000037398102,0.00022635059,0.00009403713,0.00074195507,0.000034662233,0.0006470351,0.000013877354,0.00027287597,0.0003553737],"about_ca_topic_score_codex":0.00004034152,"about_ca_topic_score_gemma":0.00009396478,"teacher_disagreement_score":0.10951372,"about_ca_system_score_codex":0.000021357971,"about_ca_system_score_gemma":0.00003563237,"threshold_uncertainty_score":0.9999493},"labels":[],"label_agreement":null},{"id":"W4386981197","doi":"10.1007/s13555-023-01035-6","title":"Efficacy and Tolerability of a Novel Topical Treatment Containing Pea Protein and Xyloglucan in the Management of Atopic Dermatitis in Children: A Prospective, Multicenter Clinical Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Tolerability; SCORAD; Medicine; Atopic dermatitis; Internal medicine; Adverse effect; Gastroenterology; Eczema Area and Severity Index; Prospective cohort study; Dermatology; Disease; Dermatology Life Quality Index","score_opus":0.03321193788164409,"score_gpt":0.34616846948883384,"score_spread":0.3129565316071897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386981197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958587,0.001131324,0.00000518021,0.00087372895,0.0000136776625,0.002036855,0.0000045179236,0.000010867865,0.00006510606],"genre_scores_gemma":[0.9988833,0.000700869,0.00006798501,0.00016868892,0.000005940557,0.00015942479,0.0000052856817,0.000004133126,0.000004383211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989515,0.00022722538,0.00039969414,0.00022247812,0.00006439532,0.0001347061],"domain_scores_gemma":[0.9995768,0.0001636288,0.00006695373,0.00014275462,0.000015118809,0.000034759152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019290755,0.000107114494,0.00045289978,0.00008087764,0.000034814657,0.0000040437767,0.000046064655,0.00007787985,0.0000026013884],"category_scores_gemma":[0.000017690525,0.00007049729,0.000028034,0.0001227615,0.00025256875,0.000031383395,0.000032936918,0.00011092301,2.3829759e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052927266,0.0022846563,0.98565805,0.00007726612,0.00021281494,0.0001361669,0.0032089544,3.6843286e-7,0.000004688422,0.0005654811,0.000004776274,0.007317496],"study_design_scores_gemma":[0.017800158,0.00045740601,0.9794693,0.00007371089,0.0000425547,0.00019470391,0.0014659379,0.0001662992,0.000046030174,0.0002041336,0.000027662722,0.000052111176],"about_ca_topic_score_codex":0.0000493385,"about_ca_topic_score_gemma":0.000054655808,"teacher_disagreement_score":0.017270885,"about_ca_system_score_codex":0.0000060764946,"about_ca_system_score_gemma":0.000015206755,"threshold_uncertainty_score":0.2874796},"labels":[],"label_agreement":null},{"id":"W4387060869","doi":"10.1007/s13555-023-01017-8","title":"Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA","year":2023,"lang":"en","type":"letter","venue":"Dermatology and Therapy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Secukinumab; Discontinuation; Ixekizumab; Medicine; Adalimumab; Psoriasis; Dermatology; Dosing; Internal medicine; Psoriatic arthritis","score_opus":0.15795601982015503,"score_gpt":0.3788201942551079,"score_spread":0.22086417443495285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387060869","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.088352226,0.0013331099,0.00042904523,0.9023543,0.003975372,0.0029281485,0.0004813208,0.00005395115,0.00009249997],"genre_scores_gemma":[0.06744155,0.00039869474,0.00004193944,0.9174654,0.011532854,0.0017964403,0.000063518615,0.000109621156,0.0011499607],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99144423,0.0037306715,0.002573505,0.0010146529,0.00026225497,0.0009746694],"domain_scores_gemma":[0.9882771,0.00871095,0.001157985,0.0016599052,0.000078430436,0.000115670584],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012534416,0.0005878723,0.0015678313,0.00057458936,0.00068721554,0.00031213003,0.0015449774,0.00085074763,0.00026974993],"category_scores_gemma":[0.001009654,0.00033478084,0.0001731795,0.00055482646,0.00025042167,0.0001908765,0.00009184939,0.001654109,0.0031025324],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013252232,0.000032301406,0.008523431,0.00007713747,0.00026299164,0.00016366766,0.0064806817,0.00003862559,1.7727477e-7,0.0003524054,0.98247063,0.000272724],"study_design_scores_gemma":[0.002415975,0.00022648743,0.03707378,0.00008833502,0.000019023546,0.00027653316,0.0003006799,0.000054780558,0.0000011383199,0.00030211534,0.9587704,0.00047075946],"about_ca_topic_score_codex":0.0006745758,"about_ca_topic_score_gemma":0.004442027,"teacher_disagreement_score":0.028550347,"about_ca_system_score_codex":0.00022137554,"about_ca_system_score_gemma":0.00025682905,"threshold_uncertainty_score":0.9999104},"labels":[],"label_agreement":null},{"id":"W4387637030","doi":"10.1007/s13555-023-01049-0","title":"Microneedling with a Novel, n-3-PUFA-Rich Formulation Accelerates Inflammation Resolution to Improve Skin Recovery Outcomes in Adults with Healthy Skin","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Advancements in Transdermal Drug Delivery","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Medical Association","funders":"","keywords":"Erythema; Hyaluronic acid; Medicine; Dermatology; Inflammation; Human skin; Wound healing; Surgery; Internal medicine","score_opus":0.04599631668778354,"score_gpt":0.3712524305762064,"score_spread":0.32525611388842285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387637030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923121,0.00034702185,0.0027400642,0.0029584311,0.00026603258,0.0011114799,0.000041218176,0.00012045668,0.00010320968],"genre_scores_gemma":[0.9947685,0.0015010268,0.0009295481,0.0022763899,0.000053939704,0.00025394798,0.0001211881,0.000032269076,0.00006318822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834293,0.00019173288,0.00041110965,0.00041045554,0.0001229846,0.00052076695],"domain_scores_gemma":[0.9991578,0.00034583,0.00014993837,0.00015458463,0.0000840618,0.00010780896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029525103,0.0002663028,0.00035095346,0.00039100496,0.00026359278,0.000019914425,0.00012461394,0.00029733725,0.00003226593],"category_scores_gemma":[0.000016966838,0.00021720582,0.00002785206,0.000515649,0.00009325482,0.00037429488,0.000031769345,0.00045191112,0.000031239168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058157522,0.0011179214,0.5864878,0.00068224495,0.0010626713,0.00030923352,0.02311966,0.054213505,0.05845035,0.0022251802,0.0004979234,0.21367593],"study_design_scores_gemma":[0.0707366,0.004482523,0.52022946,0.00051596377,0.00019076663,0.0006877965,0.0037565986,0.06717736,0.2945287,0.0021080505,0.032774664,0.0028115073],"about_ca_topic_score_codex":0.000051867395,"about_ca_topic_score_gemma":0.0003319468,"teacher_disagreement_score":0.23607835,"about_ca_system_score_codex":0.00006241362,"about_ca_system_score_gemma":0.00006188321,"threshold_uncertainty_score":0.8857396},"labels":[],"label_agreement":null},{"id":"W4387653887","doi":"10.1007/s13555-023-01042-7","title":"Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Bausch Health; Sun Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Galderma; Incyte; Les Laboratories Pierre Fabre; Valeant Pharmaceuticals International; Amgen; Pfizer","keywords":"Acne; Medicine; Scars; Lesion; Adverse effect; Incidence (geometry); Dermatology; Internal medicine; Acne scars; Gastroenterology; Surgery","score_opus":0.03201773447421207,"score_gpt":0.34535312270904195,"score_spread":0.31333538823482987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387653887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99262315,0.0028715434,0.000027614757,0.0019628312,0.0001782603,0.001992964,0.00016932863,0.00011156885,0.000062725194],"genre_scores_gemma":[0.9952814,0.003445221,0.000073161784,0.00025961542,0.00014338443,0.00027763145,0.00026761042,0.000017460248,0.00023450833],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989481,0.00014198018,0.000279379,0.0003126045,0.00007934903,0.00023858441],"domain_scores_gemma":[0.99908715,0.00047011932,0.000111777976,0.00020057769,0.0000401419,0.00009021374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019534859,0.00017025464,0.0006504412,0.00010443754,0.00025049062,0.000014599396,0.000044904224,0.00012983702,0.000013676879],"category_scores_gemma":[0.000054732493,0.000104090774,0.000121047226,0.0001308297,0.00006423519,0.000038970225,0.000009903085,0.00010436111,0.000019685373],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3583895,0.009961004,0.04930189,0.00006354266,0.013109373,0.003591007,0.01763618,0.000009068614,0.018160794,0.00012719021,0.017023185,0.51262724],"study_design_scores_gemma":[0.9182636,0.012414899,0.034613196,0.00008471824,0.0014392738,0.00040870573,0.0030534505,0.0031374763,0.011643443,0.0029830341,0.011465882,0.0004923078],"about_ca_topic_score_codex":0.00007732735,"about_ca_topic_score_gemma":0.000005282963,"teacher_disagreement_score":0.5598741,"about_ca_system_score_codex":0.00000523444,"about_ca_system_score_gemma":0.00003134404,"threshold_uncertainty_score":0.42446983},"labels":[],"label_agreement":null},{"id":"W4388341603","doi":"10.1007/s13555-023-01054-3","title":"Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review","year":2023,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"Novo Nordisk Fonden; Lundbeckfonden","keywords":"Atopic dermatitis; Medicine; Psoriasis; Narrative review; Dermatology; Immunology; Pharmacology; Intensive care medicine","score_opus":0.09997692723435789,"score_gpt":0.3631811042809679,"score_spread":0.26320417704661003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388341603","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029863414,0.9968395,0.000008768345,0.00050043064,0.00030638644,0.0016699267,0.00002679983,0.00013541785,0.00021411196],"genre_scores_gemma":[0.00009688529,0.99578875,0.000027015121,0.00247499,0.00036064442,0.0003705677,0.00043434015,0.00007467842,0.00037215525],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99788475,0.0005405874,0.0005419274,0.00053721893,0.00018073282,0.0003148094],"domain_scores_gemma":[0.99894804,0.00014312,0.00034753064,0.00027896964,0.000100847814,0.00018146573],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015975186,0.0005001204,0.00218118,0.00021917827,0.00023596268,0.000024561508,0.00010158277,0.00050421676,0.0001391473],"category_scores_gemma":[0.00006354641,0.0003355098,0.00042094087,0.00041118622,0.00019124885,0.00010791335,0.00003156139,0.0004527209,0.00015786778],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006834683,0.00018624043,0.0003809451,0.0511009,0.0012393587,0.00074051204,0.00062069524,5.3429602e-8,0.000010381479,0.00015202428,0.06900319,0.8764973],"study_design_scores_gemma":[0.0004550986,0.00011532497,0.00002547752,0.01567134,0.0004619583,0.0010977666,0.000067593464,0.000004112726,0.000027287968,0.000039087303,0.9817241,0.00031084393],"about_ca_topic_score_codex":0.000003229474,"about_ca_topic_score_gemma":0.0000027410908,"teacher_disagreement_score":0.9127209,"about_ca_system_score_codex":0.000036949958,"about_ca_system_score_gemma":0.00053238723,"threshold_uncertainty_score":0.9999097},"labels":[],"label_agreement":null},{"id":"W4388539637","doi":"10.1007/s13555-023-01059-y","title":"Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Pembrolizumab; Quality of life (healthcare); Cohort; Confidence interval; Internal medicine; Interim analysis; Cohort study; Physical therapy; Oncology; Cancer; Clinical trial","score_opus":0.026956228862862187,"score_gpt":0.29670510977548353,"score_spread":0.26974888091262134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388539637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99373364,0.0037953234,0.00002559822,0.0012132608,0.00008018256,0.0009887875,0.000026048134,0.00004776297,0.00008937189],"genre_scores_gemma":[0.9983198,0.0007181157,0.00025204947,0.00048625914,0.00000546925,0.00007251862,0.000043231343,0.000031471933,0.00007106369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819195,0.00023690224,0.0006114659,0.0003451192,0.00023252619,0.00038202418],"domain_scores_gemma":[0.9988254,0.00036936396,0.00031172246,0.00026138654,0.00010225343,0.00012991691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000111222165,0.00024162103,0.0010379968,0.00017012292,0.00008310677,0.0000036247422,0.00007403758,0.00007554653,0.00003527523],"category_scores_gemma":[0.00004797361,0.00013993222,0.000032774413,0.00048086012,0.00024757202,0.000044405988,0.000027475568,0.00022745911,0.00000584325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0891497,0.00066538836,0.89502317,0.00082606834,0.00017823192,0.00074364914,0.0025645236,0.000025498248,0.000007889926,0.000036879606,0.00018077671,0.010598214],"study_design_scores_gemma":[0.04058324,0.0074470956,0.94989705,0.00012778374,0.00004096457,0.0005178049,0.00054375257,0.00007040703,0.0002379778,0.000054835295,0.00022646732,0.00025259308],"about_ca_topic_score_codex":0.00017354828,"about_ca_topic_score_gemma":0.0005634549,"teacher_disagreement_score":0.054873895,"about_ca_system_score_codex":0.0000513345,"about_ca_system_score_gemma":0.00041169423,"threshold_uncertainty_score":0.57062703},"labels":[],"label_agreement":null},{"id":"W4389832881","doi":"10.1007/s13555-023-01080-1","title":"The Burden of Air Pollution on Skin Health: a Brief Report and Call to Action","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Air Quality and Health Impacts","field":"Environmental Science","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Air pollution; Atopic dermatitis; Air quality index; Environmental health; Medicine; Pollution; Air pollutants; Environmental protection; Environmental science; Geography; Meteorology; Dermatology; Ecology","score_opus":0.05050114616673506,"score_gpt":0.35361261426895907,"score_spread":0.303111468102224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389832881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85031915,0.00013353257,0.00007579909,0.14888433,0.000066893874,0.00016262643,0.0000021729895,0.000022142509,0.0003333414],"genre_scores_gemma":[0.987914,0.0015545675,0.000031873104,0.01025621,0.00001985007,0.000008648845,0.0000028585175,0.0000035345197,0.00020840165],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993534,0.000109619454,0.00016100604,0.00012320445,0.00008028431,0.00017249785],"domain_scores_gemma":[0.999641,0.00008202046,0.000074075986,0.00011192327,0.0000028072304,0.00008815513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035789463,0.000050887054,0.00010135915,0.000022825392,0.00027328057,0.0000040983364,0.000037610218,0.00005351189,0.000014570148],"category_scores_gemma":[0.000025918162,0.000035907127,0.000010954106,0.00011283955,0.00012853145,0.000038425536,0.000023066146,0.00006580611,0.00002713511],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000952107,0.000108353226,0.030429108,0.00009264616,0.000046097684,0.00012375134,0.02046443,0.000892199,0.0011035139,0.0052574715,0.24363674,0.6968936],"study_design_scores_gemma":[0.00040955597,0.00023739878,0.52662325,0.0000125716015,0.0000012931108,0.00045114878,0.00037676212,0.00039399718,0.0009989504,0.0022944757,0.46812612,0.00007446311],"about_ca_topic_score_codex":0.0012501972,"about_ca_topic_score_gemma":0.00014102795,"teacher_disagreement_score":0.6968191,"about_ca_system_score_codex":0.000018635723,"about_ca_system_score_gemma":0.0000141781165,"threshold_uncertainty_score":0.21018809},"labels":[],"label_agreement":null},{"id":"W4390590043","doi":"10.1007/s13555-023-01061-4","title":"Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Dupilumab; Eczema Area and Severity Index; Atopic dermatitis; Medicine; Dermatology Life Quality Index; Observational study; Quality of life (healthcare); Adverse effect; Interim analysis; Telephone interview; Pediatrics; Dermatology; Randomized controlled trial; Internal medicine; Disease","score_opus":0.014897983470864842,"score_gpt":0.28452558923269516,"score_spread":0.2696276057618303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390590043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920723,0.005966808,0.000016965905,0.0010647636,0.000087936656,0.00043692446,0.00008350358,0.000030147014,0.00024068245],"genre_scores_gemma":[0.99684656,0.0021940027,0.000035665915,0.0006308404,0.000014898018,0.000026997495,0.00022697324,0.000012219147,0.000011822788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990928,0.00022664388,0.00019299956,0.00027719163,0.00007827934,0.00013206838],"domain_scores_gemma":[0.99915904,0.0003163901,0.000045705037,0.0003963671,0.00003767343,0.000044821896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007327808,0.00012926466,0.0003126313,0.00006331052,0.00004341133,0.000015448777,0.000121821366,0.000087803375,0.000015979678],"category_scores_gemma":[0.00002944369,0.00007853123,0.000018487017,0.00011235056,0.00033971257,0.00010486172,0.00006812282,0.00019680998,0.0000033158715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006450088,0.00017855206,0.99385965,0.0005385998,0.00014700192,0.0001753341,0.0002405028,6.1215566e-8,0.000016164799,0.00057809305,0.0019114887,0.0017095434],"study_design_scores_gemma":[0.00310577,0.000042116335,0.9930106,0.0012342568,0.0000525523,0.0001456408,0.00007601631,0.00006831925,0.000518772,0.0005946537,0.0010698596,0.0000814896],"about_ca_topic_score_codex":0.00008633427,"about_ca_topic_score_gemma":0.000097574244,"teacher_disagreement_score":0.004774312,"about_ca_system_score_codex":0.000007874266,"about_ca_system_score_gemma":0.000054245018,"threshold_uncertainty_score":0.32024106},"labels":[],"label_agreement":null},{"id":"W4391689991","doi":"10.1007/s13555-023-01075-y","title":"Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McMaster University; Dermatrials Research; Probity Medical Research; University of British Columbia; SKiN Health","funders":"Celgene; Pfizer; Eli Lilly and Company; Amgen","keywords":"Ixekizumab; Plaque psoriasis; Psoriasis; Medicine; Interleukin 17; Interleukin 23; Antagonist; Interleukin; Interleukin 1 receptor antagonist; Pharmacology; Internal medicine; Receptor antagonist; Dermatology; Secukinumab; Cytokine; Receptor","score_opus":0.017409283018732104,"score_gpt":0.2538951513793576,"score_spread":0.2364858683606255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391689991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956142,0.0018424309,0.000043643333,0.00080131495,0.0004270067,0.0007928323,0.00012558661,0.00014385578,0.00020915858],"genre_scores_gemma":[0.9985375,0.0003820099,0.00008728774,0.00022875011,0.000027089192,0.00008805083,0.00017434263,0.000053811265,0.00042118717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792075,0.0003824041,0.00034652947,0.0007591812,0.00006296165,0.0005281675],"domain_scores_gemma":[0.9990179,0.00044023772,0.00007576987,0.00029371332,0.00008235219,0.000090014255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000094357136,0.0004850643,0.0006386692,0.0005353168,0.00030269622,0.00008828437,0.00014801598,0.00033816832,0.00003238552],"category_scores_gemma":[0.000020129679,0.00035034347,0.00005801043,0.00041304482,0.00020635272,0.00023264723,0.000066677094,0.0002763531,0.00006383161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4134415,0.0011903408,0.49394187,0.00011133706,0.0063528586,0.0017146455,0.018814169,0.000073068455,0.010531745,0.0028299114,0.002381679,0.048616875],"study_design_scores_gemma":[0.16258593,0.02165585,0.51179254,0.0023924236,0.0013686569,0.0043769786,0.0075945873,0.0002144499,0.24427299,0.0007504926,0.038058814,0.0049363],"about_ca_topic_score_codex":0.0001607745,"about_ca_topic_score_gemma":0.00021836911,"teacher_disagreement_score":0.25085557,"about_ca_system_score_codex":0.00009573392,"about_ca_system_score_gemma":0.00009565398,"threshold_uncertainty_score":0.99989486},"labels":[],"label_agreement":null},{"id":"W4391942083","doi":"10.1007/s13555-024-01097-0","title":"Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Placebo; Medicine; Psoriasis; Pharmacodynamics; Proinflammatory cytokine; Pharmacokinetics; Psoriasis Area and Severity Index; Internal medicine; Pharmacology; Randomized controlled trial; Gastroenterology; Inflammation; Immunology; Pathology","score_opus":0.020706768672432423,"score_gpt":0.2805420094087598,"score_spread":0.25983524073632736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391942083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96280277,0.031911157,0.000032714706,0.00025567831,0.0007771063,0.003948284,0.000012244702,0.00008026775,0.00017976282],"genre_scores_gemma":[0.9962919,0.0016019574,0.000023618884,0.00002651049,0.00004230303,0.0017341365,0.00007261258,0.000022581147,0.00018438704],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99736804,0.0011998842,0.00067471166,0.0004078174,0.00003819714,0.0003113541],"domain_scores_gemma":[0.9988127,0.00076278375,0.00017944256,0.00018511752,0.000038868897,0.000021137908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006287186,0.00029112154,0.0010398502,0.00037413815,0.0001078791,0.000025229801,0.00009079138,0.0003097302,0.00022300593],"category_scores_gemma":[0.000040969884,0.00021710593,0.00019585708,0.0001745816,0.00017735087,0.00016015691,0.00003313226,0.00030084146,0.000076393226],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8710142,0.0008535858,0.0011335333,0.000098236625,0.0022405596,0.00015723046,0.0047211186,0.0000041958347,0.10406558,0.0008308204,0.000054144646,0.014826828],"study_design_scores_gemma":[0.83854425,0.00027879616,0.000050322753,0.0002823797,0.00017911053,0.0001054106,0.0008383013,0.00009484693,0.15863891,0.00012762818,0.0006506187,0.00020941766],"about_ca_topic_score_codex":0.00016015721,"about_ca_topic_score_gemma":0.00014103715,"teacher_disagreement_score":0.054573327,"about_ca_system_score_codex":0.00005152348,"about_ca_system_score_gemma":0.00008886693,"threshold_uncertainty_score":0.8853323},"labels":[],"label_agreement":null},{"id":"W4392860426","doi":"10.1007/s13555-024-01114-2","title":"Development and Psychometric Validation of a Patient-Reported Outcome Measure to Assess the Signs and Symptoms of Chronic Hand Eczema: The Hand Eczema Symptom Diary (HESD)","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Contact Dermatitis and Allergies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Cronbach's alpha; Debriefing; Clinical psychology; Construct validity; Rasch model; Psychology; Intraclass correlation; Patient-reported outcome; Psychometrics; Cognitive interview; Reliability (semiconductor); Content validity; Cognition; Medicine; Physical therapy; Quality of life (healthcare); Psychiatry; Developmental psychology; Psychotherapist","score_opus":0.039253434468810786,"score_gpt":0.2948297921970807,"score_spread":0.2555763577282699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392860426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9689114,0.027633527,0.0004354495,0.00222191,0.0001624401,0.00053156016,0.0000053238223,0.000018100542,0.00008025247],"genre_scores_gemma":[0.9980906,0.0013387679,0.00005283795,0.00039684246,0.00002167205,0.000052259933,0.000010037317,0.000014032845,0.000022927023],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988457,0.0001084802,0.00047129713,0.00021894187,0.00019207218,0.00016350609],"domain_scores_gemma":[0.99919146,0.0003295976,0.0001278886,0.00020443468,0.00008309056,0.00006350775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025862604,0.00016901255,0.00039892519,0.00021597848,0.00018260421,0.000064168555,0.00006375612,0.00009901243,0.000018911927],"category_scores_gemma":[0.000048642374,0.000091113754,0.00004597098,0.0003210584,0.00024528627,0.00007786222,0.000040683346,0.00013844836,0.0000011198204],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004383146,0.00025812662,0.41305697,0.0009577972,0.002096801,0.00012695609,0.020703293,0.000004161546,0.020417728,0.0019677288,0.0004497139,0.5395224],"study_design_scores_gemma":[0.0065442985,0.0014963595,0.77701956,0.0011216714,0.00045506572,0.0038649675,0.0018012231,0.000561363,0.13658737,0.0007401166,0.06920868,0.0005993467],"about_ca_topic_score_codex":0.000013994411,"about_ca_topic_score_gemma":0.000018465307,"teacher_disagreement_score":0.5389231,"about_ca_system_score_codex":0.000014504237,"about_ca_system_score_gemma":0.00009536657,"threshold_uncertainty_score":0.3715511},"labels":[],"label_agreement":null},{"id":"W4393277811","doi":"10.1007/s13555-024-01129-9","title":"Maintenance of Investigator’s Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto","funders":"Bausch Health; Celgene; Amgen; Pfizer; Eli Lilly and Company; LEO Pharma; Galderma; Incyte","keywords":"Medicine; Atopic dermatitis; Dermatology","score_opus":0.022725379298938423,"score_gpt":0.3237260048102253,"score_spread":0.30100062551128687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393277811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787605,0.0037564577,0.00059683534,0.01613028,0.000051335515,0.00039108808,0.000029129766,0.00005467206,0.00022972794],"genre_scores_gemma":[0.99126536,0.00036762658,0.0011227309,0.0070626987,0.0000062449253,0.000107071886,0.000008726972,0.00001536005,0.00004421078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986291,0.00026761097,0.00030067025,0.000298578,0.00014409577,0.00035993595],"domain_scores_gemma":[0.99922657,0.00018791754,0.000047973328,0.00022037262,0.00005837396,0.0002587698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013255305,0.00019200004,0.00047849302,0.000114144896,0.000052244744,0.000019639881,0.00007010225,0.00009984348,0.000026940605],"category_scores_gemma":[0.000040765135,0.0001313441,0.000027813774,0.0003147665,0.0003534935,0.000112720176,0.000017560147,0.0001630265,0.0000083344885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054226774,0.00021878489,0.97950435,0.00034466365,0.0002895177,0.003605746,0.001562875,0.00006497515,0.00015617454,0.003169364,0.004451713,0.0012091395],"study_design_scores_gemma":[0.0039130207,0.00040411114,0.98189235,0.00081262196,0.00007476657,0.002344257,0.00042004132,0.002116877,0.0025759332,0.0023590187,0.0028774661,0.00020954845],"about_ca_topic_score_codex":0.000038738257,"about_ca_topic_score_gemma":0.00010158286,"teacher_disagreement_score":0.012504855,"about_ca_system_score_codex":0.000035565223,"about_ca_system_score_gemma":0.0005647523,"threshold_uncertainty_score":0.5356057},"labels":[],"label_agreement":null},{"id":"W4394999927","doi":"10.1007/s13555-024-01147-7","title":"Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Quality of life (healthcare); Psoriasis; Scalp; Dermatology; Physical therapy; Psoriatic arthritis; Nursing","score_opus":0.02612450247803453,"score_gpt":0.28405261176407526,"score_spread":0.2579281092860407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394999927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99049914,0.008660461,0.000007203694,0.00009283561,0.0001761516,0.0003818517,0.00012794012,0.000025211622,0.00002921457],"genre_scores_gemma":[0.99818057,0.0015049464,0.000030782976,0.000116464435,0.0000022833485,0.000020532469,0.00010541026,0.000013840317,0.000025180878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983147,0.00038367455,0.00070225523,0.00034353216,0.00004349221,0.00021235266],"domain_scores_gemma":[0.9992068,0.00030258406,0.00023828463,0.00016708621,0.000055949542,0.000029338711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014107242,0.000193001,0.00069002167,0.00008291717,0.000054143315,0.000007726555,0.000058019228,0.00025710888,0.000016824088],"category_scores_gemma":[0.000036066445,0.00014325576,0.000056934976,0.00012579537,0.0006887666,0.000108192515,0.000045409848,0.00013345639,0.0000012564849],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019974294,0.00037037308,0.94978124,0.0000581948,0.0009618988,0.000014905163,0.00077412615,7.484621e-8,0.0006286322,0.00014945587,0.00008345371,0.045180194],"study_design_scores_gemma":[0.009097947,0.00044592124,0.98784506,0.000038869526,0.00006160502,0.000006007892,0.00022291008,0.0000028931095,0.0015907845,0.00017544597,0.0003719331,0.00014062854],"about_ca_topic_score_codex":0.0004227735,"about_ca_topic_score_gemma":0.00005079075,"teacher_disagreement_score":0.045039564,"about_ca_system_score_codex":0.0000054335965,"about_ca_system_score_gemma":0.000027792514,"threshold_uncertainty_score":0.58418006},"labels":[],"label_agreement":null},{"id":"W4396592360","doi":"10.1007/s13555-024-01157-5","title":"Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; University of Calgary","funders":"","keywords":"Atopic dermatitis; Medicine; Quality of life (healthcare); Clinical trial; Dermatology; Internal medicine","score_opus":0.0809078995283674,"score_gpt":0.3963929099982119,"score_spread":0.3154850104698445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396592360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9482028,0.041963693,0.00004886196,0.0074667693,0.0009025969,0.00063297775,0.00017547322,0.0001347649,0.000472045],"genre_scores_gemma":[0.9892171,0.0057646697,0.00007435432,0.004436302,0.00007525893,0.000048146212,0.00025665344,0.000022305181,0.00010518488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99637204,0.0009914724,0.001612318,0.00056518265,0.00015010897,0.0003088548],"domain_scores_gemma":[0.9964524,0.0027203944,0.00023706643,0.00031767192,0.000052387757,0.00022010195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073414133,0.0002865673,0.001319011,0.00020815835,0.00008881335,0.00005187833,0.000071376926,0.00045306786,0.000098152756],"category_scores_gemma":[0.0012591569,0.00020943026,0.00021113257,0.00013433397,0.0003979523,0.00016734625,0.000032373056,0.0004545709,0.000016943954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00428369,0.0014287417,0.619572,0.00016626916,0.0020973457,0.006453166,0.0018159136,5.60039e-8,0.0002641382,0.00053820957,0.024006348,0.33937415],"study_design_scores_gemma":[0.06881281,0.0006622733,0.80880916,0.00061059993,0.00067031954,0.005571682,0.0007994052,0.0004686255,0.00355442,0.013038501,0.09628415,0.0007180389],"about_ca_topic_score_codex":0.000052930365,"about_ca_topic_score_gemma":0.000024277744,"teacher_disagreement_score":0.3386561,"about_ca_system_score_codex":0.0000101128135,"about_ca_system_score_gemma":0.0001594028,"threshold_uncertainty_score":0.8540318},"labels":[],"label_agreement":null},{"id":"W4396614562","doi":"10.1007/s13555-024-01158-4","title":"Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Probity Medical Research; University of British Columbia","funders":"Eli Lilly and Company","keywords":"Medicine; Eczema Area and Severity Index; Erythema; Atopic dermatitis; Placebo; Edema; Dermatology; Vital signs; Surgery; Pathology","score_opus":0.03469532938656195,"score_gpt":0.351548121458112,"score_spread":0.31685279207155004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396614562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97533923,0.016556649,0.00009655122,0.0069958135,0.00011232864,0.0007296179,0.000032967157,0.00009033001,0.000046505367],"genre_scores_gemma":[0.97814405,0.015673514,0.000086122345,0.005920818,0.000038920847,0.000050637886,0.000018833147,0.00002547948,0.000041628944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976346,0.0005460905,0.0006090312,0.0006934174,0.00011523235,0.0004016526],"domain_scores_gemma":[0.998626,0.0006111952,0.00007491489,0.00025840488,0.0000550432,0.0003744389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029914023,0.0002983022,0.0007872699,0.00013932325,0.00017955902,0.0000787108,0.00007244879,0.0004639604,0.000009306965],"category_scores_gemma":[0.00014792793,0.00022948708,0.000062897976,0.000131128,0.0009890257,0.0002116412,0.00009264151,0.00056302646,0.0000038081007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006242563,0.00029695558,0.96932155,0.0004279803,0.0002521296,0.0025585515,0.0011476139,1.8821301e-7,0.0000039702636,0.00010877905,0.0013769162,0.018262792],"study_design_scores_gemma":[0.0078108734,0.0005712698,0.97220457,0.0009523822,0.00007851647,0.011746134,0.00035362423,0.0013397322,0.00003059887,0.0008532736,0.00377075,0.00028825612],"about_ca_topic_score_codex":0.00003438919,"about_ca_topic_score_gemma":0.00022247457,"teacher_disagreement_score":0.017974535,"about_ca_system_score_codex":0.000009527492,"about_ca_system_score_gemma":0.00014687807,"threshold_uncertainty_score":0.9358212},"labels":[],"label_agreement":null},{"id":"W4396765528","doi":"10.1007/s13555-024-01155-7","title":"Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"National Center for Advancing Translational Sciences; Janssen Biotech; Allergan; LEO Pharma; Bausch Health; Regeneron Pharmaceuticals; Sun Pharma; Eli Lilly and Company; Ortho Dermatologics; Galderma; Sanofi Genzyme; Incyte; Dermira; Sanofi; Amgen; Pfizer","keywords":"Adapalene; Benzoyl peroxide; Acne; Clindamycin; Phosphate; Dermatology; Chemistry; Medicine; Pharmacology; Organic chemistry; Antibiotics; Biochemistry","score_opus":0.015053563414246117,"score_gpt":0.31822211126592104,"score_spread":0.3031685478516749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396765528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95537585,0.038313434,0.002234376,0.0030750937,0.00016076404,0.00062423345,0.00007915844,0.0000661961,0.000070900736],"genre_scores_gemma":[0.990372,0.0076595377,0.00021375802,0.0008415515,0.000049105434,0.000040294508,0.00045970117,0.00001808022,0.00034598185],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99909014,0.0000609666,0.00023755056,0.0003396234,0.000071581526,0.00020014064],"domain_scores_gemma":[0.9993508,0.00031598925,0.000047152025,0.00014452246,0.000033915043,0.0001076458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000111467256,0.00018275529,0.00051423896,0.0001591185,0.00017524711,0.000035949273,0.000031667812,0.00016973607,0.00010679812],"category_scores_gemma":[0.000015810843,0.00012718415,0.00013334102,0.00021871412,0.00007870483,0.00007819015,0.000011853796,0.0001101538,0.0000092277],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024592642,0.0041233664,0.0735793,0.0005144608,0.030489719,0.0012373858,0.0059506968,0.000007723062,0.021089131,0.0059779263,0.005598519,0.82683915],"study_design_scores_gemma":[0.2867446,0.007232407,0.242853,0.00072688924,0.02217536,0.0011176103,0.00079320406,0.07942925,0.12761934,0.008529837,0.22099969,0.001778823],"about_ca_topic_score_codex":0.000036327365,"about_ca_topic_score_gemma":0.000008242289,"teacher_disagreement_score":0.8250603,"about_ca_system_score_codex":0.000012049871,"about_ca_system_score_gemma":0.00003414475,"threshold_uncertainty_score":0.5186419},"labels":[],"label_agreement":null},{"id":"W4396813342","doi":"10.1007/s13555-024-01164-6","title":"Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AbbVie; Biogen; Amgen","keywords":"Medicine; Psoriasis; Term (time); Chart; Pediatrics; Intensive care medicine; Dermatology; Statistics; Mathematics","score_opus":0.012119976135845978,"score_gpt":0.28454329913593046,"score_spread":0.2724233230000845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396813342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98259854,0.015635254,0.00006996856,0.0001100015,0.00054125645,0.0007005353,0.00013846808,0.00007161394,0.00013435334],"genre_scores_gemma":[0.98781765,0.010660122,0.0000113351125,0.00014015874,0.000024793768,0.00016873791,0.0011185828,0.000020430565,0.000038182592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977532,0.0009962174,0.0003719194,0.00054517953,0.00011268438,0.00022082336],"domain_scores_gemma":[0.99906915,0.00034386697,0.00009722119,0.00033579802,0.00009058002,0.000063405205],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029379578,0.00027225373,0.0007872325,0.0003525444,0.000109485525,0.000019875008,0.00026035684,0.00020314351,0.0009546879],"category_scores_gemma":[0.000013827957,0.00019111413,0.00012582852,0.0004567736,0.00014757727,0.0001797008,0.000047758273,0.00017637217,0.000031759562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021394824,0.0008277791,0.95101506,0.00009508773,0.010092742,0.00010261987,0.000484046,0.0000015365238,0.000051435734,0.00009445333,0.000044965473,0.03505079],"study_design_scores_gemma":[0.0040658466,0.00035288007,0.99226266,0.0004753722,0.0012170841,0.000020612508,0.000023970835,0.000012130838,0.0011564138,0.000042339067,0.00015936012,0.00021132821],"about_ca_topic_score_codex":0.00028158026,"about_ca_topic_score_gemma":0.0004671187,"teacher_disagreement_score":0.0412476,"about_ca_system_score_codex":0.000021616466,"about_ca_system_score_gemma":0.00005348992,"threshold_uncertainty_score":0.9999586},"labels":[],"label_agreement":null},{"id":"W4396834167","doi":"10.1007/s13555-024-01175-3","title":"Comparison of the Efficacy of Clascoterone, Trifarotene, and Tazarotene for the Treatment of Acne: A Systematic Literature Review and Meta-Analysis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Impact; McMaster University","funders":"","keywords":"Tazarotene; Medicine; Confidence interval; Meta-analysis; Acne; Randomized controlled trial; Lotion; Dermatology; Internal medicine; Traditional medicine","score_opus":0.04836278206880886,"score_gpt":0.36593009688497774,"score_spread":0.3175673148161689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396834167","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1781892,0.81691617,0.00009207047,0.0032252131,0.000019291403,0.001518631,0.00002884679,0.000004149448,0.0000064168894],"genre_scores_gemma":[0.8427668,0.15675424,0.000055308064,0.00020403072,0.00000468133,0.00010325723,0.000008148088,0.0000053568415,0.000098180586],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99926114,0.00012476549,0.00033529635,0.00013902951,0.000062894236,0.000076857345],"domain_scores_gemma":[0.99904567,0.0005179138,0.00014006831,0.00023070745,0.00004073783,0.000024918414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109339904,0.00013626381,0.0015709946,0.000058583817,0.000060158036,0.0000072629705,0.00003601164,0.00007886352,0.0000070978767],"category_scores_gemma":[0.000011703362,0.000047025245,0.00041217866,0.00021629262,0.00013975025,0.000018835824,0.000007900959,0.000045312594,7.559268e-8],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014013817,0.0023039854,0.020538593,0.239474,0.7036374,0.00004998795,0.013506445,0.0000102361855,0.0022304403,0.0029653832,0.0009359317,0.012946208],"study_design_scores_gemma":[0.006682184,0.0025057734,0.012927967,0.0046334155,0.9482468,0.00068674504,0.000253998,0.0019372735,0.018854663,0.00018827351,0.0028705446,0.0002123703],"about_ca_topic_score_codex":0.000007673066,"about_ca_topic_score_gemma":0.0000025585964,"teacher_disagreement_score":0.6645776,"about_ca_system_score_codex":0.000002834336,"about_ca_system_score_gemma":0.000012942116,"threshold_uncertainty_score":0.19176339},"labels":[],"label_agreement":null},{"id":"W4400017087","doi":"10.1007/s13555-024-01204-1","title":"Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SKiN Health; University of Calgary; Guenther Dermatology Research Centre; Probity Medical Research; Innovaderm (Canada); Dermatrials Research; Dalhousie University","funders":"Bausch Health; Amgen","keywords":"Psoriasis; Tazarotene; Medicine; Lotion; Plaque psoriasis; Dermatology; Session (web analytics); Panel discussion; Consensus conference; Expert opinion; Dermatologic agents; Medical physics; Intensive care medicine; Pharmacology; Internal medicine; Computer science; World Wide Web; Business","score_opus":0.05041861591236199,"score_gpt":0.25564226531527123,"score_spread":0.20522364940290924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400017087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96335024,0.01933906,0.0000758253,0.014941936,0.0011550206,0.00071843615,0.0002573409,0.000056340865,0.00010580676],"genre_scores_gemma":[0.99620783,0.002213319,0.0000618381,0.00074891857,0.000027313736,0.00017326022,0.00012918578,0.000015703818,0.0004226098],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99916524,0.00019618706,0.00017126871,0.0002161067,0.000016736176,0.00023445078],"domain_scores_gemma":[0.9990502,0.0006790335,0.000038687824,0.00016635032,0.000040739647,0.000025007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000076871685,0.00015340326,0.0002146252,0.00012624678,0.0002210907,0.000016091572,0.000074940755,0.00026831086,0.00009881785],"category_scores_gemma":[0.000024844738,0.00009444977,0.00008424871,0.00007435965,0.0001763896,0.000032863394,0.000006858296,0.000096680014,0.000038677194],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003505829,0.00041281735,0.008232092,0.00014011348,0.0050900253,0.00022580208,0.0045730113,0.000017785756,0.108560115,0.18617408,0.09614046,0.5869279],"study_design_scores_gemma":[0.0021840553,0.00029467198,0.0026285185,0.00007526209,0.00008162564,0.0006430588,0.00012922626,0.00010313145,0.24620374,0.0015869038,0.74582016,0.00024962806],"about_ca_topic_score_codex":0.0029342887,"about_ca_topic_score_gemma":0.0019260213,"teacher_disagreement_score":0.6496797,"about_ca_system_score_codex":0.000019764331,"about_ca_system_score_gemma":0.00010555624,"threshold_uncertainty_score":0.44357863},"labels":[],"label_agreement":null},{"id":"W4400078729","doi":"10.1007/s13555-024-01210-3","title":"Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Lynde Centre for Dermatology; University of Toronto","funders":"UCB Pharma; National Institute for Health and Care Research","keywords":"Certolizumab pegol; Plaque psoriasis; Medicine; Psoriasis; Clinical Practice; Medical physics; Dermatology; Internal medicine; Physical therapy; Adalimumab","score_opus":0.05889889606803407,"score_gpt":0.34748839995163283,"score_spread":0.2885895038835988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400078729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9444726,0.04127626,0.000023977254,0.011181435,0.0012227799,0.0012475351,0.00034062497,0.000040294944,0.00019446654],"genre_scores_gemma":[0.9763187,0.02285626,0.000057009565,0.00010225424,0.00012423733,0.00023152854,0.00014223169,0.000015741476,0.00015201021],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793535,0.00084806536,0.00056196214,0.00038265152,0.0000342818,0.00023767832],"domain_scores_gemma":[0.99144197,0.00799647,0.00012736415,0.00037989306,0.000039465947,0.000014813214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025885264,0.0002024578,0.00044948942,0.000052690517,0.00019609406,0.000019296886,0.000150937,0.00027878978,0.000047950372],"category_scores_gemma":[0.00010185316,0.000103739214,0.00015433946,0.000117873395,0.00022168296,0.000059549166,0.000020275798,0.00015996276,0.000035062087],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0539162,0.010053929,0.16479956,0.000020841466,0.01502743,0.0006079146,0.045548778,0.000002791364,0.00075408485,0.0066254283,0.0053855632,0.6972575],"study_design_scores_gemma":[0.08329524,0.0064471015,0.34231442,0.00008350126,0.0022672603,0.0012461002,0.013311363,0.000094226794,0.008626486,0.0023461084,0.5393799,0.000588316],"about_ca_topic_score_codex":0.0007202636,"about_ca_topic_score_gemma":0.00040352822,"teacher_disagreement_score":0.69666916,"about_ca_system_score_codex":0.000018390845,"about_ca_system_score_gemma":0.00007216285,"threshold_uncertainty_score":0.42303625},"labels":[],"label_agreement":null},{"id":"W4400239828","doi":"10.1007/s13555-024-01200-5","title":"Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"LEO Pharma; Bausch Health; Astellas Pharma; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Sanofi Genzyme; Incyte; Castle Biosciences; Dermira; Regeneron Pharmaceuticals; Celgene; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer","keywords":"Atopic dermatitis; Dermatology; Clinical Practice; Medicine; Family medicine","score_opus":0.03828749553093205,"score_gpt":0.39440680892066493,"score_spread":0.3561193133897329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400239828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67280203,0.018865503,0.0015490333,0.2705225,0.003582601,0.0032195742,0.00008507809,0.00012448427,0.029249229],"genre_scores_gemma":[0.98768955,0.0039212443,0.002222191,0.0057360865,0.0002244265,0.000072371666,0.000014092291,0.000011217141,0.00010881739],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987341,0.000236632,0.00055394357,0.0002131056,0.00009755674,0.00016464591],"domain_scores_gemma":[0.99803555,0.0015904203,0.00007988219,0.00018041092,0.00005779312,0.00005592035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022094214,0.00010940647,0.00031790047,0.000060916347,0.000114753544,0.000016249987,0.000039399176,0.00018733926,0.000111478395],"category_scores_gemma":[0.00026624632,0.000077481774,0.00012738272,0.00010430241,0.00035242838,0.00012327253,0.00003065484,0.0002575978,0.00001022511],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001013073,0.0010835492,0.09961284,0.0010217633,0.0012006277,0.0034211609,0.0009347333,6.86659e-7,0.000017155558,0.6228403,0.24522872,0.02362541],"study_design_scores_gemma":[0.00639988,0.0001003361,0.278386,0.00041634924,0.00034897076,0.011909496,0.0008084891,0.00029053295,0.00084789935,0.032504555,0.6677913,0.00019618629],"about_ca_topic_score_codex":0.0000014765786,"about_ca_topic_score_gemma":0.0000070063343,"teacher_disagreement_score":0.5903357,"about_ca_system_score_codex":0.000011074296,"about_ca_system_score_gemma":0.00014946597,"threshold_uncertainty_score":0.3159615},"labels":[],"label_agreement":null},{"id":"W4401056715","doi":"10.1007/s13555-024-01231-y","title":"Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Dupilumab; Medicine; Placebo; Immunoglobulin E; Interquartile range; Internal medicine; Atopic dermatitis; Immunology; Gastroenterology; Antibody; Pathology","score_opus":0.008369914756186187,"score_gpt":0.24339278957256022,"score_spread":0.23502287481637404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401056715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887122,0.0074115545,0.00005549557,0.0030669838,0.00012045357,0.00033775295,0.00003123938,0.00004513338,0.00021918495],"genre_scores_gemma":[0.9980238,0.0016451137,0.000094100586,0.000087262655,0.000023039831,0.000015565447,0.000024103882,0.00002016053,0.00006684374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902165,0.000108766195,0.0002452457,0.00028271918,0.00010926041,0.00023237964],"domain_scores_gemma":[0.9994748,0.00017573363,0.00004425917,0.00017887239,0.00004935235,0.00007694146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000068938265,0.00016992049,0.0003869158,0.00016603364,0.000065630804,0.000018355135,0.00004950576,0.00019991207,0.0000948348],"category_scores_gemma":[0.000016040613,0.00012117198,0.00003763072,0.00018007464,0.00032646465,0.00009215526,0.000026387024,0.00030621103,0.0000042954234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013771892,0.003504148,0.66546106,0.00058836397,0.017427454,0.010152652,0.0092948675,0.000024556835,0.07607385,0.029309457,0.00043110523,0.17396061],"study_design_scores_gemma":[0.00896482,0.0008577252,0.96465963,0.0005606345,0.001138211,0.0041201306,0.00011957632,0.0016975752,0.01580021,0.0012980296,0.00046709916,0.00031633535],"about_ca_topic_score_codex":0.000028017064,"about_ca_topic_score_gemma":0.000019975208,"teacher_disagreement_score":0.2991986,"about_ca_system_score_codex":0.000025060197,"about_ca_system_score_gemma":0.00014432464,"threshold_uncertainty_score":0.49412498},"labels":[],"label_agreement":null},{"id":"W4401114827","doi":"10.1007/s13555-024-01224-x","title":"Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Janssen Biotech; LEO Pharma; Regeneron Pharmaceuticals; Sun Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Incyte; Dermira; Celgene; Sanofi; Amgen; Pfizer","keywords":"Randomized controlled trial; Psoriasis; Medicine; Phase (matter); Physical therapy; Internal medicine; Dermatology; Physics","score_opus":0.020853798424552844,"score_gpt":0.27203108451029606,"score_spread":0.2511772860857432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401114827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98138314,0.01343988,0.000033967102,0.0020922276,0.0007281677,0.0016102635,0.0005553217,0.00008689366,0.00007011697],"genre_scores_gemma":[0.99667984,0.0014039688,0.00009048688,0.0008781576,0.000023376479,0.00025184912,0.0005226233,0.000026287331,0.00012343352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966857,0.0014425634,0.00087249966,0.00058996957,0.000050623377,0.00035864871],"domain_scores_gemma":[0.99653316,0.002821037,0.00022130896,0.00031945566,0.000058159476,0.000046856818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006196848,0.00038249488,0.0012926256,0.00015107704,0.00021957811,0.00006781032,0.00012007179,0.0003213153,0.00004175435],"category_scores_gemma":[0.0002944996,0.00020040256,0.00013804724,0.00015714428,0.00024086445,0.00013423483,0.000043355336,0.00021479907,0.000023754572],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68263835,0.00080989435,0.030747037,0.000018523915,0.0072873933,0.00016598034,0.010577014,0.0000021552178,0.0018488652,0.00066112244,0.0011744705,0.2640692],"study_design_scores_gemma":[0.9227992,0.0013687013,0.042208508,0.00019632961,0.0010499797,0.000230814,0.00068591005,0.00005043291,0.015851226,0.004076422,0.010549503,0.0009329241],"about_ca_topic_score_codex":0.00021974146,"about_ca_topic_score_gemma":0.00007190921,"teacher_disagreement_score":0.2631363,"about_ca_system_score_codex":0.000011785167,"about_ca_system_score_gemma":0.000055032324,"threshold_uncertainty_score":0.8172179},"labels":[],"label_agreement":null},{"id":"W4401124751","doi":"10.1007/s13555-024-01240-x","title":"Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"AbbVie","keywords":"Dupilumab; Atopic dermatitis; Medicine; Dermatology","score_opus":0.017742762335356127,"score_gpt":0.30180964369604607,"score_spread":0.2840668813606899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401124751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867796,0.011561705,0.00005290833,0.0009657528,0.000036942314,0.0004045468,0.000024704766,0.000039842384,0.00013400464],"genre_scores_gemma":[0.99790275,0.0012267533,0.00024048667,0.0005581268,0.000007892166,0.000014261746,0.000026549793,0.000016050399,0.000007109762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989908,0.000113641516,0.0003110441,0.00030508198,0.00010514489,0.00017433961],"domain_scores_gemma":[0.9992619,0.00031659732,0.00007443121,0.00015869895,0.000035038393,0.0001533043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000053176496,0.00020429991,0.0007121965,0.00018000147,0.00010731149,0.000021878386,0.00004390528,0.00013559972,0.000009831628],"category_scores_gemma":[0.000013408987,0.00015051823,0.000029646942,0.00009242773,0.00027840942,0.00008971922,0.000030221841,0.00017347347,7.426985e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017231855,0.00027181525,0.9691261,0.00067592226,0.00037619556,0.00015514657,0.0049070045,0.0000050202952,0.00013242343,0.00050281244,0.00008537956,0.022038989],"study_design_scores_gemma":[0.005455047,0.00038467723,0.9839011,0.00064894464,0.00011321353,0.0016402929,0.00043128722,0.0009779109,0.0059101125,0.00011095219,0.00025400377,0.00017249731],"about_ca_topic_score_codex":0.000018124758,"about_ca_topic_score_gemma":0.000019200323,"teacher_disagreement_score":0.021866491,"about_ca_system_score_codex":0.0000044870085,"about_ca_system_score_gemma":0.000030644496,"threshold_uncertainty_score":0.6137955},"labels":[],"label_agreement":null},{"id":"W4401323330","doi":"10.1007/s13555-024-01241-w","title":"Assessing Participants’ Experiences with Vitiligo from Patient Interviews","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"melanin and skin pigmentation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Incyte","keywords":"Vitiligo; Psychology; Medicine; Dermatology","score_opus":0.03071425254390989,"score_gpt":0.3150189943196743,"score_spread":0.28430474177576437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401323330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854403,0.012596259,0.0012873436,0.00017493885,0.00018059468,0.00006150355,0.0000021103824,0.000013083637,0.00024385979],"genre_scores_gemma":[0.9984158,0.0007136437,0.00018832434,0.00052748894,0.000039123377,0.000050005023,0.000046823243,0.000006861019,0.000011880979],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995051,0.000064301916,0.00009774252,0.00018686808,0.000037672427,0.00010832998],"domain_scores_gemma":[0.99984163,0.000014679113,0.000019836156,0.00008377316,0.000008713308,0.000031371095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000030115618,0.00007539152,0.00008055891,0.000016329746,0.00004990755,0.00006088504,0.00003727965,0.000059117043,0.000052445343],"category_scores_gemma":[0.0000025932352,0.000051707124,0.00001776483,0.000027120974,0.00007156434,0.000008729077,0.000013784567,0.00003573305,0.000004612055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004189018,0.00017284417,0.031328864,0.000057611644,0.0005136023,0.00031864748,0.053175084,0.0000033357064,0.5412945,0.00062795193,0.0036598172,0.36842886],"study_design_scores_gemma":[0.00055527483,0.00028320964,0.002150659,0.00006306185,0.0000151463055,0.00021399047,0.01855947,0.0003851746,0.93251044,0.00030036646,0.044737924,0.0002252575],"about_ca_topic_score_codex":0.000010461323,"about_ca_topic_score_gemma":0.000009350935,"teacher_disagreement_score":0.39121598,"about_ca_system_score_codex":0.000001474598,"about_ca_system_score_gemma":0.00001637416,"threshold_uncertainty_score":0.21085553},"labels":[],"label_agreement":null},{"id":"W4401385117","doi":"10.1007/s13555-024-01242-9","title":"More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"Janssen Pharmaceuticals; LEO Pharma; Coherus Biosciences; Argenx; Daewoong Pharmaceutical Company; Sanofi Genzyme; Pfizer; Incyte; National Eczema Association; Celldex Therapeutics; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; AbbVie; Sanofi; GlaxoSmithKline; Celgene; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Castle Biosciences","keywords":"Dupilumab; Atopic dermatitis; Medicine; Dermatology; Placebo; Pathology","score_opus":0.010931536450276514,"score_gpt":0.26854148577621756,"score_spread":0.25760994932594106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401385117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768459,0.012831465,0.00016265947,0.0067433817,0.00013538418,0.00060435105,0.000026692009,0.00013580028,0.0025143216],"genre_scores_gemma":[0.9954665,0.0014027464,0.00049113133,0.001921758,0.000057485126,0.000083652514,0.00007009711,0.00003162497,0.0004750061],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991477,0.000039757604,0.00015824052,0.0003050027,0.0000909005,0.00025838043],"domain_scores_gemma":[0.9993965,0.00022449916,0.000032954504,0.00016720718,0.000053813073,0.00012504522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003629587,0.00019985832,0.00036805242,0.00008687921,0.00014443394,0.000034348577,0.000047742593,0.00014587422,0.00013804321],"category_scores_gemma":[0.000010188471,0.00013441466,0.00004399592,0.000081967504,0.0003728939,0.000105652245,0.000014517328,0.00014819737,0.000054072578],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055457816,0.0013889455,0.4899978,0.0057766913,0.009355575,0.017342487,0.007895023,0.000005040329,0.00048987183,0.026710985,0.26899397,0.116585806],"study_design_scores_gemma":[0.038710963,0.0021992258,0.14738774,0.00081662,0.0008016087,0.045275558,0.0006435683,0.0031616355,0.004836942,0.001519868,0.7536261,0.001020142],"about_ca_topic_score_codex":0.0000064581172,"about_ca_topic_score_gemma":0.000006698803,"teacher_disagreement_score":0.48463216,"about_ca_system_score_codex":0.000008746198,"about_ca_system_score_gemma":0.00008070024,"threshold_uncertainty_score":0.54812706},"labels":[],"label_agreement":null},{"id":"W4401431929","doi":"10.1007/s13555-024-01243-8","title":"Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Dalhousie University; University of Toronto; Queen's University; University of British Columbia; SKiN Health; University of Calgary; Ottawa Hospital; Innovaderm (Canada); Probity Medical Research; University of Ottawa","funders":"AbbVie Canada; Pfizer Canada","keywords":"Medicine; Population; Adverse effect; Clinical trial; Atopic dermatitis; Intensive care medicine; Dermatology; Internal medicine; Environmental health","score_opus":0.018453949013327173,"score_gpt":0.31425420651798586,"score_spread":0.29580025750465866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401431929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831935,0.00090260396,0.000009775655,0.014584096,0.00039269714,0.00022560313,0.000010940087,0.0000783475,0.0006023924],"genre_scores_gemma":[0.9970285,0.0004349621,0.00016530951,0.0022195566,0.000039400897,0.00003883784,0.00003643299,0.000015675409,0.00002131435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992024,0.00012751938,0.00017510857,0.00021600921,0.00009859161,0.00018041275],"domain_scores_gemma":[0.9994949,0.00022782221,0.000027036025,0.00013450668,0.000033379478,0.00008232715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000450451,0.00013701213,0.0002205844,0.00018682101,0.00008271117,0.000020594216,0.000027578464,0.00014038276,0.00005736378],"category_scores_gemma":[0.00003142281,0.00010247699,0.000025496372,0.00017171844,0.00010434296,0.0001305618,0.000008578052,0.0003191751,0.00005276943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022276859,0.0003949639,0.9759456,0.000049126476,0.000092973314,0.0006333475,0.00020455018,4.5071326e-7,0.0000030746728,0.001808372,0.013457542,0.00718726],"study_design_scores_gemma":[0.002775908,0.0002329852,0.9546752,0.00035333243,0.00002759008,0.00020236516,0.00008202718,0.000029463443,0.0014771187,0.00029957408,0.039698474,0.00014594434],"about_ca_topic_score_codex":0.000002545383,"about_ca_topic_score_gemma":0.0000023013338,"teacher_disagreement_score":0.026240932,"about_ca_system_score_codex":0.000020839903,"about_ca_system_score_gemma":0.00007415106,"threshold_uncertainty_score":0.41788903},"labels":[],"label_agreement":null},{"id":"W4401606908","doi":"10.1007/s13555-024-01253-6","title":"Extended Half-life Antibodies: A Narrative Review of a New Approach in the Management of Atopic Dermatitis","year":2024,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Atopic dermatitis; Quality of life (healthcare); Dosing; Immune system; Immunology; Immune dysregulation; Antibody; Disease; Clinical trial; Regimen; Pharmacology; Internal medicine","score_opus":0.05275818304034082,"score_gpt":0.3716207093072084,"score_spread":0.3188625262668676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401606908","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000107780375,0.99256736,0.000016607972,0.0013415837,0.00008474991,0.0016293476,0.00001399902,0.000018267523,0.004220276],"genre_scores_gemma":[0.00082916184,0.9964759,0.00019902705,0.0020242208,0.00001857076,0.00018543417,0.00011915938,0.000020048767,0.00012850328],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979001,0.00046994584,0.0009179625,0.0003343563,0.00016936721,0.00020821023],"domain_scores_gemma":[0.9989449,0.0001497732,0.00032535504,0.0004705809,0.00003602491,0.0000733584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020975055,0.0003522998,0.0024775993,0.0002163581,0.000040657636,0.0000060172893,0.00024641943,0.00028335227,0.00007368626],"category_scores_gemma":[0.00001945705,0.00020058968,0.00040631372,0.00041757897,0.00031327957,0.00003823026,0.00005272367,0.00037212644,0.000014393023],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027940183,0.0003682058,0.00021490363,0.6415811,0.002715636,0.0010516865,0.0025649113,8.807102e-9,1.9766937e-8,0.0070796506,0.05170394,0.29269198],"study_design_scores_gemma":[0.00096694933,0.000030027548,0.00053306634,0.12813126,0.0025251554,0.005783331,0.00074021524,0.0000027053231,0.0000010689639,0.00097443943,0.8601126,0.00019917458],"about_ca_topic_score_codex":0.0000069904145,"about_ca_topic_score_gemma":7.430115e-7,"teacher_disagreement_score":0.8084087,"about_ca_system_score_codex":0.000008634279,"about_ca_system_score_gemma":0.00025973454,"threshold_uncertainty_score":0.817981},"labels":[],"label_agreement":null},{"id":"W4401668701","doi":"10.1007/s13555-024-01238-5","title":"Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Bausch Health; Sanofi Genzyme; Incyte; CTI Biopharma; Les Laboratories Pierre Fabre; Celldex Therapeutics; Valeant Pharmaceuticals International; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Medac; AbbVie; Baxalta; Celgene; Biogen; Gilead Sciences; Sanofi; Amgen; Pfizer; Galderma; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Discontinuation; Psoriatic arthritis; Psoriasis; Adverse effect; Population; Internal medicine; Dermatology; Surgery","score_opus":0.04121194750481737,"score_gpt":0.3684384994092988,"score_spread":0.3272265519044814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401668701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9631674,0.035746388,0.000048082642,0.00034498784,0.0001318934,0.00040875623,0.00011345719,0.000016898804,0.000022101825],"genre_scores_gemma":[0.9910119,0.008459037,0.00004805627,0.00017007613,0.000025772191,0.000019873569,0.00025019015,0.000008728453,0.000006336476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986737,0.00030005132,0.0005422372,0.00025467097,0.000105439794,0.00012392075],"domain_scores_gemma":[0.99892014,0.00069441006,0.00009620774,0.00017065335,0.0000416493,0.00007690739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010891617,0.00012865994,0.0010239526,0.00014345696,0.000034019016,0.0000065847044,0.000028688231,0.0000791895,0.00012345842],"category_scores_gemma":[0.000035260255,0.00008162886,0.00017766687,0.00025040528,0.0001424433,0.000030922263,0.00001482748,0.00010667699,0.0000042242605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006058187,0.00041112214,0.9559278,0.000034275105,0.0055449177,0.00040516557,0.000168006,4.765297e-7,7.2464246e-7,0.00007627814,0.000027337639,0.03134573],"study_design_scores_gemma":[0.013709224,0.00024328385,0.98407435,0.00013127534,0.0012965819,0.0000057303105,0.000020722435,0.000046772067,0.000007707836,0.00014176965,0.00025365746,0.00006894824],"about_ca_topic_score_codex":0.00003726565,"about_ca_topic_score_gemma":0.000043555025,"teacher_disagreement_score":0.03127678,"about_ca_system_score_codex":0.000010406082,"about_ca_system_score_gemma":0.000035538644,"threshold_uncertainty_score":0.33287284},"labels":[],"label_agreement":null},{"id":"W4401802229","doi":"10.1007/s13555-024-01250-9","title":"Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Janssen Pharmaceuticals; Janssen Scientific Affairs","keywords":"Dermatology Life Quality Index; Adalimumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Quality of life (healthcare); Anxiety; Placebo; Depression (economics); Internal medicine; Mediation; Dermatology; Psychiatry; Pathology; Disease","score_opus":0.00909996769524771,"score_gpt":0.2415113970875818,"score_spread":0.23241142939233408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401802229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873066,0.012094392,0.000016632475,0.00005517681,0.00008071288,0.00029573438,0.00007114302,0.000022256934,0.00005735562],"genre_scores_gemma":[0.99771225,0.0020650127,0.000013733949,0.000047926118,0.000003793651,0.000044421562,0.00009509036,0.000009211457,0.000008545332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986072,0.00061069155,0.00028344165,0.00031428135,0.00004034426,0.00014402601],"domain_scores_gemma":[0.9991742,0.00053396437,0.00009724838,0.00013681712,0.000028934322,0.00002885423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023242147,0.00017995673,0.00067192415,0.0003499046,0.000058495098,0.000007634233,0.000046394907,0.00023388767,0.000015351341],"category_scores_gemma":[0.00003472374,0.00011902705,0.00004713521,0.00030487712,0.0000995513,0.000062864936,0.000020805684,0.00008731287,0.0000016150373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064719496,0.00010818762,0.96539605,0.00008190909,0.0018007861,0.0000020841017,0.0010259342,0.000013580749,0.0012074447,0.000058970658,0.00001883008,0.023814265],"study_design_scores_gemma":[0.0061725364,0.00048193897,0.9391347,0.00005632367,0.00024122997,0.000007139647,0.000024769599,0.000018060726,0.05360195,0.00003967591,0.000070656235,0.00015097196],"about_ca_topic_score_codex":0.00008121153,"about_ca_topic_score_gemma":0.00008676948,"teacher_disagreement_score":0.052394506,"about_ca_system_score_codex":0.0000069753605,"about_ca_system_score_gemma":0.000021367363,"threshold_uncertainty_score":0.4853782},"labels":[],"label_agreement":null},{"id":"W4402497013","doi":"10.1007/s13555-024-01264-3","title":"Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses","year":2024,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Post-hoc analysis; Medicine; Psoriasis; Post hoc; Dermatology; Internal medicine","score_opus":0.03730252384487797,"score_gpt":0.3197305289108256,"score_spread":0.2824280050659476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402497013","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14357425,0.8540852,9.113755e-7,0.000016999193,0.00011647731,0.0013639244,0.0008241227,0.000012613954,0.000005476149],"genre_scores_gemma":[0.0043189093,0.99411434,0.00003859243,0.000012093084,0.00000674521,0.00017192723,0.0012772026,0.000031587493,0.000028604738],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982071,0.00045358212,0.0006534341,0.0004272327,0.000029669161,0.00022900761],"domain_scores_gemma":[0.9984694,0.00065487274,0.00050790247,0.00027800782,0.000067769855,0.000022034274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008687811,0.00049189536,0.0026891502,0.00031287267,0.00006160829,0.0000045582506,0.00010849718,0.00045642562,0.00002898703],"category_scores_gemma":[0.000033242217,0.00027146417,0.00037648363,0.00023175718,0.00021244076,0.00003426631,0.00002340377,0.00010721533,0.0000041440267],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076739036,0.00053135806,0.009915843,0.01809578,0.007245931,0.0000052048745,0.00030003587,1.9184924e-8,0.00000282382,0.00005701757,0.00010802534,0.96297055],"study_design_scores_gemma":[0.021721061,0.004603592,0.012343975,0.04101651,0.024618056,0.0001672872,0.000092438415,1.3436538e-7,0.00043137494,0.00005264634,0.8939918,0.0009610937],"about_ca_topic_score_codex":0.00007092853,"about_ca_topic_score_gemma":0.000040222854,"teacher_disagreement_score":0.9620095,"about_ca_system_score_codex":0.000022686869,"about_ca_system_score_gemma":0.000102788516,"threshold_uncertainty_score":0.9999738},"labels":[],"label_agreement":null},{"id":"W4402580541","doi":"10.1007/s13555-024-01258-1","title":"Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; LEO Pharma; UCB Pharma; Regeneron Pharmaceuticals; Celgene; Eli Lilly and Company; Bristol-Myers Squibb; Ortho Dermatologics; Janssen Pharmaceuticals; UCB US; Gilead Sciences; Sanofi; Pfizer; Genentech; National Psoriasis Foundation; Amgen","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Dermatology; Disease; Arthritis; Internal medicine","score_opus":0.0255114006844872,"score_gpt":0.27182321956590577,"score_spread":0.24631181888141856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402580541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9174111,0.08102127,0.00000979934,0.00023411778,0.00041611533,0.00041623297,0.00042127242,0.00004680231,0.000023307446],"genre_scores_gemma":[0.9357885,0.06383186,0.000016403823,0.000060066675,0.000029652296,0.000035970985,0.00019477437,0.000021585578,0.000021148335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983142,0.00049475016,0.00039216137,0.00045694277,0.00006490659,0.00027704512],"domain_scores_gemma":[0.9974219,0.001781164,0.00024081179,0.0004431115,0.000061494575,0.000051488983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013459839,0.00036356173,0.00062754867,0.00013830258,0.00018340722,0.000022923294,0.00020533561,0.00020910252,0.00014315954],"category_scores_gemma":[0.000058390448,0.00018640762,0.00018202302,0.00023648098,0.00041801328,0.0001221994,0.00003173124,0.00020250476,0.0000070886404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003670449,0.00024368573,0.8889262,0.000026865062,0.0017569843,0.000013827818,0.0011334971,0.0000010166005,0.0013594921,0.00045635502,0.00028143974,0.102130175],"study_design_scores_gemma":[0.0028275936,0.0008904197,0.988948,0.0003330981,0.0001671076,0.0000085787215,0.00007683282,0.000002649592,0.0050472617,0.0009235206,0.00055716076,0.00021780936],"about_ca_topic_score_codex":0.0006329541,"about_ca_topic_score_gemma":0.00006158212,"teacher_disagreement_score":0.101912364,"about_ca_system_score_codex":0.00001886652,"about_ca_system_score_gemma":0.000092604285,"threshold_uncertainty_score":0.7601482},"labels":[],"label_agreement":null},{"id":"W4402938707","doi":"10.1007/s13555-024-01271-4","title":"Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study","year":2024,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Lynde Centre for Dermatology; University of Toronto","funders":"","keywords":"Certolizumab pegol; Plaque psoriasis; Medicine; Psoriasis; Medical physics; Dermatology; Internal medicine; Adalimumab","score_opus":0.04964615182662028,"score_gpt":0.33680599483069884,"score_spread":0.28715984300407854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402938707","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24783187,0.44950867,0.000037346857,0.044292837,0.23376748,0.010782394,0.0051587536,0.0002697888,0.008350859],"genre_scores_gemma":[0.738027,0.22143546,0.000048951046,0.0002997514,0.0021182527,0.001212595,0.0032677418,0.00010180225,0.03348845],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963415,0.0014630755,0.0010331472,0.0007292852,0.0000673214,0.00036564807],"domain_scores_gemma":[0.9902483,0.008415079,0.00049078,0.0007200258,0.00010247454,0.000023303879],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031730754,0.00047641058,0.0011073912,0.00010939161,0.00033353805,0.000030537933,0.00028804585,0.0012289601,0.00008209819],"category_scores_gemma":[0.00022526673,0.0002585032,0.00034666283,0.00017756151,0.00036114096,0.00005193043,0.00004643259,0.00073483057,0.00006783346],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033278022,0.0062353313,0.011215249,0.000024840916,0.015332726,0.00039185255,0.014705095,8.4254395e-7,0.000016284039,0.00034184434,0.75801706,0.16044088],"study_design_scores_gemma":[0.020597925,0.0024424344,0.020599157,0.00008375518,0.0018927896,0.00063840917,0.0036301117,0.000017136279,0.0002214459,0.00027311707,0.9493022,0.00030153152],"about_ca_topic_score_codex":0.0015735246,"about_ca_topic_score_gemma":0.0017017359,"teacher_disagreement_score":0.49019513,"about_ca_system_score_codex":0.00005178913,"about_ca_system_score_gemma":0.00025444248,"threshold_uncertainty_score":0.9999867},"labels":[],"label_agreement":null},{"id":"W4403061875","doi":"10.1007/s13555-024-01268-z","title":"A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"AbbVie","keywords":"Post-hoc analysis; Ethnic group; Medicine; Psoriasis; Post hoc; Descriptive statistics; Internal medicine; Dermatology; Political science; Statistics; Mathematics","score_opus":0.026430391181251064,"score_gpt":0.2666626916384742,"score_spread":0.24023230045722316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403061875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97601026,0.02321988,0.00006949279,0.0001305609,0.00009730454,0.00024715572,0.0001689479,0.00001569675,0.000040673513],"genre_scores_gemma":[0.9968406,0.002823022,0.00014549003,0.000049063787,0.0000028553443,0.00001737619,0.0000995421,0.000007768583,0.0000142692015],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991248,0.00017570761,0.0002560349,0.00026274545,0.000024998824,0.00015565896],"domain_scores_gemma":[0.99959296,0.00016350587,0.000064705964,0.0001155385,0.000039545976,0.000023714034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006204666,0.00015421947,0.0004675276,0.00044578582,0.000092974515,0.0000063482616,0.00004170076,0.00018158696,0.000049832088],"category_scores_gemma":[0.000008634758,0.00011678118,0.000050102728,0.00045064455,0.00019694249,0.000070711656,0.00003103232,0.00009138542,0.0000018345978],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040954288,0.00082053064,0.27869067,0.00012489432,0.011879554,0.00015899746,0.06595326,0.0002462437,0.017196054,0.008366488,0.000073378134,0.57553566],"study_design_scores_gemma":[0.009894083,0.0011978038,0.9767042,0.000108305154,0.0016434552,0.0002649779,0.0018986942,0.00018563966,0.0066963737,0.0003730028,0.0006705754,0.00036291862],"about_ca_topic_score_codex":0.0001656488,"about_ca_topic_score_gemma":0.0005396131,"teacher_disagreement_score":0.69801354,"about_ca_system_score_codex":0.0000100348625,"about_ca_system_score_gemma":0.000028425684,"threshold_uncertainty_score":0.47621983},"labels":[],"label_agreement":null},{"id":"W4403840641","doi":"10.1007/s13555-024-01288-9","title":"Patient and Healthcare Provider Perspectives on Disease Burden of Seborrheic Dermatitis in the United States: Results from a National Survey","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Seborrheic dermatitis; Health care; Medicine; Disease; Survey research; Family medicine; Dermatology; Psychology; Political science; Pathology","score_opus":0.02679554618663165,"score_gpt":0.316664420357197,"score_spread":0.28986887417056534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403840641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96576476,0.020111537,0.0000019525737,0.01269714,0.000024665163,0.00032516412,0.0010154137,0.0000130731605,0.00004631713],"genre_scores_gemma":[0.99160564,0.0058208434,0.000008632242,0.0015388926,0.000011606026,0.000029096722,0.0009737197,0.000006401573,0.0000051741804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922246,0.00023074621,0.00015682462,0.00017880986,0.00012366156,0.00008750816],"domain_scores_gemma":[0.9992864,0.00046698548,0.00003089847,0.00009040739,0.00006421006,0.000061056824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000063417174,0.000086785294,0.00013711516,0.00011385143,0.000040856135,0.000013819639,0.000022005093,0.000037140813,0.000008087661],"category_scores_gemma":[0.00005431054,0.00005293166,0.000022767395,0.00013902894,0.00008499624,0.00003160795,0.0000070816263,0.00008425707,0.000001763472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012459758,0.0017516507,0.79768825,0.00063775666,0.0012768134,0.002833776,0.14015126,0.000045291832,0.000011982545,0.013799004,0.0050416826,0.02430275],"study_design_scores_gemma":[0.0033923353,0.0002467114,0.98228544,0.00024965397,0.00003041837,0.000062530264,0.0045051407,0.0019278408,0.000019729905,0.0051205307,0.0020784312,0.00008121474],"about_ca_topic_score_codex":0.0023016036,"about_ca_topic_score_gemma":0.00008513346,"teacher_disagreement_score":0.1845972,"about_ca_system_score_codex":0.000015971074,"about_ca_system_score_gemma":0.00008531265,"threshold_uncertainty_score":0.34793514},"labels":[],"label_agreement":null},{"id":"W4404293285","doi":"10.1007/s13555-024-01303-z","title":"Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Kyowa Kirin International","keywords":"Atopic dermatitis; Placebo; Double blind; Medicine; Dermatology; Double blind study; Internal medicine; Alternative medicine; Pathology","score_opus":0.01786456798619309,"score_gpt":0.30138050329688326,"score_spread":0.2835159353106902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404293285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870683,0.004712254,0.000037200432,0.0036836523,0.000208063,0.0035147576,0.000052808307,0.00018994084,0.0005330366],"genre_scores_gemma":[0.9966291,0.00021652832,0.000097557335,0.0019486189,0.000026308715,0.00078987,0.00016331745,0.000036036476,0.00009266794],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976287,0.00020389885,0.0008505908,0.00070005626,0.0002138895,0.00040289632],"domain_scores_gemma":[0.9986601,0.00044945287,0.00014297354,0.00044350864,0.00008774168,0.00021625611],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001050183,0.0003963019,0.0011189169,0.00035133894,0.00013824325,0.00006779492,0.00010921551,0.00023271635,0.00003899789],"category_scores_gemma":[0.00006774983,0.000270596,0.00009860536,0.0002728996,0.00012173819,0.00020433389,0.000037957754,0.00035320886,0.000028158365],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62427515,0.0054057934,0.3106674,0.00020042052,0.003827786,0.016753603,0.022323709,0.000016899523,0.000086658896,0.000120006946,0.001487372,0.014835236],"study_design_scores_gemma":[0.8594287,0.0015680289,0.12390097,0.0006650517,0.0005405696,0.0033470886,0.0037991866,0.0032027473,0.0013444382,0.0006957863,0.00076719536,0.00074026006],"about_ca_topic_score_codex":0.00017222465,"about_ca_topic_score_gemma":0.00022838917,"teacher_disagreement_score":0.23515354,"about_ca_system_score_codex":0.000021452714,"about_ca_system_score_gemma":0.00019475783,"threshold_uncertainty_score":0.9999746},"labels":[],"label_agreement":null},{"id":"W4404544951","doi":"10.1007/s13555-024-01308-8","title":"A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab","year":2024,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Atopic dermatitis; Focus (optics); Narrative; Dermatology; Medicine; Narrative review; Immunology; Intensive care medicine; Art; Literature; Physics","score_opus":0.019116775874798195,"score_gpt":0.3224888187418461,"score_spread":0.3033720428670479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404544951","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00090579176,0.99232155,0.000002459341,0.0037834784,0.00023971414,0.0016519483,0.000037009326,0.000037718633,0.0010203173],"genre_scores_gemma":[0.03260522,0.9613977,0.000014508474,0.00547809,0.00003424653,0.0002958779,0.00005218588,0.000042878033,0.00007929658],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99730515,0.00081898726,0.000850074,0.000506345,0.00019532884,0.00032408143],"domain_scores_gemma":[0.9987928,0.00024180242,0.00032583997,0.00048492395,0.00005732789,0.00009728956],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015968319,0.00053410156,0.0023596617,0.00023821607,0.00011748782,0.000017030658,0.00020659987,0.0005119183,0.00008533324],"category_scores_gemma":[0.000067707595,0.00030690743,0.00043195256,0.00036856628,0.00048416734,0.00005439768,0.000083219056,0.0007783871,0.00003195752],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015224174,0.0005537386,0.0007465282,0.16615187,0.0017088632,0.0018519796,0.0020565086,3.6513857e-8,0.000001658762,0.0066102888,0.004323408,0.81584287],"study_design_scores_gemma":[0.0020920688,0.0001794109,0.0010383164,0.124916084,0.0015643863,0.020696446,0.00021606416,0.000008982337,0.000050952116,0.008246369,0.8404865,0.0005043844],"about_ca_topic_score_codex":0.000009645113,"about_ca_topic_score_gemma":0.000003897826,"teacher_disagreement_score":0.8361631,"about_ca_system_score_codex":0.000024742725,"about_ca_system_score_gemma":0.00053012796,"threshold_uncertainty_score":0.9999383},"labels":[],"label_agreement":null},{"id":"W4404627081","doi":"10.1007/s13555-024-01295-w","title":"Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"UCB Pharma; XBiotech; National Institute for Health and Care Research; Sanofi; Manchester Biomedical Research Centre; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Scalp; Medicine; Dermatology; Randomized controlled trial; Psoriasis; Internal medicine; Surgery","score_opus":0.016499543770947603,"score_gpt":0.29786979812062464,"score_spread":0.28137025434967705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404627081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87906563,0.11848074,0.000037356756,0.00042034974,0.00047985898,0.0011137946,0.0002754609,0.00007171978,0.000055072967],"genre_scores_gemma":[0.97812206,0.020605719,0.00003205975,0.000110713925,0.000044062785,0.0002317589,0.0007687825,0.000021520626,0.000063301915],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936269,0.004115977,0.001173711,0.00060475105,0.000048754737,0.00042991608],"domain_scores_gemma":[0.99227595,0.0071576103,0.00022863134,0.00025893285,0.000024963698,0.000053906242],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016998494,0.00045270368,0.004852151,0.0011091499,0.000107475375,0.00006370834,0.00012959093,0.00059594784,0.0008674418],"category_scores_gemma":[0.00034158817,0.00028446366,0.00076471624,0.000576591,0.00028193314,0.00011492391,0.000027420705,0.00028353013,0.000055758308],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72244644,0.0017286151,0.06436556,0.000032224307,0.063480206,0.0010596301,0.0033907583,0.000014795983,0.009077313,0.0016042507,0.00038128495,0.13241895],"study_design_scores_gemma":[0.9422317,0.00017102879,0.041476157,0.00010235011,0.0059034126,0.00018471379,0.00019343654,0.0002476537,0.006218907,0.0022296626,0.0005513813,0.00048956036],"about_ca_topic_score_codex":0.0009544567,"about_ca_topic_score_gemma":0.00022189712,"teacher_disagreement_score":0.21978532,"about_ca_system_score_codex":0.00003008424,"about_ca_system_score_gemma":0.00007298441,"threshold_uncertainty_score":0.9999608},"labels":[],"label_agreement":null},{"id":"W4406730782","doi":"10.1007/s13555-024-01323-9","title":"Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto; Memorial University of Newfoundland","funders":"Eli Lilly and Company; Bristol-Myers Squibb; Galderma; Incyte; XBiotech; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Teijin Pharma; Teva Pharmaceutical Industries; Sanofi; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Ixekizumab; Psoriatic arthritis; Medicine; Psoriasis; Post-hoc analysis; Arthritis; Term (time); Dermatology; Internal medicine","score_opus":0.006849029917933229,"score_gpt":0.24418872447783002,"score_spread":0.23733969455989679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406730782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9623273,0.036189012,0.00002548851,0.00012640277,0.00012517616,0.0009443803,0.00015891486,0.000016197404,0.000087123604],"genre_scores_gemma":[0.96720445,0.032202438,0.0000977966,0.000084731546,0.000011205153,0.00008647466,0.00026693952,0.00001542204,0.000030522857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831903,0.00015192211,0.0005990049,0.00039534667,0.00023378145,0.00030089435],"domain_scores_gemma":[0.9990737,0.00010042694,0.00016185724,0.00043156734,0.00016436665,0.000068121604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000772481,0.00029386402,0.0016433577,0.00057899504,0.00009084776,0.000004880182,0.000068898196,0.00016118484,0.00008906583],"category_scores_gemma":[0.00001929609,0.00020847458,0.00036690058,0.00081859634,0.00018337456,0.00006535079,0.000029663795,0.00008777057,0.000001459244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014799503,0.0014137687,0.77091587,0.000065504246,0.015123199,0.00021990847,0.00036775114,0.000003713241,0.0000032472308,0.00011245649,0.0000036348786,0.19697146],"study_design_scores_gemma":[0.05071653,0.0023203015,0.9438626,0.00036975002,0.0018258746,0.00006243536,0.000094665374,0.000004838851,0.0002384179,0.000030474937,0.0003275636,0.00014650694],"about_ca_topic_score_codex":0.00016794754,"about_ca_topic_score_gemma":0.0007864301,"teacher_disagreement_score":0.19682495,"about_ca_system_score_codex":0.00006344385,"about_ca_system_score_gemma":0.00012103334,"threshold_uncertainty_score":0.8501347},"labels":[],"label_agreement":null},{"id":"W4407134354","doi":"10.1007/s13555-025-01342-0","title":"Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto; Lynde Centre for Dermatology","funders":"AbbVie","keywords":"Observational study; Interim; Medicine; Psoriasis; Interim analysis; Value (mathematics); Dermatology; Internal medicine; Clinical trial; Political science; Statistics; Mathematics","score_opus":0.013512419789648596,"score_gpt":0.26710814172110503,"score_spread":0.2535957219314564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407134354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969101,0.0010746572,0.000025820787,0.00012998944,0.00018567308,0.0011309764,0.00022237083,0.000023859213,0.00029657627],"genre_scores_gemma":[0.9992558,0.000050037885,0.00003717491,0.00014274774,0.0000049832906,0.00019964905,0.0002599781,0.000007902385,0.00004172707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724996,0.0016871879,0.00033139365,0.00044746615,0.000052976557,0.00023100794],"domain_scores_gemma":[0.9983276,0.0010901024,0.00013640252,0.00028779704,0.000142257,0.000015811742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003173958,0.0002467477,0.00063237135,0.00017488665,0.00024221493,0.000011748039,0.00019059778,0.00015191553,0.00004095366],"category_scores_gemma":[0.00004526904,0.00016258872,0.00008948306,0.00079943397,0.0001264242,0.000056766807,0.00009379622,0.00011856661,0.000004708437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02626128,0.00074949156,0.9634211,0.000009514888,0.0054277442,0.0000065396357,0.0009011652,0.00009031899,0.00019032432,0.0005853541,0.00001875602,0.0023383764],"study_design_scores_gemma":[0.0096628405,0.00024583007,0.98710924,0.000055166372,0.0004873308,0.0000021357214,0.00031453162,0.000014216673,0.0015328635,0.00040491667,0.000022381122,0.00014852207],"about_ca_topic_score_codex":0.0017501139,"about_ca_topic_score_gemma":0.003039141,"teacher_disagreement_score":0.023688128,"about_ca_system_score_codex":0.00010771987,"about_ca_system_score_gemma":0.00006550622,"threshold_uncertainty_score":0.6630176},"labels":[],"label_agreement":null},{"id":"W4407567762","doi":"10.1007/s13555-025-01357-7","title":"Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy","year":2025,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; SKiN Health","funders":"Sanofi Genzyme; Genentech; Glenmark Pharmaceuticals; Pfizer; Biogen; Incyte; Moderna; UCB Pharma; Valeant Pharmaceuticals International; Argenx; Kiniksa Pharmaceuticals; Ribon Therapeutics; Sun Pharma; Dermira; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; LEO Pharma; Gilead Sciences; Bausch Health; L'Oreal USA; Sanofi; Celgene; GlaxoSmithKline; Amgen; Galderma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atopic dermatitis; Medicine; Meta-analysis; Systemic therapy; Dermatology; Internal medicine","score_opus":0.07042809012567897,"score_gpt":0.35360654330752384,"score_spread":0.28317845318184487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407567762","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002618024,0.99464065,0.0011007247,0.000545978,0.00015939804,0.0026325812,0.00029742977,0.00008209904,0.00027931322],"genre_scores_gemma":[0.006122465,0.98769855,0.00033114705,0.003775215,0.00005165003,0.0011197391,0.00027097095,0.00005914164,0.0005710999],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.996958,0.00057059433,0.0012093477,0.00064413657,0.00014771373,0.0004702077],"domain_scores_gemma":[0.99694484,0.0014905825,0.0005042948,0.00075695827,0.0001487325,0.00015456199],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017369312,0.0006718284,0.008650074,0.0007557298,0.00018653841,0.00002579495,0.000281388,0.00078529026,0.00020469984],"category_scores_gemma":[0.000055757835,0.00047995456,0.0029394212,0.00081794144,0.00019329932,0.00005378991,0.000048773578,0.00026517326,0.000012736271],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092328613,0.00045607757,0.0011738894,0.04197138,0.7821733,0.00016460792,0.00048450963,0.0001205905,1.7057127e-7,0.004672097,0.020569982,0.14729013],"study_design_scores_gemma":[0.0019321197,0.000059403617,0.00016809907,0.0018040081,0.31222242,0.001187916,0.000017856522,0.000081882165,0.0000054136553,0.0004638829,0.6815946,0.00046242515],"about_ca_topic_score_codex":0.000010032667,"about_ca_topic_score_gemma":0.000009296105,"teacher_disagreement_score":0.6610246,"about_ca_system_score_codex":0.00002107653,"about_ca_system_score_gemma":0.0003047483,"threshold_uncertainty_score":0.9997652},"labels":[],"label_agreement":null},{"id":"W4407589934","doi":"10.1007/s13555-025-01343-z","title":"Abstracts of the 9th Annual Symposium on Hidradenitis Suppurativa Advances 2024","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of California, San Francisco; Sjællands Universitetshospital; University College Dublin; Cardiff University; University of Southern California; Hidradenitis Suppurativa Foundation; Erasmus Universitair Medisch Centrum Rotterdam; Northwell Health; Queen's University; Charles and Helen Schwab Foundation; Brigham and Women's Hospital","keywords":"Hidradenitis suppurativa; Medicine; Dermatology; Internal medicine; Disease","score_opus":0.007087350014536145,"score_gpt":0.2757539418132613,"score_spread":0.26866659179872515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407589934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82630914,0.008275654,0.000016047119,0.10878464,0.001475203,0.00073403213,0.00008816105,0.000048619484,0.054268494],"genre_scores_gemma":[0.9933599,0.0020094123,0.000029963228,0.00020017603,0.000020076823,0.000020905523,0.0000103838975,0.0000073108677,0.004341825],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99928266,0.00007714709,0.00021310638,0.00017468803,0.000096611475,0.00015579701],"domain_scores_gemma":[0.99951106,0.00013683058,0.00006660512,0.00020205409,0.000042522715,0.000040909767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000035489877,0.00013871059,0.00027976395,0.000078176905,0.00012352371,0.0000066043394,0.0000731072,0.00011042482,0.00008389514],"category_scores_gemma":[0.000014791017,0.000082415834,0.000067281406,0.0001416768,0.00023900486,0.00008623842,0.000017478664,0.00016172238,0.000012290547],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037411489,0.002870533,0.77955943,0.00060159457,0.0021688465,0.02457307,0.007485046,0.0000029164025,0.013189076,0.04768026,0.021874428,0.096253626],"study_design_scores_gemma":[0.016143098,0.0013223204,0.1773012,0.0008821575,0.00031602697,0.14063247,0.0018821544,0.000034189674,0.32754153,0.0106705455,0.32273722,0.00053711777],"about_ca_topic_score_codex":0.00000979506,"about_ca_topic_score_gemma":0.00000711772,"teacher_disagreement_score":0.60225827,"about_ca_system_score_codex":0.000009615226,"about_ca_system_score_gemma":0.00007142955,"threshold_uncertainty_score":0.336082},"labels":[],"label_agreement":null},{"id":"W4408191973","doi":"10.1007/s13555-024-01317-7","title":"Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials","year":2025,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Psoriasis; Randomized controlled trial; Medicine; Internal medicine; Dermatology","score_opus":0.01633031962578176,"score_gpt":0.26834044493712034,"score_spread":0.2520101253113386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408191973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9577735,0.01057435,0.00004926014,0.0020991233,0.022559516,0.0044254838,0.001776316,0.00009934851,0.0006430818],"genre_scores_gemma":[0.9417209,0.009468563,0.00019626602,0.006042255,0.0002618297,0.001955104,0.0126872305,0.00012520886,0.027542634],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942859,0.002646369,0.0014625003,0.0009985681,0.00008447904,0.0005221958],"domain_scores_gemma":[0.9947075,0.003653859,0.000792496,0.00059244374,0.00018006792,0.00007359856],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071741955,0.0007695085,0.002888912,0.00035669503,0.00039560956,0.000070385024,0.00023422555,0.0010281443,0.000038784663],"category_scores_gemma":[0.0012418908,0.00045008192,0.00024162883,0.00026366918,0.00022630373,0.00010076529,0.00009552299,0.0006533193,0.00001703204],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66294235,0.0008127802,0.006246528,0.000020024341,0.006792792,0.000048217644,0.004014223,0.000002198907,0.00012506067,0.00003748854,0.18857798,0.13038033],"study_design_scores_gemma":[0.8597168,0.0020037736,0.02586019,0.0006835145,0.0020256448,0.00011802189,0.0005766364,0.000022208806,0.0030410895,0.000799265,0.10366493,0.0014879557],"about_ca_topic_score_codex":0.00082494476,"about_ca_topic_score_gemma":0.0005117313,"teacher_disagreement_score":0.1967744,"about_ca_system_score_codex":0.000035550103,"about_ca_system_score_gemma":0.00019773473,"threshold_uncertainty_score":0.9997951},"labels":[],"label_agreement":null},{"id":"W4408552243","doi":"10.1007/s13555-025-01369-3","title":"Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: A Retrospective Cohort Analysis of up to 4 Years","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SKiN Health; University of Calgary; McMaster University; Lynde Centre for Dermatology; Dalhousie University; University of Toronto; Probity Medical Research; Bausch Health (Canada); Health Canada","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Retrospective cohort study; Cohort; Dermatology; Internal medicine","score_opus":0.012138154383044289,"score_gpt":0.2727859351044288,"score_spread":0.2606477807213845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408552243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398315,0.0012256609,0.000023535402,0.0021190764,0.00032393803,0.00058059406,0.000143699,0.0000134066595,0.0015869405],"genre_scores_gemma":[0.9977102,0.00045666887,0.000037089583,0.00092013297,0.0000070210585,0.0001846189,0.00015149366,0.0000058076457,0.00052695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989684,0.00024182237,0.00023609742,0.00026044768,0.00002189713,0.00027132122],"domain_scores_gemma":[0.9993207,0.00030332757,0.00006378372,0.00024211538,0.00005008816,0.000019979238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028540601,0.00013032807,0.000460664,0.00083206384,0.00017921293,0.000009614933,0.00017014409,0.00020705171,0.00004675523],"category_scores_gemma":[0.000028383922,0.00010252107,0.000116709154,0.0009128276,0.00010718887,0.000023218328,0.000012659534,0.000103298225,0.0000053774384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004371547,0.00004830899,0.9648538,0.000005897079,0.0032463137,0.000010617208,0.002763343,0.0000034256745,0.00048161406,0.016736668,0.0028120782,0.008600776],"study_design_scores_gemma":[0.0016570352,0.000048295155,0.9767947,0.000008399526,0.00046913174,0.000010010487,0.0002532015,0.0000065808426,0.0029099404,0.0009122875,0.01683163,0.00009874464],"about_ca_topic_score_codex":0.03603107,"about_ca_topic_score_gemma":0.37831986,"teacher_disagreement_score":0.3422888,"about_ca_system_score_codex":0.000060079445,"about_ca_system_score_gemma":0.00012725267,"threshold_uncertainty_score":0.97038805},"labels":[],"label_agreement":null},{"id":"W4409039284","doi":"10.1007/s13555-025-01366-6","title":"Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injector","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB","keywords":"Medicine; Adverse effect; Syringe; Injection site; Discontinuation; Anesthesia; Pharmacokinetics; Adalimumab; Placebo; Bioequivalence; Self-administration; Surgery; Pharmacology; Internal medicine; Rheumatoid arthritis","score_opus":0.022848295447719286,"score_gpt":0.2676768045114574,"score_spread":0.24482850906373813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409039284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97644216,0.020537745,0.000990043,0.0004818493,0.0006080767,0.00036807868,0.000064508975,0.00006627712,0.00044128488],"genre_scores_gemma":[0.9969982,0.0019459939,0.0002889813,0.00012804978,0.000012944645,0.000074254065,0.00006250905,0.000009745389,0.0004793295],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99919564,0.000117010255,0.0002421452,0.0002368125,0.000010938606,0.00019747893],"domain_scores_gemma":[0.9994729,0.00024583106,0.000085542575,0.0001443482,0.000036007343,0.000015344564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007875781,0.0001537934,0.00032286881,0.00015608808,0.0002661325,0.0000087198,0.00006133164,0.0002593177,0.000031925927],"category_scores_gemma":[0.000016917853,0.00013538275,0.00006889286,0.00009663201,0.00018104484,0.000056358433,0.00002993154,0.000070822985,0.0000038885846],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058895196,0.00064178964,0.029675256,0.0002493601,0.0020830606,0.00001518272,0.001690349,0.0000020889559,0.4611652,0.021063114,0.0004348337,0.47709024],"study_design_scores_gemma":[0.029844262,0.0021482343,0.14915435,0.00028811273,0.00068789517,0.002259232,0.00086134195,0.00016542552,0.5715961,0.005031945,0.2370679,0.00089523883],"about_ca_topic_score_codex":0.000019095829,"about_ca_topic_score_gemma":0.000021180178,"teacher_disagreement_score":0.476195,"about_ca_system_score_codex":0.000012420204,"about_ca_system_score_gemma":0.0000348725,"threshold_uncertainty_score":0.55207485},"labels":[],"label_agreement":null},{"id":"W4409476142","doi":"10.1007/s13555-025-01395-1","title":"Complete/Near-Complete Itch Response Observed in Patients with Moderate-to-Severe Atopic Dermatitis Initiating Dupilumab: 3-Year, Real-World, Interim Data from the PROSE Registry","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Dupilumab; Atopic dermatitis; Interim; Dermatology; Medicine; Interim analysis; Clinical trial; Internal medicine; Geography","score_opus":0.05460224207085992,"score_gpt":0.3047415583324011,"score_spread":0.2501393162615412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409476142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884303,0.000857885,0.000072668845,0.008591018,0.00012089859,0.0008198667,0.00034377933,0.000069694404,0.00069387443],"genre_scores_gemma":[0.9860967,0.00016269862,0.00064626767,0.011980618,0.000017511278,0.00007440435,0.00089096685,0.00002237734,0.000108471504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978804,0.0006275225,0.00046474207,0.00052013947,0.00015060104,0.00035659998],"domain_scores_gemma":[0.99778813,0.00082953967,0.00013016761,0.0010560261,0.000090726644,0.000105433624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017352185,0.00026729732,0.0005923923,0.00012349384,0.00032924488,0.00006937342,0.0004319933,0.0001596516,0.000085567524],"category_scores_gemma":[0.00018153577,0.00019154708,0.00003914076,0.00033728394,0.0003483746,0.00018108457,0.00022689396,0.00039498816,0.000023381095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059445575,0.00021780134,0.983467,0.00005726867,0.00020453366,0.00019686074,0.0006160478,0.0000031249429,0.000022803873,0.00025432583,0.0081978,0.0008179111],"study_design_scores_gemma":[0.0076188813,0.000051907107,0.9805609,0.00034982315,0.000046376466,0.0000784749,0.00017915547,0.0005718849,0.00006681368,0.0007411742,0.009539624,0.00019498654],"about_ca_topic_score_codex":0.00028715542,"about_ca_topic_score_gemma":0.0005770586,"teacher_disagreement_score":0.0033896004,"about_ca_system_score_codex":0.00002837774,"about_ca_system_score_gemma":0.00020670528,"threshold_uncertainty_score":0.7811063},"labels":[],"label_agreement":null},{"id":"W4409602439","doi":"10.1007/s13555-025-01402-5","title":"Canadian Consensus Guidelines for the Management of Vitiligo","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"melanin and skin pigmentation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Trent University; Lynde Centre for Dermatology; Dalhousie University; Women's College Hospital; University of Toronto; Nova Chemicals (Canada); Centre de Recherche Dermatologique du Québec Métropolitain; Vancouver Coastal Health Research Institute; University of British Columbia; Probity Medical Research; Blackberry (Canada); Calgary Laboratory Services; SKiN Health; McGill University; University of Calgary","funders":"Incyte","keywords":"Vitiligo; Medicine; Political science; Dermatology","score_opus":0.024369523344469252,"score_gpt":0.3249563532079566,"score_spread":0.3005868298634874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409602439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96765846,0.01375307,0.002732309,0.012825422,0.00024830806,0.00039291062,0.000019173653,0.0000035438627,0.0023668115],"genre_scores_gemma":[0.9927749,0.003360178,0.0006455419,0.0026786309,0.000013643052,0.00003350928,0.000025462508,0.0000026054945,0.00046552403],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99973595,0.000014456814,0.000091687245,0.00007486616,0.000013978594,0.00006905255],"domain_scores_gemma":[0.99980724,0.000016738002,0.000019187075,0.000091205584,0.000051548934,0.000014067904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005470502,0.000040182334,0.000052075062,0.00001899143,0.000066510824,0.0000030289573,0.000049528382,0.000047826008,0.0000041549583],"category_scores_gemma":[0.0000048845527,0.000028357039,0.000019909145,0.00002170879,0.000044026412,3.0414668e-7,0.000007867987,0.000011520069,2.6249685e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011463244,0.00010099734,0.042168863,0.00037751478,0.003205042,0.00003064042,0.00027945018,0.0000628659,0.1590481,0.1637469,0.30251762,0.3273157],"study_design_scores_gemma":[0.0021569363,0.000061157516,0.007243344,0.00002319014,0.00004608153,0.0000570855,0.0007086968,0.0003432111,0.31501904,0.0036450604,0.6705784,0.00011776233],"about_ca_topic_score_codex":0.00050082983,"about_ca_topic_score_gemma":0.0012965407,"teacher_disagreement_score":0.36806083,"about_ca_system_score_codex":0.0000016150144,"about_ca_system_score_gemma":0.000027695833,"threshold_uncertainty_score":0.11563665},"labels":[],"label_agreement":null},{"id":"W4409602973","doi":"10.1007/s13555-025-01399-x","title":"In Vitro and In Vivo Assessment of an Innovative Peeling System with Azelaic and Tranexamic Acids for Targeted Hyperpigmentation Reduction","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"melanin and skin pigmentation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Covenant Health","funders":"","keywords":"Hyperpigmentation; Tranexamic acid; In vivo; Azelaic acid; Dermatology; In vitro; Reduction (mathematics); Medicine; Pharmacology; Chemistry; Surgery; Biology; Biochemistry; Blood loss; Mathematics; Biotechnology","score_opus":0.007048688154364181,"score_gpt":0.2857926015899777,"score_spread":0.27874391343561356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409602973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652386,0.00062552746,0.0023709452,0.00010535424,0.0000406583,0.00028140747,0.0000059220706,0.000002434685,0.000043911805],"genre_scores_gemma":[0.99830973,0.000295963,0.0011970695,0.00006683986,0.00000667518,0.00004973944,0.00006300336,0.0000037559937,0.0000071927225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995547,0.00006932044,0.0001381918,0.00014989132,0.000022902854,0.00006498376],"domain_scores_gemma":[0.9998587,0.0000117848085,0.00004477644,0.000044421966,0.000030614265,0.000009710574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010002808,0.00006260996,0.000118268,0.000092088325,0.000030116375,0.0000054124926,0.000016869099,0.00007571663,4.778989e-7],"category_scores_gemma":[0.0000022688087,0.000055369637,0.000004750897,0.000084885265,0.00005033884,0.00000985158,0.0000044135977,0.00003303312,5.233857e-9],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006999528,0.000032250235,0.011622553,0.00007398795,0.000026659565,0.0000016361968,0.00036013185,0.000010609804,0.98499274,0.0005451053,0.000003077046,0.0016313053],"study_design_scores_gemma":[0.0034747934,0.00019405033,0.025569579,0.00002974945,0.00000610841,0.000084915264,0.0015812727,0.0018128869,0.96700954,0.00010817604,0.00005699688,0.000071915325],"about_ca_topic_score_codex":0.000014861455,"about_ca_topic_score_gemma":0.000015447324,"teacher_disagreement_score":0.017983174,"about_ca_system_score_codex":0.0000068457803,"about_ca_system_score_gemma":0.000025236588,"threshold_uncertainty_score":0.22579083},"labels":[],"label_agreement":null},{"id":"W4409783088","doi":"10.1007/s13555-025-01386-2","title":"Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical Therapies","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Dalhousie University; McGill University; Blackberry (Canada); University of Toronto; Lynde Centre for Dermatology; Centre de Recherche Dermatologique du Québec Métropolitain; Vancouver Coastal Health Research Institute; University of British Columbia; Probity Medical Research; SKiN Health; Women's College Hospital; Queen's University","funders":"Incyte","keywords":"Atopic dermatitis; Medicine; Dermatology; Consensus conference; Internal medicine","score_opus":0.025676813470825493,"score_gpt":0.3126022110351191,"score_spread":0.2869253975642936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409783088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7550942,0.049559277,0.00091207656,0.1894633,0.00019035993,0.00097093626,0.00001518717,0.000033948207,0.003760763],"genre_scores_gemma":[0.9843734,0.0030031824,0.0007786693,0.011311228,0.000010643214,0.00008156199,0.0000072310913,0.000004803465,0.00042929608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99949044,0.000028192215,0.00017791722,0.00011333816,0.000039961775,0.00015012857],"domain_scores_gemma":[0.9994953,0.000144205,0.000032046384,0.00017753737,0.00010275998,0.000048106795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041008174,0.000090618945,0.00021904956,0.000065725,0.00014603026,0.0000054673496,0.00006554171,0.00007828517,0.00003198358],"category_scores_gemma":[0.0000085470365,0.000051895535,0.000042249532,0.00006254411,0.00024835797,0.000010753358,0.000008599677,0.00005299863,0.0000010834805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050022017,0.00009880162,0.75951856,0.0005830039,0.0029736236,0.00037602705,0.00035052744,0.0000029528808,0.000010641247,0.10609098,0.06817145,0.061323196],"study_design_scores_gemma":[0.005878897,0.000074852214,0.5578252,0.00021247758,0.0003406625,0.0015178624,0.0010488016,0.00034351723,0.0011959499,0.009743337,0.4216661,0.00015234912],"about_ca_topic_score_codex":0.0004955575,"about_ca_topic_score_gemma":0.0012111127,"teacher_disagreement_score":0.35349464,"about_ca_system_score_codex":0.000006036136,"about_ca_system_score_gemma":0.00010428159,"threshold_uncertainty_score":0.21162385},"labels":[],"label_agreement":null},{"id":"W4410112845","doi":"10.1007/s13555-025-01420-3","title":"Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months","year":2025,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto; Lynde Centre for Dermatology","funders":"LEO Pharma; Sanofi; Eisai; Celgene; Eli Lilly and Company; Amgen","keywords":"Observational study; Psoriasis; Interim; Medicine; Interim analysis; Value (mathematics); Dermatology; Internal medicine; Clinical trial; Political science; Statistics; Mathematics","score_opus":0.0881417380056911,"score_gpt":0.3694065200282699,"score_spread":0.2812647820225788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410112845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98325723,0.002015242,0.0001697758,0.0018565075,0.0046034227,0.0028771409,0.0015631911,0.000028590046,0.0036288826],"genre_scores_gemma":[0.9950824,0.0002202111,0.00009082185,0.0019191575,0.00013849536,0.0005481824,0.0008837667,0.000027744823,0.0010892397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935961,0.0025702605,0.002402175,0.00096859975,0.00014710338,0.00031577295],"domain_scores_gemma":[0.9937541,0.0035009643,0.0018209941,0.0005858666,0.00026538275,0.00007273077],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045823124,0.00039880653,0.0021854865,0.00050949294,0.0003093927,0.000057311743,0.0003513339,0.0003510167,0.00008986366],"category_scores_gemma":[0.00095411437,0.00036881393,0.00015996417,0.0010244201,0.00010531284,0.00015744592,0.00012329893,0.00044881538,0.000015329675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032212078,0.00038219648,0.9741617,0.00012383322,0.0025202343,0.0000020528528,0.0015225671,0.0006275959,1.6319879e-8,0.0015259662,0.015815025,0.00009759571],"study_design_scores_gemma":[0.003464885,0.00018112108,0.9903337,0.00031135173,0.000115783005,0.0000013463417,0.0005599686,0.0019259072,6.051382e-7,0.0015797835,0.0012034305,0.00032214768],"about_ca_topic_score_codex":0.011349341,"about_ca_topic_score_gemma":0.014536666,"teacher_disagreement_score":0.016171962,"about_ca_system_score_codex":0.0009261982,"about_ca_system_score_gemma":0.00032940487,"threshold_uncertainty_score":0.9998764},"labels":[],"label_agreement":null},{"id":"W4410386249","doi":"10.1007/s13555-025-01425-y","title":"Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023","year":2025,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly Canada; Eli Lilly and Company","keywords":"Alopecia areata; Atopic dermatitis; Dermatology; Medicine","score_opus":0.05614012639521138,"score_gpt":0.3888074622409804,"score_spread":0.332667335845769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410386249","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000067854446,0.9925811,0.0000037577968,0.0014370019,0.000116880605,0.005336529,0.000100305566,0.000016851956,0.00033968675],"genre_scores_gemma":[0.00016725915,0.9954302,0.000037929567,0.0016162066,0.000039497434,0.0020931622,0.0002520821,0.000016156118,0.00034752858],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99743295,0.0008334743,0.0009929956,0.00038994115,0.0001064065,0.00024425762],"domain_scores_gemma":[0.99553293,0.00344979,0.00034931928,0.0005306418,0.000074728116,0.000062581195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021550563,0.00043400165,0.003526635,0.00026127763,0.00009769086,0.000022429815,0.0001772396,0.0003314515,0.000016160751],"category_scores_gemma":[0.00018889733,0.00023831292,0.00037487672,0.0005411693,0.00018270909,0.0000689676,0.000018801114,0.00019410904,0.0000028860413],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030537863,0.0001851972,0.0016896188,0.9045013,0.0005417379,0.0007619676,0.000294993,4.2905794e-9,1.7958746e-8,0.0007529926,0.008071797,0.08316985],"study_design_scores_gemma":[0.00094995607,0.00009019563,0.0010144039,0.5903481,0.0022592042,0.004217175,0.000023022005,0.0000016387329,9.2204664e-7,0.00020402382,0.40072417,0.00016717601],"about_ca_topic_score_codex":0.000008820789,"about_ca_topic_score_gemma":0.000038974944,"teacher_disagreement_score":0.39265236,"about_ca_system_score_codex":0.000026681024,"about_ca_system_score_gemma":0.0002087432,"threshold_uncertainty_score":0.9718119},"labels":[],"label_agreement":null},{"id":"W4410417696","doi":"10.1007/s13555-025-01426-x","title":"Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Barrie Urology Group","funders":"Novartis Pharma; Incyte; Beth Israel Deaconess Medical Center; Sanofi; Novartis; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Hidradenitis suppurativa; Post-hoc analysis; Medicine; Secukinumab; Term (time); Post hoc; Sunburn; Dermatology; Internal medicine; Disease","score_opus":0.030757738874637695,"score_gpt":0.36117694443044535,"score_spread":0.33041920555580767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410417696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779198,0.0023824433,0.00037631558,0.018453276,0.00003827406,0.0006947321,0.000033800694,0.000015713147,0.000085639556],"genre_scores_gemma":[0.99900347,0.0004496292,0.00011596378,0.00016290485,0.000009743934,0.00006757804,0.000076145094,0.000010000034,0.00010459459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982038,0.0008131752,0.00041157633,0.00028507865,0.00010671384,0.00017965194],"domain_scores_gemma":[0.9991969,0.0003035575,0.00013683313,0.00021590815,0.0000813978,0.000065392094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006130096,0.0002009223,0.0010283513,0.00042500702,0.00013804076,0.000046101286,0.000050856946,0.000122837,0.00005193997],"category_scores_gemma":[0.0000666475,0.00011557632,0.00011802141,0.0007916324,0.00015001578,0.00018815705,0.000019526551,0.0001491274,2.647205e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023421621,0.001998473,0.81335217,0.0002762825,0.025590992,0.012394085,0.009329194,0.000011122562,0.010444794,0.00079859194,0.00011761085,0.10226505],"study_design_scores_gemma":[0.10233986,0.0038996106,0.6965155,0.0012677488,0.024563722,0.10503383,0.004483407,0.0025903368,0.056293234,0.0015035166,0.00028167214,0.001227565],"about_ca_topic_score_codex":0.00007088953,"about_ca_topic_score_gemma":0.00029418973,"teacher_disagreement_score":0.11683669,"about_ca_system_score_codex":0.000025159667,"about_ca_system_score_gemma":0.00010463264,"threshold_uncertainty_score":0.47130653},"labels":[],"label_agreement":null},{"id":"W4410443520","doi":"10.1007/s13555-025-01440-z","title":"Efficacy and Safety of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel: Post Hoc Analysis by Baseline Disease Severity","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Adapalene; Benzoyl peroxide; Post-hoc analysis; Post hoc; Clindamycin; Medicine; Phosphate; Dermatology; Baseline (sea); Acne; Internal medicine; Chemistry; Organic chemistry; Antibiotics; Political science","score_opus":0.005670551036702147,"score_gpt":0.26776364810348513,"score_spread":0.26209309706678297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410443520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9555081,0.03941637,0.00028837915,0.004164435,0.00004751322,0.00031625578,0.00011553596,0.000026066587,0.00011733674],"genre_scores_gemma":[0.97643745,0.02010783,0.000094641146,0.0026299444,0.000013108095,0.000008488549,0.00026393597,0.000009234599,0.0004353508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990106,0.000119832606,0.00028627002,0.0002993254,0.00008106632,0.0002029064],"domain_scores_gemma":[0.9992534,0.00020144196,0.000079493846,0.00023718184,0.000063480096,0.0001650142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013135246,0.00019289408,0.0006301441,0.00013967324,0.00014770702,0.000008287711,0.000044972403,0.00013280964,0.00009438639],"category_scores_gemma":[0.00002800068,0.00013639055,0.00011939609,0.00026990537,0.00018438055,0.000048072474,0.00002861897,0.0001166712,0.000002840635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023580942,0.0016361753,0.88075525,0.0003356488,0.0060435273,0.0003402696,0.00047917434,0.0000065840914,0.0028163898,0.00055532233,0.0047756946,0.07867505],"study_design_scores_gemma":[0.024378588,0.00059869594,0.91680086,0.00015866198,0.0032486373,0.00009902317,0.00013705567,0.0014370948,0.0125460895,0.00020546404,0.04002289,0.0003669511],"about_ca_topic_score_codex":0.00005169382,"about_ca_topic_score_gemma":0.000011528308,"teacher_disagreement_score":0.0783081,"about_ca_system_score_codex":0.000008286846,"about_ca_system_score_gemma":0.000057977464,"threshold_uncertainty_score":0.55618453},"labels":[],"label_agreement":null},{"id":"W4410850742","doi":"10.1007/s13555-025-01434-x","title":"Tildrakizumab Treatment Patterns in Adults With Moderate-to-Severe Plaque Psoriasis: A Retrospective Analysis From the Canadian Patient Support Program","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Brampton Civic Hospital; Nova Chemicals (Canada); Bayer (Canada); Probity Medical Research; Calgary Laboratory Services; SKiN Health; University of Calgary","funders":"Sun Pharma","keywords":"Medicine; Plaque psoriasis; Psoriasis; Retrospective cohort study; Dermatology; Internal medicine","score_opus":0.007483775893738951,"score_gpt":0.22781465538256276,"score_spread":0.22033087948882382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410850742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99410737,0.0018866675,0.000017969433,0.0018466391,0.00017659628,0.0010059426,0.00035220676,0.000048387705,0.0005582209],"genre_scores_gemma":[0.99672765,0.0008296923,0.000045483932,0.00095124403,0.000009420128,0.0006984262,0.0006018826,0.0000117718155,0.00012443853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984983,0.00028368967,0.0002524428,0.0004973138,0.00003309757,0.00043514365],"domain_scores_gemma":[0.99935687,0.000115131465,0.000069392016,0.0003505353,0.00005396817,0.00005411747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004614285,0.00029650985,0.0005242489,0.0003223574,0.0003669295,0.00003300918,0.00014542209,0.0003065965,0.00017263816],"category_scores_gemma":[0.00000519071,0.0001817052,0.000099044424,0.0004999954,0.00010668167,0.0000488144,0.000020148023,0.00015403662,0.000026917776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002765031,0.00033968937,0.88544816,0.0000030880328,0.0043193107,0.0001438431,0.005437316,0.000014922367,0.000014738495,0.00042351775,0.00023011216,0.1008603],"study_design_scores_gemma":[0.009359379,0.0009080181,0.9727921,0.000053759322,0.0005718905,0.00009188119,0.0009254827,0.000028146173,0.0034284214,0.00028738423,0.0112278415,0.00032571942],"about_ca_topic_score_codex":0.098503344,"about_ca_topic_score_gemma":0.6515349,"teacher_disagreement_score":0.55303156,"about_ca_system_score_codex":0.00016981839,"about_ca_system_score_gemma":0.00023954565,"threshold_uncertainty_score":0.9074998},"labels":[],"label_agreement":null},{"id":"W4410949005","doi":"10.1007/s13555-025-01443-w","title":"Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; University of Calgary","funders":"AbbVie","keywords":"Eczema Area and Severity Index; Medicine; Placebo; Dupilumab; Atopic dermatitis; Dermatology Life Quality Index; Clinical trial; Quality of life (healthcare); Internal medicine; Dermatology; Pathology","score_opus":0.052138522535357085,"score_gpt":0.34514272975325316,"score_spread":0.2930042072178961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410949005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98694736,0.0074620508,0.00016020355,0.0027951333,0.00055876764,0.0016458173,0.00016861499,0.000047839927,0.00021423174],"genre_scores_gemma":[0.99542147,0.0023642178,0.00015027402,0.001738148,0.000036383888,0.000104692,0.00012643953,0.000024426361,0.000033957345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969453,0.00074159744,0.0009055633,0.0007622575,0.00023890908,0.0004063281],"domain_scores_gemma":[0.99734515,0.0016010874,0.00024719205,0.00037900347,0.0001471082,0.00028048814],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067582406,0.0004079364,0.0013697541,0.0001779452,0.00024693675,0.000057738827,0.00009801814,0.00042540062,0.00002307525],"category_scores_gemma":[0.00046867854,0.00030327495,0.00006238809,0.00018152507,0.0005000234,0.00017946398,0.000055236113,0.00044361904,0.0000023738069],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35743773,0.0004955514,0.46951723,0.00012978801,0.001140508,0.00018530937,0.0009652121,0.0000012873918,0.000009608007,0.00015164615,0.002651769,0.16731437],"study_design_scores_gemma":[0.35307324,0.0015554691,0.6399934,0.00047072864,0.0003737927,0.00010554873,0.00037863702,0.00031379535,0.00047507478,0.00035420505,0.0024616476,0.00044445376],"about_ca_topic_score_codex":0.00005897815,"about_ca_topic_score_gemma":0.00039274403,"teacher_disagreement_score":0.17047618,"about_ca_system_score_codex":0.00002087525,"about_ca_system_score_gemma":0.000192771,"threshold_uncertainty_score":0.99994195},"labels":[],"label_agreement":null},{"id":"W4411000674","doi":"10.1007/s13555-025-01453-8","title":"Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; University of Calgary; Probity Medical Research; Health Sciences Centre; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Sanofi Genzyme; LEO Pharma; Galderma; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dupilumab; Atopic dermatitis; Medicine; Retrospective cohort study; Multicenter study; Cohort; Dermatology; Internal medicine; Randomized controlled trial","score_opus":0.005650236608070343,"score_gpt":0.26809496436534785,"score_spread":0.2624447277572775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411000674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99657,0.0006350289,0.0000200288,0.00036054244,0.00008359038,0.0012333182,0.00001684547,0.00002096755,0.0010596924],"genre_scores_gemma":[0.9986122,0.00086044864,0.00003901212,0.0003374558,0.000004388349,0.000081364786,0.00002568611,0.000008777244,0.00003065407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893516,0.00022296043,0.00028902656,0.0002976183,0.000104935476,0.00015027664],"domain_scores_gemma":[0.99941134,0.00020758295,0.000084563464,0.00014774635,0.00009811495,0.000050664534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010606614,0.00016365151,0.00055545924,0.00024639937,0.00007470318,0.00001000452,0.00005179716,0.000087254,0.000022607514],"category_scores_gemma":[0.00003064705,0.00013012455,0.000024303863,0.00014620357,0.0003138237,0.00010379266,0.00003452841,0.00015459511,5.0156467e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021418512,0.0009635857,0.9938988,0.00011719229,0.00053180754,0.00008562801,0.00052622537,1.8412659e-7,0.0000043794726,0.0005214611,0.00005022779,0.001158645],"study_design_scores_gemma":[0.0174188,0.00016566063,0.981177,0.00020209387,0.000082948485,0.00005056829,0.00016600722,0.000024814153,0.0001341077,0.0003192566,0.00015780874,0.00010095843],"about_ca_topic_score_codex":0.0000904622,"about_ca_topic_score_gemma":0.00013099411,"teacher_disagreement_score":0.015276949,"about_ca_system_score_codex":0.000026158812,"about_ca_system_score_gemma":0.00003380891,"threshold_uncertainty_score":0.5306325},"labels":[],"label_agreement":null},{"id":"W4411539937","doi":"10.1007/s13555-025-01452-9","title":"Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Dermira; Eli Lilly and Company","keywords":"Extension (predicate logic); Atopic dermatitis; Term (time); Dermatology; Medicine; Pediatrics; Computer science; Physics; Programming language","score_opus":0.007114266231606919,"score_gpt":0.254723067199235,"score_spread":0.24760880096762808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411539937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99502593,0.0023454041,0.000078151796,0.0011724175,0.000050737057,0.0005868715,0.0000069559187,0.000026622116,0.0007069124],"genre_scores_gemma":[0.9967193,0.0006223885,0.00013316989,0.0024255887,0.000004588555,0.000018814942,0.000032555825,0.000010286008,0.000033294888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990509,0.00010247156,0.00028866046,0.00026741953,0.00008373856,0.00020679743],"domain_scores_gemma":[0.99944794,0.000107016895,0.000058174173,0.00022267232,0.00007603815,0.00008815109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003947262,0.00016665483,0.00049950584,0.00020674823,0.000083743646,0.000007893397,0.000053988002,0.00013445895,0.0000265048],"category_scores_gemma":[0.000024314722,0.0001306304,0.000027441669,0.00016576807,0.00019499507,0.00007885697,0.00003832923,0.00014362647,0.0000038573617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040866695,0.0003483506,0.9884214,0.00014772003,0.00012107978,0.00014564587,0.00022722987,0.0000032574983,0.000012465423,0.0010803114,0.000238433,0.0051674624],"study_design_scores_gemma":[0.018596817,0.000102029626,0.9796073,0.00034308806,0.000042426775,0.00027546502,0.00003523013,0.000028198918,0.0004544678,0.00028778065,0.00010980798,0.000117392636],"about_ca_topic_score_codex":0.000008168011,"about_ca_topic_score_gemma":0.0000164761,"teacher_disagreement_score":0.014510147,"about_ca_system_score_codex":0.000009681572,"about_ca_system_score_gemma":0.000066312045,"threshold_uncertainty_score":0.53269535},"labels":[],"label_agreement":null},{"id":"W4411698955","doi":"10.1007/s13555-025-01469-0","title":"Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic Dermatitis","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trent University; Probity Medical Research; SKiN Health; Queen's University","funders":"AbbVie","keywords":"Atopic dermatitis; Quality of life (healthcare); Medicine; Disease; Dermatology; Internal medicine; Nursing","score_opus":0.01439431996463099,"score_gpt":0.30945580545963347,"score_spread":0.2950614854950025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411698955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935991,0.0048070652,0.000009677356,0.001135148,0.000018755682,0.00036142787,0.000033635268,0.000009772687,0.000025397068],"genre_scores_gemma":[0.9985901,0.0011343335,0.000029240851,0.00020667414,0.0000014107796,0.000012219958,0.000018594767,0.000004402691,0.000002990343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991546,0.00021785159,0.00027690243,0.00016685673,0.000056026583,0.00012774293],"domain_scores_gemma":[0.99943763,0.00016693206,0.00014785654,0.000110012814,0.000025478714,0.000112074544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004601366,0.00012905143,0.00052650116,0.0001298338,0.000058378773,0.0000028042068,0.000014424137,0.00008371796,0.000008894734],"category_scores_gemma":[0.000033188728,0.00009182263,0.00003852964,0.00007293627,0.00020547738,0.00006434465,0.000009706646,0.00007785654,1.2775449e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039044146,0.0005214036,0.98198867,0.00019406968,0.00026314164,0.000012204992,0.00026598707,0.00000288888,0.000014642882,0.00010973203,0.00003247868,0.01269037],"study_design_scores_gemma":[0.007569805,0.0005214208,0.9914721,0.0000913605,0.000024888752,0.000014541403,0.000022023398,0.000051823627,0.000082009174,0.00008439422,0.0000060762895,0.000059536134],"about_ca_topic_score_codex":0.00026463217,"about_ca_topic_score_gemma":0.000033802608,"teacher_disagreement_score":0.012630834,"about_ca_system_score_codex":0.00002164215,"about_ca_system_score_gemma":0.00013140401,"threshold_uncertainty_score":0.37444183},"labels":[],"label_agreement":null},{"id":"W4412395244","doi":"10.1007/s13555-025-01485-0","title":"Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trent University; Probity Medical Research; SKiN Health; Queen's University","funders":"AbbVie","keywords":"Atopic dermatitis; Measure (data warehouse); Medicine; Dermatology; Computer science; Data mining","score_opus":0.02678635831070938,"score_gpt":0.3347314174133577,"score_spread":0.30794505910264836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412395244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97102404,0.023891693,0.0014777029,0.0027160544,0.00003511238,0.00063823955,0.0001550017,0.000030052694,0.00003213265],"genre_scores_gemma":[0.9959707,0.0024366127,0.00045350892,0.0008402971,0.000006038302,0.0001372077,0.000063489795,0.000009095205,0.00008303462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906087,0.00011146865,0.00022178402,0.00033382914,0.00006321769,0.00020884],"domain_scores_gemma":[0.99918395,0.00028517918,0.000078149904,0.00016302578,0.00012840203,0.00016131921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000051187453,0.00023831043,0.0008619047,0.00029255473,0.00019121608,0.000015037196,0.000035735655,0.000101863065,0.000008263914],"category_scores_gemma":[0.0000565065,0.00016566452,0.00008172422,0.00024179573,0.0003370816,0.00009145014,0.000022109354,0.00007478452,1.7434483e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02311215,0.0010950395,0.92176765,0.00067708176,0.015898919,0.00031767273,0.0022581553,0.00002967705,0.00039606323,0.00065436435,0.0008696016,0.0329236],"study_design_scores_gemma":[0.03640858,0.0012427585,0.9298526,0.00046084277,0.008393546,0.00054706953,0.0017552684,0.009336216,0.008008415,0.00039647994,0.0030367072,0.0005614935],"about_ca_topic_score_codex":0.000008699015,"about_ca_topic_score_gemma":0.000024097286,"teacher_disagreement_score":0.032362107,"about_ca_system_score_codex":0.000014251666,"about_ca_system_score_gemma":0.00011262879,"threshold_uncertainty_score":0.6755603},"labels":[],"label_agreement":null},{"id":"W4412492282","doi":"10.1007/s13555-025-01463-6","title":"Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Alberta; University of Saskatchewan; EVERSANA (Canada); Western University; University of Toronto; Dalhousie University; Dermatrials Research; Probity Medical Research; McMaster University","funders":"LEO Pharma; Bausch Health; Astellas Pharma; Mylan; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Valeant Pharmaceuticals International; Janssen Canada; Sanofi; Amgen; Pfizer; Meiji Seika Pharma; Galderma; Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Psoriasis Area and Severity Index; Secukinumab; Internal medicine; Onset of action; Psoriasis; Confidence interval; Meta-analysis; Dermatology; Psoriatic arthritis","score_opus":0.031940586587068345,"score_gpt":0.2905279435827251,"score_spread":0.25858735699565677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412492282","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21318367,0.78418905,0.000056037115,0.0009802204,0.00007856481,0.0013132761,0.00016137233,0.000020913016,0.000016905895],"genre_scores_gemma":[0.8626239,0.13243555,0.00038508215,0.0017788664,0.000006298371,0.0008715381,0.0006949912,0.0000119738015,0.0011918024],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99843377,0.00062632776,0.0004096247,0.0003111205,0.0000136382605,0.0002055201],"domain_scores_gemma":[0.99918395,0.0003988618,0.00015530738,0.00018907685,0.00005311703,0.000019690513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026288786,0.0002265546,0.0016572376,0.00025616479,0.00010953391,0.000008328577,0.00006548434,0.00030404888,0.00005683643],"category_scores_gemma":[0.000041054223,0.00014907731,0.00021083614,0.00053664466,0.000083443476,0.000044056884,0.000022244427,0.00006904837,0.000004802398],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045763403,0.0012181855,0.05117368,0.02677538,0.86752385,0.000078058016,0.002644463,0.000028513123,0.015373687,0.0019984785,0.0094930995,0.019116294],"study_design_scores_gemma":[0.026196329,0.0023114919,0.08099029,0.0054609138,0.8168547,0.0012940322,0.0005223971,0.00017866239,0.042141493,0.007702518,0.014054642,0.0022925364],"about_ca_topic_score_codex":0.0000068342883,"about_ca_topic_score_gemma":0.000012632347,"teacher_disagreement_score":0.6517535,"about_ca_system_score_codex":0.000007888487,"about_ca_system_score_gemma":0.00001368282,"threshold_uncertainty_score":0.60791963},"labels":[],"label_agreement":null},{"id":"W4412530626","doi":"10.1007/s13555-025-01478-z","title":"Correction: Complete/Near-Complete Itch Response Observed in Patients with Moderate-to-Severe Atopic Dermatitis Initiating Dupilumab: 3-Year, Real-World, Interim Data from the PROSE Registry","year":2025,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto","funders":"","keywords":"Dupilumab; Atopic dermatitis; Interim; Dermatology; Medicine; Interim analysis; Clinical trial; Internal medicine; History","score_opus":0.05136536911327145,"score_gpt":0.2977765509348031,"score_spread":0.24641118182153166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412530626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9583437,0.0057608187,0.00008247863,0.01254482,0.008808872,0.0029427337,0.0026148667,0.00025920908,0.0086425375],"genre_scores_gemma":[0.9452661,0.002064341,0.0005625149,0.019854805,0.00032409118,0.00031555796,0.017853584,0.00012163503,0.013637324],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9962624,0.0011203837,0.0007953701,0.000979629,0.00030637148,0.00053586875],"domain_scores_gemma":[0.996244,0.0012357227,0.00037562626,0.0017711672,0.00019874758,0.00017473717],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021880714,0.00059671834,0.001310379,0.00023519882,0.0005231784,0.00013221493,0.0007432961,0.0006365467,0.0002001035],"category_scores_gemma":[0.00036656874,0.0004476737,0.00008918178,0.00046879408,0.0004907594,0.00020964198,0.00038371707,0.0015830791,0.00003546538],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053245937,0.00020355849,0.45730636,0.0001380577,0.00034759057,0.00035215885,0.00046307646,0.0000019148872,8.4720637e-7,0.000022709919,0.53522134,0.0006178176],"study_design_scores_gemma":[0.0060984544,0.00009331979,0.8193309,0.0015553476,0.00012983728,0.0002555342,0.0001625696,0.00077704794,0.00000768162,0.00019196817,0.17098096,0.00041643047],"about_ca_topic_score_codex":0.00060171523,"about_ca_topic_score_gemma":0.0016556169,"teacher_disagreement_score":0.36424038,"about_ca_system_score_codex":0.00007353073,"about_ca_system_score_gemma":0.000756883,"threshold_uncertainty_score":0.9997975},"labels":[],"label_agreement":null},{"id":"W4412703250","doi":"10.1007/s13555-025-01484-1","title":"Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Genentech; LEO Pharma; Bausch Health; Glenmark Pharmaceuticals; Sanofi Genzyme; Incyte; CTI Biopharma; BioCryst; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Celldex Therapeutics; Amgen; Pfizer; Galderma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atopic dermatitis; Dermatology; Medicine","score_opus":0.012931610498249884,"score_gpt":0.2713952044670975,"score_spread":0.2584635939688476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412703250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930014,0.00051710184,0.00012696382,0.0038257404,0.00006070992,0.0010178011,0.000019345585,0.000096236734,0.0013347276],"genre_scores_gemma":[0.9793592,0.00067431404,0.00011468656,0.01886565,0.00001605568,0.00010193991,0.00004446164,0.000041590905,0.00078209006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977674,0.00025655827,0.00060110615,0.00061744836,0.00019176453,0.00056573394],"domain_scores_gemma":[0.9990086,0.000104558894,0.00013989815,0.0004099675,0.00009420082,0.00024277387],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009421626,0.00040313683,0.0009263316,0.0002467902,0.00025019798,0.0000321108,0.00017921838,0.00034676093,0.000093923176],"category_scores_gemma":[0.00003143146,0.00027424068,0.0000763005,0.0003598965,0.0003152864,0.00014446973,0.00006875832,0.00040207102,0.000036757505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052274197,0.0009293854,0.93431485,0.00027352918,0.00046383103,0.0018825255,0.00069069426,0.000009609584,0.000043280274,0.0001251367,0.0024092728,0.0065836925],"study_design_scores_gemma":[0.033688862,0.0021129588,0.94970953,0.0015818193,0.00019177215,0.003504958,0.00038838692,0.00039620072,0.0041132863,0.0002600962,0.0034784658,0.00057367823],"about_ca_topic_score_codex":0.00007489814,"about_ca_topic_score_gemma":0.00043742845,"teacher_disagreement_score":0.018585335,"about_ca_system_score_codex":0.00006708962,"about_ca_system_score_gemma":0.00017857063,"threshold_uncertainty_score":0.999971},"labels":[],"label_agreement":null},{"id":"W4413052347","doi":"10.1007/s13555-025-01498-9","title":"The Urticaria Voices Study: Physicians’ Perspectives on the Real-World Patient Burden, Treatments, and Outcomes in Chronic Spontaneous Urticaria","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharma; Asthma and Allergy Foundation of America","keywords":"Medicine; Omalizumab; Guideline; Quality of life (healthcare); Chronic urticaria; Family medicine; Cross-sectional study; Pediatrics; Internal medicine; Nursing; Immunoglobulin E","score_opus":0.008665839796341288,"score_gpt":0.2836571114187984,"score_spread":0.2749912716224571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413052347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9641117,0.005025159,0.0000019698823,0.026840635,0.00011058061,0.00081358384,0.0000033393512,0.00003137341,0.0030616806],"genre_scores_gemma":[0.9923772,0.0063054087,0.0000039618526,0.0006086727,0.000021116959,0.00012817938,0.0000029887747,0.000008890997,0.0005435762],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99902326,0.00020155075,0.00021179827,0.00024950723,0.00008839637,0.0002255149],"domain_scores_gemma":[0.998909,0.00069510425,0.000045365017,0.00028637933,0.00003055374,0.000033603454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057670513,0.00016397645,0.0002909407,0.00010373087,0.000409066,0.00003345681,0.000071507384,0.00007783568,0.000017484346],"category_scores_gemma":[0.00002371291,0.000080617654,0.000049590817,0.00018781953,0.00034051467,0.00002638885,0.000025237208,0.00026711778,0.0000050500685],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019478478,0.002627516,0.40105802,0.000011698824,0.018594211,0.0021617396,0.050199825,0.0000107016685,0.0013992104,0.4743365,0.00053647795,0.04711623],"study_design_scores_gemma":[0.006496398,0.0012516122,0.9477537,0.000100150704,0.0018868623,0.00027959977,0.029642522,0.0005489939,0.0004450909,0.008050001,0.0033198893,0.00022514051],"about_ca_topic_score_codex":0.0002398743,"about_ca_topic_score_gemma":0.00048079144,"teacher_disagreement_score":0.5466957,"about_ca_system_score_codex":0.00006825775,"about_ca_system_score_gemma":0.00007093044,"threshold_uncertainty_score":0.32874924},"labels":[],"label_agreement":null},{"id":"W4413992604","doi":"10.1007/s13555-025-01503-1","title":"Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada); University of British Columbia; EVERSANA (Canada); SKiN Health","funders":"Incyte","keywords":"Ruxolitinib; Atopic dermatitis; Medicine; Dermatology; Meta-analysis; Internal medicine; Myelofibrosis","score_opus":0.08300561932064904,"score_gpt":0.34513289262683955,"score_spread":0.2621272733061905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413992604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9290296,0.06701406,0.000058834423,0.0017000553,0.00008290003,0.00037110344,0.000019549863,0.00001112577,0.0017127658],"genre_scores_gemma":[0.99284315,0.0054749968,0.000026387212,0.0014495846,0.0000065664076,0.000093488205,0.000041557687,0.0000040586287,0.000060212908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987724,0.00036790228,0.00043675883,0.00016533292,0.00008128822,0.00017631365],"domain_scores_gemma":[0.99895424,0.0005251881,0.00012866136,0.0003172155,0.000045346915,0.000029339564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008630557,0.00014643636,0.0012497476,0.00022174518,0.000060432005,0.0000045111024,0.00008758488,0.00013026242,0.00010237483],"category_scores_gemma":[0.000011982862,0.00008882172,0.00039489337,0.0004465115,0.0001765148,0.000027435835,0.000007951849,0.000059133865,0.000001336814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001909853,0.002243263,0.7483558,0.0003454232,0.21713473,0.00051189767,0.0034484447,0.00042710762,0.00001341573,0.020455655,0.0031966527,0.0019577416],"study_design_scores_gemma":[0.016691409,0.0005188482,0.780359,0.000070951886,0.18132538,0.00065670034,0.0010531528,0.003305613,0.0021344116,0.0061089965,0.0074687093,0.0003067772],"about_ca_topic_score_codex":0.000050739753,"about_ca_topic_score_gemma":0.000034508794,"teacher_disagreement_score":0.063813545,"about_ca_system_score_codex":0.00000918527,"about_ca_system_score_gemma":0.00004856939,"threshold_uncertainty_score":0.36220446},"labels":[],"label_agreement":null},{"id":"W4414371190","doi":"10.1007/s13555-025-01533-9","title":"Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health","keywords":"Narrative review; Psoriasis; Biologic Agents; Mechanism (biology); Observational study; Action (physics)","score_opus":0.015095661325495979,"score_gpt":0.25821738763741076,"score_spread":0.24312172631191478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414371190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96478724,0.03301349,0.000038062633,0.001329278,0.00030507735,0.00035149846,0.000025658586,0.000040570638,0.00010909458],"genre_scores_gemma":[0.9821238,0.016433528,0.000052631993,0.0007982469,0.000007835723,0.00013526365,0.000032936292,0.000009694348,0.00040607445],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981493,0.00095054245,0.00030381302,0.00033423898,0.000016383903,0.00024575187],"domain_scores_gemma":[0.9992978,0.0003307594,0.00010161041,0.00021516328,0.000037927715,0.000016738952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028185316,0.00023045254,0.0004561065,0.0003278581,0.000100016354,0.000007334003,0.00009606962,0.0005921605,0.00035794594],"category_scores_gemma":[0.000023537947,0.00018016092,0.00006622735,0.00018478472,0.00022014257,0.000073633455,0.00003159599,0.00018657149,0.000012414612],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042232037,0.0005354051,0.02976144,0.000057407375,0.0012029704,0.0001012732,0.0020994006,2.2380533e-7,0.72000235,0.011111694,0.00026931395,0.19262646],"study_design_scores_gemma":[0.013673879,0.001170096,0.10291422,0.00006798573,0.000053847943,0.00065535796,0.00067500665,0.0000033325057,0.83530605,0.016928473,0.028211571,0.00034017692],"about_ca_topic_score_codex":0.000031212614,"about_ca_topic_score_gemma":0.0000814205,"teacher_disagreement_score":0.19228628,"about_ca_system_score_codex":0.000012240663,"about_ca_system_score_gemma":0.00006704857,"threshold_uncertainty_score":0.73467493},"labels":[],"label_agreement":null},{"id":"W4414554196","doi":"10.1007/s13555-025-01534-8","title":"Physician-Reported Treatment Patterns in Moderate to Severe Chronic Hand Eczema: the RWEAL Multinational Medical Chart Review","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Contact Dermatitis and Allergies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Hotel Dieu Hospital","funders":"LEO Pharma","keywords":"Chart; MEDLINE; Chronic disease; Medical treatment","score_opus":0.017299568554015127,"score_gpt":0.31295557948642244,"score_spread":0.29565601093240734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414554196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85887027,0.03912567,0.0001419432,0.10028717,0.00010890822,0.0007329455,0.000007813741,0.000021972686,0.0007033388],"genre_scores_gemma":[0.92488855,0.04827344,0.000007130136,0.026331946,0.00004083008,0.00014969193,0.000036347363,0.0000056759977,0.00026637487],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991905,0.00007596001,0.0002626287,0.00017549086,0.000118477845,0.00017694975],"domain_scores_gemma":[0.99960816,0.000092844944,0.00004399076,0.00015798061,0.000039858125,0.00005713824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008626153,0.00012895119,0.00036012195,0.000059361006,0.00010712177,0.000013121626,0.000054709562,0.00007184009,0.00014296565],"category_scores_gemma":[0.000021029713,0.00007778309,0.00005310239,0.00010351292,0.000057343063,0.000033894194,0.000020537173,0.00011676588,0.000008853914],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053401844,0.00090727,0.11488441,0.0010360966,0.0011206563,0.0015991336,0.0018395289,0.000008206911,0.00045838114,0.004408698,0.010597891,0.8626057],"study_design_scores_gemma":[0.017079815,0.00037437634,0.59918743,0.0055105505,0.00014062894,0.0025683749,0.00018190559,0.0045703193,0.004467522,0.0008463527,0.36465266,0.00042005687],"about_ca_topic_score_codex":0.000067024994,"about_ca_topic_score_gemma":0.0003593253,"teacher_disagreement_score":0.86218566,"about_ca_system_score_codex":0.0000420362,"about_ca_system_score_gemma":0.00018539009,"threshold_uncertainty_score":0.3171902},"labels":[],"label_agreement":null},{"id":"W4414927188","doi":"10.1007/s13555-025-01557-1","title":"Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"Manchester Biomedical Research Centre; Allergan; LEO Pharma; National Institute for Health and Care Research; Incyte; Sun Pharma; Regeneron Pharmaceuticals; UCB; Celgene; Biogen; Valeant Pharmaceuticals International; Sanofi; Amgen; Meiji Seika Pharma; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Clinical trial; Post-hoc analysis; Psoriasis; Post hoc; Phases of clinical research","score_opus":0.04833259873561692,"score_gpt":0.38336368143340194,"score_spread":0.33503108269778503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414927188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9496874,0.04809548,0.000064683285,0.0007051978,0.0006870462,0.00032219916,0.00018925114,0.000033633376,0.00021509042],"genre_scores_gemma":[0.98635024,0.0123346,0.000025904124,0.0004830742,0.000011686136,0.000037489423,0.00053468347,0.000008600781,0.00021370867],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9957644,0.002339615,0.001158721,0.00041421666,0.000026529731,0.00029652924],"domain_scores_gemma":[0.99666834,0.0026003793,0.00031171448,0.0003349718,0.000057420046,0.000027156304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011856436,0.00023899476,0.0016532083,0.00066797744,0.00010578904,0.000008537461,0.00019269869,0.00062221504,0.00030977276],"category_scores_gemma":[0.00024111016,0.00018859498,0.00044332058,0.0007846897,0.00032701954,0.00005450143,0.000033639815,0.00019966741,0.000022434237],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014392286,0.0048493203,0.13355222,0.000022250988,0.020889994,0.00004629478,0.00071759813,0.0000011633686,0.046173926,0.0026275753,0.004314039,0.7724133],"study_design_scores_gemma":[0.20222284,0.0029291739,0.39091635,0.00012349257,0.012189018,0.00013213599,0.0009982203,0.00009582216,0.24201187,0.0011899613,0.14583279,0.0013583265],"about_ca_topic_score_codex":0.00008156445,"about_ca_topic_score_gemma":0.000057666817,"teacher_disagreement_score":0.771055,"about_ca_system_score_codex":0.0000111767085,"about_ca_system_score_gemma":0.00006622292,"threshold_uncertainty_score":0.769068},"labels":[],"label_agreement":null},{"id":"W4414973762","doi":"10.1007/s13555-025-01535-7","title":"Considerations for Treating Generalized Pustular Psoriasis (GPP): A Narrative Review","year":2025,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Centre de Recherche Dermatologique du Québec Métropolitain; Centre de Recherche Industrielle du Québec; Women's College Hospital; Hospital for Sick Children; Dermatrials Research; Health Sciences Centre; Ottawa Hospital; McGill University; University of Ottawa; Sunnybrook Health Science Centre; Quest University Canada; Queen's University; Probity Medical Research; University of British Columbia; McMaster University; SKiN Health; University of Calgary; Lynde Centre for Dermatology; University of Toronto","funders":"Boehringer Ingelheim","keywords":"Generalized pustular psoriasis; Psoriasis; Narrative review; Biologic Agents; Plaque psoriasis; Pathogenesis","score_opus":0.04927849051615285,"score_gpt":0.3358533445554728,"score_spread":0.2865748540393199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414973762","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000042580326,0.9950783,0.00003897334,0.0005248407,0.00081714924,0.0026567958,0.0003385575,0.00009277422,0.00041000717],"genre_scores_gemma":[0.00001682423,0.9928637,0.0003738465,0.0009421027,0.000052976717,0.0026749992,0.0013704917,0.000034510875,0.0016705131],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99697083,0.0011667168,0.0007969996,0.0006261326,0.000025061425,0.00041423764],"domain_scores_gemma":[0.9970163,0.0020264261,0.0004164662,0.00040235044,0.000106925065,0.000031521606],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021370806,0.0006375432,0.002888358,0.00022874528,0.0007162974,0.000023023684,0.00016069716,0.0009018076,0.00033967625],"category_scores_gemma":[0.00020702867,0.00047522606,0.0006759812,0.00020458452,0.00019311898,0.00005930991,0.00004150954,0.00025273085,0.000044100176],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055900888,0.00010822653,0.0000081773915,0.012302419,0.0035437217,0.000026296717,0.00038295446,2.2856003e-8,0.000010434947,0.0039014812,0.020830281,0.95883006],"study_design_scores_gemma":[0.002378743,0.000070109294,0.0000011031709,0.0089500835,0.0025257186,0.0009520085,0.000040229334,2.0072173e-7,0.00012415752,0.0009422409,0.98360646,0.00040892742],"about_ca_topic_score_codex":0.000010619243,"about_ca_topic_score_gemma":0.000010912728,"teacher_disagreement_score":0.9627762,"about_ca_system_score_codex":0.000027306547,"about_ca_system_score_gemma":0.00034176503,"threshold_uncertainty_score":0.9997699},"labels":[],"label_agreement":null},{"id":"W4415133357","doi":"10.1007/s13555-025-01543-7","title":"Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Clinical trial; Alopecia areata; Phase (matter); Phases of clinical research; MEDLINE","score_opus":0.0657944768740517,"score_gpt":0.3830563487242735,"score_spread":0.3172618718502218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415133357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96312696,0.0075232945,0.026002072,0.0011920973,0.00007338117,0.0017967736,0.000025190056,0.0000075602557,0.00025270254],"genre_scores_gemma":[0.9946183,0.0030290647,0.0015720908,0.00056859694,0.00003148021,0.00009911482,0.000009671213,0.0000063560665,0.00006533527],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991279,0.00010575335,0.00041036692,0.00019051308,0.000052985357,0.000112449736],"domain_scores_gemma":[0.9983659,0.0013278677,0.000095929994,0.000094826595,0.000049601018,0.000065901666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003263712,0.00010493238,0.00060578564,0.00009464435,0.000056258574,0.0000070010205,0.00002954877,0.00013531998,0.000014870903],"category_scores_gemma":[0.00025997838,0.0000810618,0.000049203347,0.000038365204,0.00033719183,0.00003301427,0.0000121933135,0.00007169595,1.0564348e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89050186,0.0022185661,0.015522306,0.00034147897,0.0007861626,0.000019527983,0.0006070286,9.1296704e-7,0.008658718,0.008648789,0.0007718388,0.071922794],"study_design_scores_gemma":[0.979055,0.0023220023,0.002734688,0.00014876296,0.0002739319,0.00026962985,0.00019648434,0.004412662,0.0019535988,0.0042238724,0.0042642877,0.00014510745],"about_ca_topic_score_codex":0.000004333089,"about_ca_topic_score_gemma":0.0000038923026,"teacher_disagreement_score":0.08855309,"about_ca_system_score_codex":0.0000014299928,"about_ca_system_score_gemma":0.00009263787,"threshold_uncertainty_score":0.33056042},"labels":[],"label_agreement":null},{"id":"W4415261130","doi":"10.1007/s13555-025-01565-1","title":"Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic Dermatitis","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SKiN Health","funders":"LEO Pharma","keywords":"Dupilumab; Atopic dermatitis; MEDLINE; Monoclonal; Disease","score_opus":0.010955849818308397,"score_gpt":0.26775586455114536,"score_spread":0.256800014732837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415261130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925593,0.0005610236,0.0024053406,0.0033935797,0.000023481864,0.00094222167,0.00000916391,0.000016969763,0.000088919485],"genre_scores_gemma":[0.9957546,0.00007496933,0.00026368126,0.003587459,0.0000020969292,0.00017650246,0.00007529615,0.0000073766187,0.000058030037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913305,0.00009105079,0.00023307028,0.0002601167,0.000073707684,0.00020903091],"domain_scores_gemma":[0.99955523,0.00013453561,0.000037548387,0.00013975264,0.00006290089,0.00007000437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003643453,0.00014603903,0.00046945093,0.0004198348,0.00007037142,0.00001716504,0.000042064126,0.00013848991,0.000017638307],"category_scores_gemma":[0.000015169425,0.00011045889,0.00002832814,0.0002954432,0.00010967871,0.0000902294,0.000012072813,0.00011688808,7.892431e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035254364,0.00035705394,0.9902955,0.000058304082,0.00026961445,0.000049764785,0.00038426838,0.00002079101,0.0000017971967,0.00071350177,0.0000995221,0.004224407],"study_design_scores_gemma":[0.018490069,0.00020498455,0.9789087,0.000052067422,0.00012215941,0.000071617884,0.000066747634,0.000673641,0.00009364308,0.00064116047,0.00055637944,0.00011883775],"about_ca_topic_score_codex":0.000014056477,"about_ca_topic_score_gemma":0.00022344978,"teacher_disagreement_score":0.014964632,"about_ca_system_score_codex":0.000021172196,"about_ca_system_score_gemma":0.000055974666,"threshold_uncertainty_score":0.4504383},"labels":[],"label_agreement":null},{"id":"W4415436310","doi":"10.1007/s13555-025-01555-3","title":"Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"melanin and skin pigmentation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"LEO Pharma; Bausch Health; Kyowa Hakko Kirin; Horizon Therapeutics; Incyte; Dermira; Celltrion; Valeant Pharmaceuticals International; Sanofi; Amgen; Meiji Seika Pharma; Pfizer; Concert Pharmaceuticals; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Ruxolitinib; Vitiligo; Clinical trial; Phase (matter); Phases of clinical research","score_opus":0.027316679752416022,"score_gpt":0.3794274668762527,"score_spread":0.35211078712383664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415436310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975813,0.0010931649,0.00058773125,0.000055058143,0.000082619954,0.00024032098,0.000066478795,0.0000023069267,0.00029103755],"genre_scores_gemma":[0.9970236,0.002005626,0.00007363022,0.00020725482,0.0000091244165,0.000008634084,0.0006383027,0.000004087571,0.000029781057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986272,0.000475543,0.00062126655,0.00015262564,0.000038152542,0.00008519677],"domain_scores_gemma":[0.999465,0.00013172836,0.00019126554,0.00012704231,0.000062552535,0.000022393255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043543262,0.00008304722,0.00038816824,0.000058109734,0.000016255724,0.000002155514,0.00006116671,0.0001617818,0.000021184482],"category_scores_gemma":[0.00009605977,0.00006092286,0.000052776482,0.00006438633,0.000150062,0.0000027867377,0.000015078011,0.00006097319,1.5170714e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055931094,0.001041346,0.95491534,0.00003686786,0.00015243763,0.0000039798447,0.000040350267,3.425836e-7,0.008949336,0.0003010822,0.00020465771,0.028761124],"study_design_scores_gemma":[0.021863332,0.0011482395,0.70095795,0.00010104489,0.000033213273,0.000006668342,0.00007449506,0.000015352494,0.27295664,0.00020422334,0.002507503,0.00013134959],"about_ca_topic_score_codex":0.000008235534,"about_ca_topic_score_gemma":0.000017809172,"teacher_disagreement_score":0.26400733,"about_ca_system_score_codex":0.0000019263198,"about_ca_system_score_gemma":0.000056156623,"threshold_uncertainty_score":0.24843621},"labels":[],"label_agreement":null},{"id":"W4415494179","doi":"10.1007/s13555-025-01562-4","title":"Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trent University; University of British Columbia; SKiN Health; Queen's University; Probity Medical Research; University of Toronto","funders":"LEO Pharma; Bausch Health; Sanofi Genzyme; Incyte; Castle Biosciences; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Helsinn; Celgene; Celltrion; Valeant Pharmaceuticals International; Sanofi; Amgen; Helsinn Therapeutics; Meiji Seika Pharma; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company","keywords":"Dermis; Clinical trial; Roflumilast; Plaque psoriasis; Phases of clinical research","score_opus":0.015043720830515493,"score_gpt":0.25846577537987603,"score_spread":0.24342205454936053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415494179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670809,0.029255401,0.000025827641,0.0018553848,0.00045656302,0.0007578988,0.00029154788,0.000046465557,0.00023000585],"genre_scores_gemma":[0.9927793,0.0054932465,0.000016505448,0.00077025074,0.00003852449,0.0001251272,0.0005947182,0.0000145933145,0.0001677228],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99744356,0.001046831,0.00060785934,0.0004922235,0.00003645176,0.0003731068],"domain_scores_gemma":[0.9978405,0.001502749,0.00022596444,0.0003570008,0.000045257166,0.000028486005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036044422,0.00032558164,0.0008286387,0.00013078161,0.00033652145,0.000027321928,0.00018005758,0.00043591214,0.00006728068],"category_scores_gemma":[0.00008843766,0.00019663869,0.00007514082,0.00018328657,0.000323612,0.00009138967,0.000046884008,0.00024122033,0.00001557691],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06714163,0.0034316075,0.41186342,0.000030811818,0.006404309,0.00010545986,0.0039775604,0.0000021642638,0.0049545784,0.0016599938,0.0074552526,0.4929732],"study_design_scores_gemma":[0.2794332,0.0015031273,0.60539985,0.00025028843,0.0008141322,0.00008378567,0.00058595266,0.000009221396,0.047592927,0.0018179932,0.06181068,0.0006988249],"about_ca_topic_score_codex":0.00034294615,"about_ca_topic_score_gemma":0.00048738494,"teacher_disagreement_score":0.4922744,"about_ca_system_score_codex":0.00002734293,"about_ca_system_score_gemma":0.0001160465,"threshold_uncertainty_score":0.80186933},"labels":[],"label_agreement":null},{"id":"W4415729826","doi":"10.1007/s13555-025-01582-0","title":"A 6-Month, Prospective, Multi-arm Study for the Efficacy of Standardized Nutraceuticals to Improve Hair Fiber Thickness and Strength","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"","keywords":"Fiber; Nutraceutical; Materials testing","score_opus":0.014058727314546446,"score_gpt":0.33167289595468863,"score_spread":0.3176141686401422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415729826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850706,0.004472014,0.0023897805,0.004010963,0.0000872669,0.0035401345,0.000020318912,0.000032533168,0.0003764236],"genre_scores_gemma":[0.9978917,0.00023009679,0.00046703365,0.0009220902,0.000011632746,0.0002649183,0.0000022707281,0.00000945278,0.00020080442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921864,0.000062165,0.00021522383,0.00024283346,0.00007289346,0.00018824582],"domain_scores_gemma":[0.9989154,0.00066809676,0.000038123064,0.00020494634,0.0001023838,0.00007107538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017556686,0.00013388244,0.0004010124,0.00007327683,0.00014541723,0.00001155841,0.000059840906,0.00010088287,0.00001472337],"category_scores_gemma":[0.00017371938,0.00008193297,0.00005351728,0.00012813261,0.00018944271,0.000024970053,0.000026385449,0.0001244339,7.799691e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03229097,0.0075708902,0.6468082,0.0006121273,0.0027708553,0.00004371219,0.015522489,0.000004255415,0.0030614035,0.012966035,0.0012230824,0.27712598],"study_design_scores_gemma":[0.12171055,0.0035407187,0.79348356,0.00015238397,0.00063157146,0.00010068561,0.010178211,0.0008381132,0.022553835,0.0029931043,0.04335549,0.00046178233],"about_ca_topic_score_codex":0.00001832482,"about_ca_topic_score_gemma":0.00003350377,"teacher_disagreement_score":0.2766642,"about_ca_system_score_codex":0.000006393589,"about_ca_system_score_gemma":0.0000745689,"threshold_uncertainty_score":0.33411297},"labels":[],"label_agreement":null},{"id":"W4416247285","doi":"10.1007/s13555-025-01592-y","title":"Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"LEO Pharma","keywords":"Dupilumab; Hand eczema; Atopic dermatitis; MEDLINE; Immunopathology","score_opus":0.024648016801837466,"score_gpt":0.3149663567128831,"score_spread":0.2903183399110456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416247285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98922116,0.007857783,0.000021273465,0.0018519062,0.000047019446,0.0005054686,0.000009688516,0.000005757493,0.00047996457],"genre_scores_gemma":[0.99857223,0.00075042946,0.00003235925,0.00057206774,0.0000039195425,0.000022722512,0.0000058452197,0.0000041984204,0.000036233836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991436,0.00021881057,0.00031946067,0.00013493514,0.0000662102,0.00011699192],"domain_scores_gemma":[0.99918425,0.00042975214,0.00010230859,0.00022177373,0.00003552109,0.000026404725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057281264,0.00011644467,0.0005723852,0.00010069533,0.00008080621,0.000004023895,0.0000828266,0.000113104164,0.000008608152],"category_scores_gemma":[0.000019466142,0.00006482225,0.00006260635,0.00017338648,0.0003041618,0.000017360584,0.000016404667,0.000076722055,2.9311067e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021856811,0.0017016125,0.9660074,0.00020000954,0.00035797112,0.000026104928,0.015323245,0.000021906093,0.0004160618,0.0017825656,0.00031458342,0.011662853],"study_design_scores_gemma":[0.007334096,0.0002611773,0.9491305,0.00016821758,0.0001296787,0.0002220333,0.0011407267,0.00013470952,0.038586047,0.002034554,0.0007873662,0.000070942464],"about_ca_topic_score_codex":0.00005910336,"about_ca_topic_score_gemma":0.000066803535,"teacher_disagreement_score":0.038169984,"about_ca_system_score_codex":0.0000054390953,"about_ca_system_score_gemma":0.000056519824,"threshold_uncertainty_score":0.26433745},"labels":[],"label_agreement":null},{"id":"W4416364435","doi":"10.1007/s13555-025-01589-7","title":"Burden, Treatment Patterns and Real-World Barriers to Prescribing Advanced Treatments in Adults with Atopic Dermatitis in Brazil and Colombia","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Formulary; Atopic dermatitis; Quality of life (healthcare); Disease; Health care; Quality (philosophy)","score_opus":0.006890003228127471,"score_gpt":0.2758173758415932,"score_spread":0.2689273726134657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416364435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905484,0.003682368,0.000005992054,0.0042098747,0.00003659465,0.000748714,0.000011550226,0.000027278349,0.0007292578],"genre_scores_gemma":[0.98959243,0.007702252,0.00007198834,0.0022174714,0.000004478964,0.00019230264,0.000019923174,0.000009483437,0.00018965766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907225,0.000094479816,0.00021931929,0.0003208672,0.000045668017,0.0002474051],"domain_scores_gemma":[0.9995197,0.00010921418,0.000034583594,0.00014905204,0.000016055998,0.00017136244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000024308758,0.0001934746,0.00045010293,0.00028527336,0.00009057936,0.000012299952,0.000032887747,0.00010276493,0.000020952282],"category_scores_gemma":[0.00001445044,0.00015217302,0.00001787801,0.00016927806,0.00012657873,0.00008080625,0.000020555524,0.00008287172,9.1435476e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079391396,0.000098423494,0.97386205,0.00009951068,0.00011843848,0.0008380314,0.0020848238,0.000001234068,0.000018378048,0.00021072528,0.00012037965,0.021754107],"study_design_scores_gemma":[0.012412234,0.0001923226,0.9833245,0.0004790574,0.00004030984,0.00037113915,0.0005708827,0.000060549613,0.0007996489,0.00026100987,0.0013643658,0.00012396797],"about_ca_topic_score_codex":0.0007711466,"about_ca_topic_score_gemma":0.0048527936,"teacher_disagreement_score":0.021630138,"about_ca_system_score_codex":0.000036986716,"about_ca_system_score_gemma":0.00007256421,"threshold_uncertainty_score":0.62054354},"labels":[],"label_agreement":null},{"id":"W4416573257","doi":"10.1007/s13555-025-01573-1","title":"Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare Professionals","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Royal College of Physicians of Ireland; LEO Pharma; Galderma; AbbVie; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriasis; Health care; Multinational corporation; Clinical Practice; Health professionals; Infographic","score_opus":0.02146915936222471,"score_gpt":0.30855008643268034,"score_spread":0.2870809270704556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416573257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97882223,0.016460488,0.000016046995,0.0035561512,0.00022610983,0.00062348536,0.0001417822,0.000019033134,0.00013469919],"genre_scores_gemma":[0.99593586,0.0024614062,0.0001305034,0.0009227453,0.0000026621924,0.00013133754,0.0001578566,0.00000854555,0.00024911377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984048,0.00064327335,0.00034109046,0.00032699786,0.000041515003,0.0002423374],"domain_scores_gemma":[0.9989551,0.00058535085,0.00015154007,0.00015963097,0.000120587974,0.0000278188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026041156,0.00020200916,0.0004905152,0.00021403452,0.00016465512,0.0000058229984,0.00007545034,0.00022947282,0.00007953742],"category_scores_gemma":[0.00002316207,0.00015643013,0.000033446366,0.0002681347,0.00020503647,0.000060246904,0.000046791152,0.00011608831,0.000004067763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022672936,0.00060789695,0.9714447,0.00010267963,0.0014555816,0.000014829563,0.0027603256,7.4182554e-7,0.00008745831,0.004071517,0.001012033,0.016174939],"study_design_scores_gemma":[0.00908739,0.00011864481,0.9859185,0.0000981761,0.000073588344,0.000042781794,0.0010302528,0.000011443546,0.002397127,0.00077071204,0.00031168334,0.00013970559],"about_ca_topic_score_codex":0.00052157906,"about_ca_topic_score_gemma":0.0006721411,"teacher_disagreement_score":0.017113624,"about_ca_system_score_codex":0.000011848335,"about_ca_system_score_gemma":0.00012573764,"threshold_uncertainty_score":0.6379036},"labels":[],"label_agreement":null},{"id":"W4417103507","doi":"10.1007/s13555-025-01595-9","title":"Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"UCB Pharma","keywords":"MEDLINE; Population; Feature (linguistics); Component (thermodynamics)","score_opus":0.020032016934352907,"score_gpt":0.2725003341250734,"score_spread":0.2524683171907205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417103507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98266786,0.006527773,0.0000022649238,0.0077153775,0.0007134827,0.00042097183,0.00095628784,0.000087050495,0.00090893515],"genre_scores_gemma":[0.99116516,0.0039419113,0.000030160247,0.0031479765,0.000015244638,0.00005625259,0.001189123,0.000021304273,0.00043284058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770117,0.00052896864,0.0006067138,0.0006495242,0.00005174456,0.00046187176],"domain_scores_gemma":[0.99811274,0.0011024321,0.00021412226,0.00047743157,0.000045816818,0.000047479876],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001632101,0.0004310929,0.00081795966,0.00032933053,0.0002547642,0.000025489475,0.00015236401,0.0007159608,0.000113854294],"category_scores_gemma":[0.00008406837,0.00031464838,0.00012636586,0.00018754131,0.00026075437,0.00010690558,0.000054567863,0.00030441262,0.0000136228755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023455705,0.0016287647,0.8740781,0.000024677935,0.0072595915,0.00073447666,0.0054843593,0.0000030921767,0.007281956,0.00377881,0.026606437,0.049664017],"study_design_scores_gemma":[0.036304016,0.0006671809,0.7729953,0.00009135274,0.00031661175,0.0003634508,0.00059485633,0.000005619763,0.07805888,0.0020237686,0.10783635,0.00074260944],"about_ca_topic_score_codex":0.001345959,"about_ca_topic_score_gemma":0.0003913822,"teacher_disagreement_score":0.10108282,"about_ca_system_score_codex":0.00003373492,"about_ca_system_score_gemma":0.00009197693,"threshold_uncertainty_score":0.99993056},"labels":[],"label_agreement":null},{"id":"W4417103769","doi":"10.1007/s13555-025-01609-6","title":"A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase 2b Study","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto","funders":"Sanofi","keywords":"Post-hoc analysis; Head and neck; Atopic dermatitis; Post hoc; Head (geology)","score_opus":0.013489900040541701,"score_gpt":0.31094682926323164,"score_spread":0.29745692922268996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417103769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96685755,0.025748648,0.000023179038,0.006614973,0.000042489442,0.0004050458,0.000110285146,0.000012942484,0.0001849142],"genre_scores_gemma":[0.9935882,0.001834165,0.00001638642,0.004473728,0.0000050486165,0.000020298985,0.00001614699,0.000005913393,0.00004009812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990304,0.0002585869,0.0003023863,0.0002026277,0.00007801504,0.00012795991],"domain_scores_gemma":[0.9989707,0.00040767298,0.00012038642,0.00039845172,0.000058541395,0.000044266984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058242465,0.000139668,0.000548643,0.00012818526,0.00016655381,0.0000091661,0.00010354126,0.00010799369,0.00003730555],"category_scores_gemma":[0.0000392686,0.000079544014,0.0000985784,0.00032022994,0.0005895789,0.000036483227,0.000051822757,0.00012317467,3.5696354e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035668802,0.0006703416,0.98883915,0.000032020514,0.0025965248,0.000032827953,0.002631653,1.4330205e-7,0.00013017765,0.0009068952,0.0005808572,0.0032227323],"study_design_scores_gemma":[0.005889316,0.00013174856,0.98670197,0.00006156247,0.0014292615,0.00012449126,0.0012583077,0.00014085895,0.00054234173,0.0010557211,0.002596509,0.00006793319],"about_ca_topic_score_codex":0.00022747359,"about_ca_topic_score_gemma":0.0003044559,"teacher_disagreement_score":0.02673069,"about_ca_system_score_codex":0.0000028529055,"about_ca_system_score_gemma":0.00004795219,"threshold_uncertainty_score":0.3243711},"labels":[],"label_agreement":null},{"id":"W4417280112","doi":"10.1007/s13555-025-01612-x","title":"Exploring New Dimensions in Longitudinal Rosacea Management","year":2025,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Galderma","keywords":"Rosacea; Patient Empowerment; Quality of life (healthcare); Disease; Empowerment; Disease management; Health professionals; Health care","score_opus":0.15711213282398953,"score_gpt":0.3675673124102598,"score_spread":0.21045517958627027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417280112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007222983,0.9967511,0.0000135685505,0.00022949964,0.00021904608,0.0007446422,0.0000024132155,0.00003185505,0.0012855263],"genre_scores_gemma":[0.00026740503,0.99769413,0.00011041859,0.0001966568,0.000039344453,0.00015962266,0.000055379962,0.0000163211,0.0014607002],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990572,0.00006438036,0.000263429,0.00031803438,0.00005801712,0.00023894127],"domain_scores_gemma":[0.9995283,0.00009797011,0.000056691417,0.00022143309,0.0000059301447,0.000089681744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041187657,0.00028162752,0.0012288787,0.00029493668,0.00008194355,0.000009088429,0.000050895636,0.0001866095,0.000025088404],"category_scores_gemma":[0.0000032157407,0.00018270493,0.0001670559,0.00021638803,0.000035597117,0.00004579322,0.00004802895,0.0002283674,0.000020164467],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034257468,0.00010851956,0.00087608915,0.005078425,0.0005174534,0.0015632459,0.000049846843,1.1996548e-7,3.2081456e-8,0.00075637037,0.0009804593,0.9900352],"study_design_scores_gemma":[0.0015742794,0.000056975692,0.0004181192,0.009525319,0.0005211904,0.00044291976,0.000014767175,0.0000014926031,0.0000017906037,0.000061133964,0.98722684,0.0001551886],"about_ca_topic_score_codex":0.000019056373,"about_ca_topic_score_gemma":0.000003796391,"teacher_disagreement_score":0.98987997,"about_ca_system_score_codex":0.00002241295,"about_ca_system_score_gemma":0.00008576031,"threshold_uncertainty_score":0.74504906},"labels":[],"label_agreement":null},{"id":"W4417289733","doi":"10.1007/s13555-025-01583-z","title":"Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Amgen","keywords":"Apremilast; Placebo; Palmoplantar pustulosis; Randomized controlled trial; Quality of life (healthcare); Clinical trial","score_opus":0.023753988291548504,"score_gpt":0.2986026229296635,"score_spread":0.274848634638115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417289733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842568,0.013158533,0.000003200141,0.00020381437,0.0003012724,0.0011057949,0.000042803564,0.000019674173,0.0009080931],"genre_scores_gemma":[0.9965092,0.0026285702,0.000011279751,0.000095144926,0.000008039586,0.00023140974,0.00020913046,0.000007782644,0.00029942516],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977953,0.0012320515,0.0003596658,0.00026727834,0.000041328058,0.00030441288],"domain_scores_gemma":[0.99858975,0.0010152917,0.00008915478,0.00021059261,0.00007852988,0.000016684988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047166547,0.00017024654,0.0007117679,0.0004013611,0.00012694311,0.0000055964483,0.0001347303,0.00028516827,0.000049618604],"category_scores_gemma":[0.000058339996,0.00011524691,0.00007349175,0.00028614418,0.0006719246,0.00005563256,0.000034718953,0.00021416452,0.000012246949],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93948543,0.0015298511,0.047365557,0.00003806693,0.00084087666,0.000030179615,0.0012110362,1.862095e-7,0.0007198406,0.00053350575,0.0006614809,0.007583959],"study_design_scores_gemma":[0.9830319,0.00047504462,0.004742054,0.00011496537,0.000084108935,0.000028513468,0.0003181163,0.0000015979319,0.008170881,0.0004954403,0.0024036241,0.00013369921],"about_ca_topic_score_codex":0.000092624214,"about_ca_topic_score_gemma":0.000044980363,"teacher_disagreement_score":0.043546494,"about_ca_system_score_codex":0.000010487535,"about_ca_system_score_gemma":0.00006207995,"threshold_uncertainty_score":0.46996328},"labels":[],"label_agreement":null},{"id":"W4417477681","doi":"10.1007/s13555-025-01618-5","title":"Tailoring Abrocitinib Treatment for Moderate-to-Severe Atopic Dermatitis to Patient Disease Course: A Narrative Review","year":2025,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"","keywords":"Dosing; Adverse effect; Narrative review; Atopic dermatitis; Randomized controlled trial; Quality of life (healthcare); Clinical trial; Disease","score_opus":0.036729150973519205,"score_gpt":0.3661624990328075,"score_spread":0.3294333480592883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417477681","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025931484,0.9858497,0.000120026634,0.005768663,0.00028597692,0.006866516,0.00037640173,0.00008849934,0.00038491475],"genre_scores_gemma":[0.00062431896,0.97580826,0.00019549,0.016222246,0.000056462297,0.005935817,0.0005804183,0.00004392574,0.00053303986],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997631,0.00029348632,0.0007631162,0.0006960076,0.00013091844,0.00048548053],"domain_scores_gemma":[0.9980817,0.00045735377,0.00020415647,0.0005239272,0.00014754607,0.00058531365],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000510488,0.00067748455,0.0029481892,0.00022414398,0.00031806613,0.000024817567,0.00014915345,0.00031686554,0.00008755879],"category_scores_gemma":[0.00012310881,0.0005051039,0.0005671363,0.00027099185,0.000093082446,0.00005963998,0.000055351396,0.00019497993,0.00004927532],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030453684,0.00039100452,0.00026754636,0.05890478,0.001266309,0.0006647631,0.0006261527,5.310491e-7,2.9048516e-8,0.00044565374,0.06555701,0.87157166],"study_design_scores_gemma":[0.001539033,0.0001808501,0.00010348523,0.043830927,0.0017283846,0.0010877295,0.00005251412,0.0000034688246,0.000003961292,0.00024540006,0.9508009,0.0004233247],"about_ca_topic_score_codex":0.0000029781695,"about_ca_topic_score_gemma":0.0000037440238,"teacher_disagreement_score":0.8852439,"about_ca_system_score_codex":0.00007738487,"about_ca_system_score_gemma":0.0008085194,"threshold_uncertainty_score":0.99974006},"labels":[],"label_agreement":null},{"id":"W4417494321","doi":"10.1007/s13555-025-01619-4","title":"Clinical Implications of the Skin Microbiota in the Therapy of Cutaneous T Cell Lymphoma: A Scoping Review","year":2025,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; Sunnybrook Hospital; Richmond Hospital; University of Calgary","funders":"","keywords":"T cell; Dysbiosis; Cutaneous T-cell lymphoma; Cell; Microbiome; Mycosis fungoides; Immunotherapy","score_opus":0.06600939437309242,"score_gpt":0.438828839239316,"score_spread":0.37281944486622354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417494321","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009675714,0.99094033,0.0000035556309,0.0022352024,0.000058653917,0.0050016576,0.000036714,0.0000072103003,0.00074910006],"genre_scores_gemma":[0.001049881,0.99622625,0.000024208708,0.0022857871,0.00001816569,0.00026666984,0.00003596475,0.000022483564,0.00007057675],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99622923,0.0016279974,0.0013278183,0.00038803281,0.00016307892,0.0002638294],"domain_scores_gemma":[0.99632794,0.0019970117,0.00052412896,0.0009692221,0.00014413719,0.000037584632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005159239,0.00031534303,0.0024466554,0.00016941842,0.00009594728,0.0000075022394,0.00059549964,0.00039932624,0.00003411978],"category_scores_gemma":[0.00015794575,0.00016001391,0.0006506349,0.00074293505,0.0006443499,0.000013384291,0.00008951111,0.00040652347,0.0000033321307],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008680651,0.0009016511,0.0022880984,0.078448914,0.00026406374,0.000045692803,0.0001803457,1.6864712e-8,0.000010626248,0.00023276825,0.00094191235,0.9165991],"study_design_scores_gemma":[0.004716798,0.00030987727,0.0005084158,0.31587666,0.0005089527,0.023627523,0.00006608194,0.0000017449938,0.00013807563,0.00034993034,0.6534851,0.00041081914],"about_ca_topic_score_codex":0.000022635078,"about_ca_topic_score_gemma":0.000024126091,"teacher_disagreement_score":0.9161883,"about_ca_system_score_codex":0.000024862486,"about_ca_system_score_gemma":0.0015404058,"threshold_uncertainty_score":0.6525178},"labels":[],"label_agreement":null},{"id":"W4417525267","doi":"10.1007/s13555-025-01620-x","title":"Short-Term Efficacy of Lebrikizumab Versus Dupilumab in Combination with Topical Corticosteroids in Adults with Moderate-to-Severe Atopic Dermatitis: Matching-Adjusted Indirect Comparison","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"LEO Pharma; Sun Pharma; Castle Biosciences; Biogen; Celgene; Celldex Therapeutics; Mylan; Canadian Dermatology Foundation; Samsung; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Galderma; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dupilumab; Atopic dermatitis; Monoclonal antibody; Clinical efficacy; Monoclonal","score_opus":0.015945744629677808,"score_gpt":0.28306203331305496,"score_spread":0.26711628868337717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417525267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958079,0.0013488136,0.00020665595,0.0012401063,0.00008057663,0.0007036572,0.0000031860118,0.00003855439,0.00057055394],"genre_scores_gemma":[0.99901867,0.00016835624,0.000119874145,0.000545275,0.000004307412,0.00006528502,0.00004982308,0.000011409963,0.000017009892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987637,0.0001557642,0.00042102998,0.0002885417,0.00012056229,0.00025044126],"domain_scores_gemma":[0.9993725,0.00021533461,0.000069047324,0.00021438529,0.000053295258,0.000075478834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041339183,0.00019746444,0.00070003036,0.00033286997,0.000057758316,0.000011402293,0.00008969748,0.00019465451,0.0000142516365],"category_scores_gemma":[0.00001800415,0.00015790666,0.000030510248,0.00028968134,0.00017113306,0.00009085771,0.00002581485,0.0002679977,0.0000021988676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016363189,0.0008192504,0.9698896,0.00023944776,0.00014969842,0.00042672214,0.0016629337,0.00004090042,0.000015702086,0.00076702336,0.00007663281,0.009548908],"study_design_scores_gemma":[0.027860563,0.0003575366,0.9683379,0.0006529444,0.000046113993,0.0004243771,0.00031086776,0.0005065695,0.0011448275,0.00016909905,0.000039191862,0.00015003074],"about_ca_topic_score_codex":0.000037638132,"about_ca_topic_score_gemma":0.00041835153,"teacher_disagreement_score":0.011497375,"about_ca_system_score_codex":0.000032648415,"about_ca_system_score_gemma":0.00009977392,"threshold_uncertainty_score":0.6439247},"labels":[],"label_agreement":null}]}